	Data.source	Date.of.update	Alternative.name	Product.type	Antibacterial.class	Indications	Route.of.administration	R.D.phase	Clinical.trials	Developer	Pathogen.category	Pathogen.name	Pathogen.activity	Active.against.priority.pathogens.	Innovative.	NCE.	Mycobacterium.tuberculosis	Clostridioides.difficile	Combined.Categories
0	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Bacteriophage	Gram positive and Gram negative	Inhalation	Phase III	NCT04682964	"Tashkent Pediatric Medical
Institute"	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	Yes	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
1	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Bacteriophage	Gram positive and Gram negative	Inhalation	Phase III	NCT04682964	"Tashkent Pediatric Medical
Institute"	Priority pathogens	Staphylococcus aureus	Other priority pathogens	Yes	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
2	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Bacteriophage	Gram positive and Gram negative	Inhalation	Phase III	NCT04682964	"Tashkent Pediatric Medical
Institute"	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	Yes	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
3	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Bacteriophage	Gram positive and Gram negative	Inhalation	Phase III	NCT04682964	"Tashkent Pediatric Medical
Institute"	Priority pathogens	Other priority pathogens	Other priority pathogens	Yes	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
4	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Bacteriophage	Gram positive and Gram negative	Inhalation	Phase III	NCT04682964	"Tashkent Pediatric Medical
Institute"	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
5	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Bacteriophage	Gram positive and Gram negative	Inhalation	Phase III	NCT04682964	"Tashkent Pediatric Medical
Institute"	Priority pathogens	Helicobacter pylori	Other priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
6	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Bacteriophage	Gram positive and Gram negative	Inhalation	Phase III	NCT04682964	"Tashkent Pediatric Medical
Institute"	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	Yes	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
7	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Bacteriophage	Gram positive and Gram negative	Inhalation	Phase III	NCT04682964	"Tashkent Pediatric Medical
Institute"	Priority pathogens	Enterococcus faecium	Other priority pathogens	Yes	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
8	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Bacteriophage	Gram positive and Gram negative	Inhalation	Phase III	NCT04682964	"Tashkent Pediatric Medical
Institute"	Priority pathogens	Enterobacterales	Critical priority pathogens	Yes	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
9	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Bacteriophage	Gram positive and Gram negative	Inhalation	Phase III	NCT04682964	"Tashkent Pediatric Medical
Institute"	Priority pathogens	Critical priority pathogens	Critical priority pathogens	Yes	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
10	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Bacteriophage	Gram positive and Gram negative	Inhalation	Phase III	NCT04682964	"Tashkent Pediatric Medical
Institute"	Priority pathogens	Campylobacter spp.	Other priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
11	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Bacteriophage	Gram positive and Gram negative	Inhalation	Phase III	NCT04682964	"Tashkent Pediatric Medical
Institute"	Priority pathogens	All critical priority pathogens	Critical priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
12	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Bacteriophage	Gram positive and Gram negative	Inhalation	Phase III	NCT04682964	"Tashkent Pediatric Medical
Institute"	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
13	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Monoclonal antibody	S. aureus	IV	Phase I	NCT04784312	Mabwell Bioscience	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	No	No	Yes	No	Unknown	Antibodies
14	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Monoclonal antibody	S. aureus	IV	Phase I	NCT04784312	Mabwell Bioscience	Priority pathogens	Staphylococcus aureus	Other priority pathogens	Yes	No	Yes	No	Unknown	Antibodies
15	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Monoclonal antibody	S. aureus	IV	Phase I	NCT04784312	Mabwell Bioscience	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	No	No	Yes	No	Unknown	Antibodies
16	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Monoclonal antibody	S. aureus	IV	Phase I	NCT04784312	Mabwell Bioscience	Priority pathogens	Other priority pathogens	Other priority pathogens	Yes	No	Yes	No	Unknown	Antibodies
17	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Monoclonal antibody	S. aureus	IV	Phase I	NCT04784312	Mabwell Bioscience	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	No	No	Yes	No	Unknown	Antibodies
18	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Monoclonal antibody	S. aureus	IV	Phase I	NCT04784312	Mabwell Bioscience	Priority pathogens	Helicobacter pylori	Other priority pathogens	No	No	Yes	No	Unknown	Antibodies
19	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Monoclonal antibody	S. aureus	IV	Phase I	NCT04784312	Mabwell Bioscience	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	Yes	No	Yes	No	Unknown	Antibodies
20	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Monoclonal antibody	S. aureus	IV	Phase I	NCT04784312	Mabwell Bioscience	Priority pathogens	Enterococcus faecium	Other priority pathogens	No	No	Yes	No	Unknown	Antibodies
21	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Monoclonal antibody	S. aureus	IV	Phase I	NCT04784312	Mabwell Bioscience	Priority pathogens	Enterobacterales	Critical priority pathogens	No	No	Yes	No	Unknown	Antibodies
22	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Monoclonal antibody	S. aureus	IV	Phase I	NCT04784312	Mabwell Bioscience	Priority pathogens	Critical priority pathogens	Critical priority pathogens	No	No	Yes	No	Unknown	Antibodies
23	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Monoclonal antibody	S. aureus	IV	Phase I	NCT04784312	Mabwell Bioscience	Priority pathogens	Campylobacter spp.	Other priority pathogens	No	No	Yes	No	Unknown	Antibodies
24	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Monoclonal antibody	S. aureus	IV	Phase I	NCT04784312	Mabwell Bioscience	Priority pathogens	All critical priority pathogens	Critical priority pathogens	No	No	Yes	No	Unknown	Antibodies
25	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Monoclonal antibody	S. aureus	IV	Phase I	NCT04784312	Mabwell Bioscience	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	No	No	Yes	No	Unknown	Antibodies
26	WHO AMR pipeline analysis	2021-11-01	Reltecimod	Non-traditional	Antagonist of superantigen exotoxins and CD28 T-cell	S. aureus necrotizing soft tissue infection, acute kidney injury, peritonitis	IV	Preregistration	NCT02469857, NCT03403751	Atox Bio	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	No	No	Yes	No	Unknown	Immunomodulating agents
27	WHO AMR pipeline analysis	2021-11-01	Reltecimod	Non-traditional	Antagonist of superantigen exotoxins and CD28 T-cell	S. aureus necrotizing soft tissue infection, acute kidney injury, peritonitis	IV	Preregistration	NCT02469857, NCT03403751	Atox Bio	Priority pathogens	Staphylococcus aureus	Other priority pathogens	Yes	No	Yes	No	Unknown	Immunomodulating agents
28	WHO AMR pipeline analysis	2021-11-01	Reltecimod	Non-traditional	Antagonist of superantigen exotoxins and CD28 T-cell	S. aureus necrotizing soft tissue infection, acute kidney injury, peritonitis	IV	Preregistration	NCT02469857, NCT03403751	Atox Bio	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	No	No	Yes	No	Unknown	Immunomodulating agents
29	WHO AMR pipeline analysis	2021-11-01	Reltecimod	Non-traditional	Antagonist of superantigen exotoxins and CD28 T-cell	S. aureus necrotizing soft tissue infection, acute kidney injury, peritonitis	IV	Preregistration	NCT02469857, NCT03403751	Atox Bio	Priority pathogens	Other priority pathogens	Other priority pathogens	Yes	No	Yes	No	Unknown	Immunomodulating agents
30	WHO AMR pipeline analysis	2021-11-01	Reltecimod	Non-traditional	Antagonist of superantigen exotoxins and CD28 T-cell	S. aureus necrotizing soft tissue infection, acute kidney injury, peritonitis	IV	Preregistration	NCT02469857, NCT03403751	Atox Bio	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	No	No	Yes	No	Unknown	Immunomodulating agents
31	WHO AMR pipeline analysis	2021-11-01	Reltecimod	Non-traditional	Antagonist of superantigen exotoxins and CD28 T-cell	S. aureus necrotizing soft tissue infection, acute kidney injury, peritonitis	IV	Preregistration	NCT02469857, NCT03403751	Atox Bio	Priority pathogens	Helicobacter pylori	Other priority pathogens	No	No	Yes	No	Unknown	Immunomodulating agents
32	WHO AMR pipeline analysis	2021-11-01	Reltecimod	Non-traditional	Antagonist of superantigen exotoxins and CD28 T-cell	S. aureus necrotizing soft tissue infection, acute kidney injury, peritonitis	IV	Preregistration	NCT02469857, NCT03403751	Atox Bio	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	Yes	No	Yes	No	Unknown	Immunomodulating agents
33	WHO AMR pipeline analysis	2021-11-01	Reltecimod	Non-traditional	Antagonist of superantigen exotoxins and CD28 T-cell	S. aureus necrotizing soft tissue infection, acute kidney injury, peritonitis	IV	Preregistration	NCT02469857, NCT03403751	Atox Bio	Priority pathogens	Enterococcus faecium	Other priority pathogens	No	No	Yes	No	Unknown	Immunomodulating agents
34	WHO AMR pipeline analysis	2021-11-01	Reltecimod	Non-traditional	Antagonist of superantigen exotoxins and CD28 T-cell	S. aureus necrotizing soft tissue infection, acute kidney injury, peritonitis	IV	Preregistration	NCT02469857, NCT03403751	Atox Bio	Priority pathogens	Enterobacterales	Critical priority pathogens	No	No	Yes	No	Unknown	Immunomodulating agents
35	WHO AMR pipeline analysis	2021-11-01	Reltecimod	Non-traditional	Antagonist of superantigen exotoxins and CD28 T-cell	S. aureus necrotizing soft tissue infection, acute kidney injury, peritonitis	IV	Preregistration	NCT02469857, NCT03403751	Atox Bio	Priority pathogens	Critical priority pathogens	Critical priority pathogens	No	No	Yes	No	Unknown	Immunomodulating agents
36	WHO AMR pipeline analysis	2021-11-01	Reltecimod	Non-traditional	Antagonist of superantigen exotoxins and CD28 T-cell	S. aureus necrotizing soft tissue infection, acute kidney injury, peritonitis	IV	Preregistration	NCT02469857, NCT03403751	Atox Bio	Priority pathogens	Campylobacter spp.	Other priority pathogens	No	No	Yes	No	Unknown	Immunomodulating agents
37	WHO AMR pipeline analysis	2021-11-01	Reltecimod	Non-traditional	Antagonist of superantigen exotoxins and CD28 T-cell	S. aureus necrotizing soft tissue infection, acute kidney injury, peritonitis	IV	Preregistration	NCT02469857, NCT03403751	Atox Bio	Priority pathogens	All critical priority pathogens	Critical priority pathogens	No	No	Yes	No	Unknown	Immunomodulating agents
38	WHO AMR pipeline analysis	2021-11-01	Reltecimod	Non-traditional	Antagonist of superantigen exotoxins and CD28 T-cell	S. aureus necrotizing soft tissue infection, acute kidney injury, peritonitis	IV	Preregistration	NCT02469857, NCT03403751	Atox Bio	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	No	No	Yes	No	Unknown	Immunomodulating agents
39	WHO AMR pipeline analysis	2021-11-01	Debio 1450	Antibiotics	FabI inhibitor	ABSSI (caused by S. aureus), osteomyelitis	IV, Oral	Phase II	NCT02426918, NCT03723551	Debiopharm International SA	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	No	Yes	Yes	No	Unknown	Afabicin
40	WHO AMR pipeline analysis	2021-11-01	Debio 1450	Antibiotics	FabI inhibitor	ABSSI (caused by S. aureus), osteomyelitis	IV, Oral	Phase II	NCT02426918, NCT03723551	Debiopharm International SA	Priority pathogens	Staphylococcus aureus	Other priority pathogens	Yes	Yes	Yes	No	Unknown	Afabicin
41	WHO AMR pipeline analysis	2021-11-01	Debio 1450	Antibiotics	FabI inhibitor	ABSSI (caused by S. aureus), osteomyelitis	IV, Oral	Phase II	NCT02426918, NCT03723551	Debiopharm International SA	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	No	Yes	Yes	No	Unknown	Afabicin
42	WHO AMR pipeline analysis	2021-11-01	Debio 1450	Antibiotics	FabI inhibitor	ABSSI (caused by S. aureus), osteomyelitis	IV, Oral	Phase II	NCT02426918, NCT03723551	Debiopharm International SA	Priority pathogens	Other priority pathogens	Other priority pathogens	Yes	Yes	Yes	No	Unknown	Afabicin
43	WHO AMR pipeline analysis	2021-11-01	Debio 1450	Antibiotics	FabI inhibitor	ABSSI (caused by S. aureus), osteomyelitis	IV, Oral	Phase II	NCT02426918, NCT03723551	Debiopharm International SA	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	No	Yes	Yes	No	Unknown	Afabicin
44	WHO AMR pipeline analysis	2021-11-01	Debio 1450	Antibiotics	FabI inhibitor	ABSSI (caused by S. aureus), osteomyelitis	IV, Oral	Phase II	NCT02426918, NCT03723551	Debiopharm International SA	Priority pathogens	Helicobacter pylori	Other priority pathogens	No	Yes	Yes	No	Unknown	Afabicin
45	WHO AMR pipeline analysis	2021-11-01	Debio 1450	Antibiotics	FabI inhibitor	ABSSI (caused by S. aureus), osteomyelitis	IV, Oral	Phase II	NCT02426918, NCT03723551	Debiopharm International SA	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	Yes	Yes	Yes	No	Unknown	Afabicin
46	WHO AMR pipeline analysis	2021-11-01	Debio 1450	Antibiotics	FabI inhibitor	ABSSI (caused by S. aureus), osteomyelitis	IV, Oral	Phase II	NCT02426918, NCT03723551	Debiopharm International SA	Priority pathogens	Enterococcus faecium	Other priority pathogens	No	Yes	Yes	No	Unknown	Afabicin
47	WHO AMR pipeline analysis	2021-11-01	Debio 1450	Antibiotics	FabI inhibitor	ABSSI (caused by S. aureus), osteomyelitis	IV, Oral	Phase II	NCT02426918, NCT03723551	Debiopharm International SA	Priority pathogens	Enterobacterales	Critical priority pathogens	No	Yes	Yes	No	Unknown	Afabicin
48	WHO AMR pipeline analysis	2021-11-01	Debio 1450	Antibiotics	FabI inhibitor	ABSSI (caused by S. aureus), osteomyelitis	IV, Oral	Phase II	NCT02426918, NCT03723551	Debiopharm International SA	Priority pathogens	Critical priority pathogens	Critical priority pathogens	No	Yes	Yes	No	Unknown	Afabicin
49	WHO AMR pipeline analysis	2021-11-01	Debio 1450	Antibiotics	FabI inhibitor	ABSSI (caused by S. aureus), osteomyelitis	IV, Oral	Phase II	NCT02426918, NCT03723551	Debiopharm International SA	Priority pathogens	Campylobacter spp.	Other priority pathogens	No	Yes	Yes	No	Unknown	Afabicin
50	WHO AMR pipeline analysis	2021-11-01	Debio 1450	Antibiotics	FabI inhibitor	ABSSI (caused by S. aureus), osteomyelitis	IV, Oral	Phase II	NCT02426918, NCT03723551	Debiopharm International SA	Priority pathogens	All critical priority pathogens	Critical priority pathogens	No	Yes	Yes	No	Unknown	Afabicin
51	WHO AMR pipeline analysis	2021-11-01	Debio 1450	Antibiotics	FabI inhibitor	ABSSI (caused by S. aureus), osteomyelitis	IV, Oral	Phase II	NCT02426918, NCT03723551	Debiopharm International SA	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	No	Yes	Yes	No	Unknown	Afabicin
52	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Staphyloxanthin biosynthesis inhibition	S. aureus	Oral	Phase I	Not registered	Aptorum Group	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	No	No	Yes	No	Unknown	Miscellaneous
53	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Staphyloxanthin biosynthesis inhibition	S. aureus	Oral	Phase I	Not registered	Aptorum Group	Priority pathogens	Staphylococcus aureus	Other priority pathogens	Yes	No	Yes	No	Unknown	Miscellaneous
54	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Staphyloxanthin biosynthesis inhibition	S. aureus	Oral	Phase I	Not registered	Aptorum Group	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	No	No	Yes	No	Unknown	Miscellaneous
55	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Staphyloxanthin biosynthesis inhibition	S. aureus	Oral	Phase I	Not registered	Aptorum Group	Priority pathogens	Other priority pathogens	Other priority pathogens	Yes	No	Yes	No	Unknown	Miscellaneous
56	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Staphyloxanthin biosynthesis inhibition	S. aureus	Oral	Phase I	Not registered	Aptorum Group	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	No	No	Yes	No	Unknown	Miscellaneous
57	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Staphyloxanthin biosynthesis inhibition	S. aureus	Oral	Phase I	Not registered	Aptorum Group	Priority pathogens	Helicobacter pylori	Other priority pathogens	No	No	Yes	No	Unknown	Miscellaneous
58	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Staphyloxanthin biosynthesis inhibition	S. aureus	Oral	Phase I	Not registered	Aptorum Group	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	Yes	No	Yes	No	Unknown	Miscellaneous
59	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Staphyloxanthin biosynthesis inhibition	S. aureus	Oral	Phase I	Not registered	Aptorum Group	Priority pathogens	Enterococcus faecium	Other priority pathogens	No	No	Yes	No	Unknown	Miscellaneous
60	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Staphyloxanthin biosynthesis inhibition	S. aureus	Oral	Phase I	Not registered	Aptorum Group	Priority pathogens	Enterobacterales	Critical priority pathogens	No	No	Yes	No	Unknown	Miscellaneous
61	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Staphyloxanthin biosynthesis inhibition	S. aureus	Oral	Phase I	Not registered	Aptorum Group	Priority pathogens	Critical priority pathogens	Critical priority pathogens	No	No	Yes	No	Unknown	Miscellaneous
62	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Staphyloxanthin biosynthesis inhibition	S. aureus	Oral	Phase I	Not registered	Aptorum Group	Priority pathogens	Campylobacter spp.	Other priority pathogens	No	No	Yes	No	Unknown	Miscellaneous
63	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Staphyloxanthin biosynthesis inhibition	S. aureus	Oral	Phase I	Not registered	Aptorum Group	Priority pathogens	All critical priority pathogens	Critical priority pathogens	No	No	Yes	No	Unknown	Miscellaneous
64	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Staphyloxanthin biosynthesis inhibition	S. aureus	Oral	Phase I	Not registered	Aptorum Group	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	No	No	Yes	No	Unknown	Miscellaneous
65	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT04596319	Armata Pharmaceuticals	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
66	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT04596319	Armata Pharmaceuticals	Priority pathogens	Staphylococcus aureus	Other priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
67	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT04596319	Armata Pharmaceuticals	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	Yes	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
68	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT04596319	Armata Pharmaceuticals	Priority pathogens	Other priority pathogens	Other priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
69	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT04596319	Armata Pharmaceuticals	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
70	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT04596319	Armata Pharmaceuticals	Priority pathogens	Helicobacter pylori	Other priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
71	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT04596319	Armata Pharmaceuticals	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
72	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT04596319	Armata Pharmaceuticals	Priority pathogens	Enterococcus faecium	Other priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
73	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT04596319	Armata Pharmaceuticals	Priority pathogens	Enterobacterales	Critical priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
74	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT04596319	Armata Pharmaceuticals	Priority pathogens	Critical priority pathogens	Critical priority pathogens	Yes	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
75	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT04596319	Armata Pharmaceuticals	Priority pathogens	Campylobacter spp.	Other priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
76	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT04596319	Armata Pharmaceuticals	Priority pathogens	All critical priority pathogens	Critical priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
77	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT04596319	Armata Pharmaceuticals	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
78	WHO AMR pipeline analysis	2021-11-01	Tosatoxumab	Non-traditional	anti-S. aureus IgM monoclonal Ab	S. aureus HAP, VAP	IV	Phase III	NCT03816956	Aridis Pharmaceuticals, Inc.	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	No	No	Yes	No	Unknown	Antibodies
79	WHO AMR pipeline analysis	2021-11-01	Tosatoxumab	Non-traditional	anti-S. aureus IgM monoclonal Ab	S. aureus HAP, VAP	IV	Phase III	NCT03816956	Aridis Pharmaceuticals, Inc.	Priority pathogens	Staphylococcus aureus	Other priority pathogens	Yes	No	Yes	No	Unknown	Antibodies
80	WHO AMR pipeline analysis	2021-11-01	Tosatoxumab	Non-traditional	anti-S. aureus IgM monoclonal Ab	S. aureus HAP, VAP	IV	Phase III	NCT03816956	Aridis Pharmaceuticals, Inc.	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	No	No	Yes	No	Unknown	Antibodies
81	WHO AMR pipeline analysis	2021-11-01	Tosatoxumab	Non-traditional	anti-S. aureus IgM monoclonal Ab	S. aureus HAP, VAP	IV	Phase III	NCT03816956	Aridis Pharmaceuticals, Inc.	Priority pathogens	Other priority pathogens	Other priority pathogens	No	No	Yes	No	Unknown	Antibodies
82	WHO AMR pipeline analysis	2021-11-01	Tosatoxumab	Non-traditional	anti-S. aureus IgM monoclonal Ab	S. aureus HAP, VAP	IV	Phase III	NCT03816956	Aridis Pharmaceuticals, Inc.	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	No	No	Yes	No	Unknown	Antibodies
83	WHO AMR pipeline analysis	2021-11-01	Tosatoxumab	Non-traditional	anti-S. aureus IgM monoclonal Ab	S. aureus HAP, VAP	IV	Phase III	NCT03816956	Aridis Pharmaceuticals, Inc.	Priority pathogens	Helicobacter pylori	Other priority pathogens	No	No	Yes	No	Unknown	Antibodies
84	WHO AMR pipeline analysis	2021-11-01	Tosatoxumab	Non-traditional	anti-S. aureus IgM monoclonal Ab	S. aureus HAP, VAP	IV	Phase III	NCT03816956	Aridis Pharmaceuticals, Inc.	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	Yes	No	Yes	No	Unknown	Antibodies
85	WHO AMR pipeline analysis	2021-11-01	Tosatoxumab	Non-traditional	anti-S. aureus IgM monoclonal Ab	S. aureus HAP, VAP	IV	Phase III	NCT03816956	Aridis Pharmaceuticals, Inc.	Priority pathogens	Enterococcus faecium	Other priority pathogens	No	No	Yes	No	Unknown	Antibodies
86	WHO AMR pipeline analysis	2021-11-01	Tosatoxumab	Non-traditional	anti-S. aureus IgM monoclonal Ab	S. aureus HAP, VAP	IV	Phase III	NCT03816956	Aridis Pharmaceuticals, Inc.	Priority pathogens	Enterobacterales	Critical priority pathogens	No	No	Yes	No	Unknown	Antibodies
87	WHO AMR pipeline analysis	2021-11-01	Tosatoxumab	Non-traditional	anti-S. aureus IgM monoclonal Ab	S. aureus HAP, VAP	IV	Phase III	NCT03816956	Aridis Pharmaceuticals, Inc.	Priority pathogens	Critical priority pathogens	Critical priority pathogens	No	No	Yes	No	Unknown	Antibodies
88	WHO AMR pipeline analysis	2021-11-01	Tosatoxumab	Non-traditional	anti-S. aureus IgM monoclonal Ab	S. aureus HAP, VAP	IV	Phase III	NCT03816956	Aridis Pharmaceuticals, Inc.	Priority pathogens	Campylobacter spp.	Other priority pathogens	No	No	Yes	No	Unknown	Antibodies
89	WHO AMR pipeline analysis	2021-11-01	Tosatoxumab	Non-traditional	anti-S. aureus IgM monoclonal Ab	S. aureus HAP, VAP	IV	Phase III	NCT03816956	Aridis Pharmaceuticals, Inc.	Priority pathogens	All critical priority pathogens	Critical priority pathogens	No	No	Yes	No	Unknown	Antibodies
90	WHO AMR pipeline analysis	2021-11-01	Tosatoxumab	Non-traditional	anti-S. aureus IgM monoclonal Ab	S. aureus HAP, VAP	IV	Phase III	NCT03816956	Aridis Pharmaceuticals, Inc.	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	No	No	Yes	No	Unknown	Antibodies
91	WHO AMR pipeline analysis	2021-11-01	MEDI-4893, Suvratoxumab	Non-traditional	anti-S. aureus IgG monoclonal Ab	 S. aureus HAP, VAP	IV	Phase II	NCT02296320	"Aridis
AstraZeneca/ MedImmune"	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	No	No	Yes	No	Unknown	Antibodies
92	WHO AMR pipeline analysis	2021-11-01	MEDI-4893, Suvratoxumab	Non-traditional	anti-S. aureus IgG monoclonal Ab	 S. aureus HAP, VAP	IV	Phase II	NCT02296320	"Aridis
AstraZeneca/ MedImmune"	Priority pathogens	Staphylococcus aureus	Other priority pathogens	Yes	No	Yes	No	Unknown	Antibodies
93	WHO AMR pipeline analysis	2021-11-01	MEDI-4893, Suvratoxumab	Non-traditional	anti-S. aureus IgG monoclonal Ab	 S. aureus HAP, VAP	IV	Phase II	NCT02296320	"Aridis
AstraZeneca/ MedImmune"	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	No	No	Yes	No	Unknown	Antibodies
94	WHO AMR pipeline analysis	2021-11-01	MEDI-4893, Suvratoxumab	Non-traditional	anti-S. aureus IgG monoclonal Ab	 S. aureus HAP, VAP	IV	Phase II	NCT02296320	"Aridis
AstraZeneca/ MedImmune"	Priority pathogens	Other priority pathogens	Other priority pathogens	No	No	Yes	No	Unknown	Antibodies
95	WHO AMR pipeline analysis	2021-11-01	MEDI-4893, Suvratoxumab	Non-traditional	anti-S. aureus IgG monoclonal Ab	 S. aureus HAP, VAP	IV	Phase II	NCT02296320	"Aridis
AstraZeneca/ MedImmune"	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	No	No	Yes	No	Unknown	Antibodies
96	WHO AMR pipeline analysis	2021-11-01	MEDI-4893, Suvratoxumab	Non-traditional	anti-S. aureus IgG monoclonal Ab	 S. aureus HAP, VAP	IV	Phase II	NCT02296320	"Aridis
AstraZeneca/ MedImmune"	Priority pathogens	Helicobacter pylori	Other priority pathogens	No	No	Yes	No	Unknown	Antibodies
97	WHO AMR pipeline analysis	2021-11-01	MEDI-4893, Suvratoxumab	Non-traditional	anti-S. aureus IgG monoclonal Ab	 S. aureus HAP, VAP	IV	Phase II	NCT02296320	"Aridis
AstraZeneca/ MedImmune"	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	Yes	No	Yes	No	Unknown	Antibodies
98	WHO AMR pipeline analysis	2021-11-01	MEDI-4893, Suvratoxumab	Non-traditional	anti-S. aureus IgG monoclonal Ab	 S. aureus HAP, VAP	IV	Phase II	NCT02296320	"Aridis
AstraZeneca/ MedImmune"	Priority pathogens	Enterococcus faecium	Other priority pathogens	No	No	Yes	No	Unknown	Antibodies
99	WHO AMR pipeline analysis	2021-11-01	MEDI-4893, Suvratoxumab	Non-traditional	anti-S. aureus IgG monoclonal Ab	 S. aureus HAP, VAP	IV	Phase II	NCT02296320	"Aridis
AstraZeneca/ MedImmune"	Priority pathogens	Enterobacterales	Critical priority pathogens	No	No	Yes	No	Unknown	Antibodies
100	WHO AMR pipeline analysis	2021-11-01	MEDI-4893, Suvratoxumab	Non-traditional	anti-S. aureus IgG monoclonal Ab	 S. aureus HAP, VAP	IV	Phase II	NCT02296320	"Aridis
AstraZeneca/ MedImmune"	Priority pathogens	Critical priority pathogens	Critical priority pathogens	No	No	Yes	No	Unknown	Antibodies
101	WHO AMR pipeline analysis	2021-11-01	MEDI-4893, Suvratoxumab	Non-traditional	anti-S. aureus IgG monoclonal Ab	 S. aureus HAP, VAP	IV	Phase II	NCT02296320	"Aridis
AstraZeneca/ MedImmune"	Priority pathogens	Campylobacter spp.	Other priority pathogens	No	No	Yes	No	Unknown	Antibodies
102	WHO AMR pipeline analysis	2021-11-01	MEDI-4893, Suvratoxumab	Non-traditional	anti-S. aureus IgG monoclonal Ab	 S. aureus HAP, VAP	IV	Phase II	NCT02296320	"Aridis
AstraZeneca/ MedImmune"	Priority pathogens	All critical priority pathogens	Critical priority pathogens	No	No	Yes	No	Unknown	Antibodies
103	WHO AMR pipeline analysis	2021-11-01	MEDI-4893, Suvratoxumab	Non-traditional	anti-S. aureus IgG monoclonal Ab	 S. aureus HAP, VAP	IV	Phase II	NCT02296320	"Aridis
AstraZeneca/ MedImmune"	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	No	No	Yes	No	Unknown	Antibodies
104	WHO AMR pipeline analysis	2021-11-01	Oral Avibactam prodrug	Antibiotics	DBO-BLI + β-lactam	 Gram-negative infections	Oral	Phase I	NCT03931876	Pfizer/ Arixa Pharmaceuticals	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	No	No	Yes	No	Unknown	ARX-1796
105	WHO AMR pipeline analysis	2021-11-01	Oral Avibactam prodrug	Antibiotics	DBO-BLI + β-lactam	 Gram-negative infections	Oral	Phase I	NCT03931876	Pfizer/ Arixa Pharmaceuticals	Priority pathogens	Staphylococcus aureus	Other priority pathogens	No	No	Yes	No	Unknown	ARX-1796
106	WHO AMR pipeline analysis	2021-11-01	Oral Avibactam prodrug	Antibiotics	DBO-BLI + β-lactam	 Gram-negative infections	Oral	Phase I	NCT03931876	Pfizer/ Arixa Pharmaceuticals	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	Possibly	No	Yes	No	Unknown	ARX-1796
107	WHO AMR pipeline analysis	2021-11-01	Oral Avibactam prodrug	Antibiotics	DBO-BLI + β-lactam	 Gram-negative infections	Oral	Phase I	NCT03931876	Pfizer/ Arixa Pharmaceuticals	Priority pathogens	Other priority pathogens	Other priority pathogens	No	No	Yes	No	Unknown	ARX-1796
108	WHO AMR pipeline analysis	2021-11-01	Oral Avibactam prodrug	Antibiotics	DBO-BLI + β-lactam	 Gram-negative infections	Oral	Phase I	NCT03931876	Pfizer/ Arixa Pharmaceuticals	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	No	No	Yes	No	Unknown	ARX-1796
109	WHO AMR pipeline analysis	2021-11-01	Oral Avibactam prodrug	Antibiotics	DBO-BLI + β-lactam	 Gram-negative infections	Oral	Phase I	NCT03931876	Pfizer/ Arixa Pharmaceuticals	Priority pathogens	Helicobacter pylori	Other priority pathogens	No	No	Yes	No	Unknown	ARX-1796
110	WHO AMR pipeline analysis	2021-11-01	Oral Avibactam prodrug	Antibiotics	DBO-BLI + β-lactam	 Gram-negative infections	Oral	Phase I	NCT03931876	Pfizer/ Arixa Pharmaceuticals	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	No	No	Yes	No	Unknown	ARX-1796
111	WHO AMR pipeline analysis	2021-11-01	Oral Avibactam prodrug	Antibiotics	DBO-BLI + β-lactam	 Gram-negative infections	Oral	Phase I	NCT03931876	Pfizer/ Arixa Pharmaceuticals	Priority pathogens	Enterococcus faecium	Other priority pathogens	No	No	Yes	No	Unknown	ARX-1796
112	WHO AMR pipeline analysis	2021-11-01	Oral Avibactam prodrug	Antibiotics	DBO-BLI + β-lactam	 Gram-negative infections	Oral	Phase I	NCT03931876	Pfizer/ Arixa Pharmaceuticals	Priority pathogens	Enterobacterales	Critical priority pathogens	Yes	No	Yes	No	Unknown	ARX-1796
113	WHO AMR pipeline analysis	2021-11-01	Oral Avibactam prodrug	Antibiotics	DBO-BLI + β-lactam	 Gram-negative infections	Oral	Phase I	NCT03931876	Pfizer/ Arixa Pharmaceuticals	Priority pathogens	Critical priority pathogens	Critical priority pathogens	Yes	No	Yes	No	Unknown	ARX-1796
114	WHO AMR pipeline analysis	2021-11-01	Oral Avibactam prodrug	Antibiotics	DBO-BLI + β-lactam	 Gram-negative infections	Oral	Phase I	NCT03931876	Pfizer/ Arixa Pharmaceuticals	Priority pathogens	Campylobacter spp.	Other priority pathogens	No	No	Yes	No	Unknown	ARX-1796
115	WHO AMR pipeline analysis	2021-11-01	Oral Avibactam prodrug	Antibiotics	DBO-BLI + β-lactam	 Gram-negative infections	Oral	Phase I	NCT03931876	Pfizer/ Arixa Pharmaceuticals	Priority pathogens	All critical priority pathogens	Critical priority pathogens	No	No	Yes	No	Unknown	ARX-1796
116	WHO AMR pipeline analysis	2021-11-01	Oral Avibactam prodrug	Antibiotics	DBO-BLI + β-lactam	 Gram-negative infections	Oral	Phase I	NCT03931876	Pfizer/ Arixa Pharmaceuticals	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	Possibly	No	Yes	No	Unknown	ARX-1796
117	WHO AMR pipeline analysis	2021-11-01		Antibiotics	Carbapenem	cUTI	IV	Phase III	NCT03578588, CTR20190760, CTR20181302	Sichuan Pharmaceutical Holdings Group Ltd	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	No	No	Yes	No	Unknown	Benapenem
118	WHO AMR pipeline analysis	2021-11-01		Antibiotics	Carbapenem	cUTI	IV	Phase III	NCT03578588, CTR20190760, CTR20181302	Sichuan Pharmaceutical Holdings Group Ltd	Priority pathogens	Staphylococcus aureus	Other priority pathogens	No	No	Yes	No	Unknown	Benapenem
119	WHO AMR pipeline analysis	2021-11-01		Antibiotics	Carbapenem	cUTI	IV	Phase III	NCT03578588, CTR20190760, CTR20181302	Sichuan Pharmaceutical Holdings Group Ltd	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	Possibly	No	Yes	No	Unknown	Benapenem
120	WHO AMR pipeline analysis	2021-11-01		Antibiotics	Carbapenem	cUTI	IV	Phase III	NCT03578588, CTR20190760, CTR20181302	Sichuan Pharmaceutical Holdings Group Ltd	Priority pathogens	Other priority pathogens	Other priority pathogens	No	No	Yes	No	Unknown	Benapenem
121	WHO AMR pipeline analysis	2021-11-01		Antibiotics	Carbapenem	cUTI	IV	Phase III	NCT03578588, CTR20190760, CTR20181302	Sichuan Pharmaceutical Holdings Group Ltd	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	No	No	Yes	No	Unknown	Benapenem
122	WHO AMR pipeline analysis	2021-11-01		Antibiotics	Carbapenem	cUTI	IV	Phase III	NCT03578588, CTR20190760, CTR20181302	Sichuan Pharmaceutical Holdings Group Ltd	Priority pathogens	Helicobacter pylori	Other priority pathogens	No	No	Yes	No	Unknown	Benapenem
123	WHO AMR pipeline analysis	2021-11-01		Antibiotics	Carbapenem	cUTI	IV	Phase III	NCT03578588, CTR20190760, CTR20181302	Sichuan Pharmaceutical Holdings Group Ltd	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	No	No	Yes	No	Unknown	Benapenem
124	WHO AMR pipeline analysis	2021-11-01		Antibiotics	Carbapenem	cUTI	IV	Phase III	NCT03578588, CTR20190760, CTR20181302	Sichuan Pharmaceutical Holdings Group Ltd	Priority pathogens	Enterococcus faecium	Other priority pathogens	No	No	Yes	No	Unknown	Benapenem
125	WHO AMR pipeline analysis	2021-11-01		Antibiotics	Carbapenem	cUTI	IV	Phase III	NCT03578588, CTR20190760, CTR20181302	Sichuan Pharmaceutical Holdings Group Ltd	Priority pathogens	Enterobacterales	Critical priority pathogens	Possibly	No	Yes	No	Unknown	Benapenem
126	WHO AMR pipeline analysis	2021-11-01		Antibiotics	Carbapenem	cUTI	IV	Phase III	NCT03578588, CTR20190760, CTR20181302	Sichuan Pharmaceutical Holdings Group Ltd	Priority pathogens	Critical priority pathogens	Critical priority pathogens	Yes	No	Yes	No	Unknown	Benapenem
127	WHO AMR pipeline analysis	2021-11-01		Antibiotics	Carbapenem	cUTI	IV	Phase III	NCT03578588, CTR20190760, CTR20181302	Sichuan Pharmaceutical Holdings Group Ltd	Priority pathogens	Campylobacter spp.	Other priority pathogens	No	No	Yes	No	Unknown	Benapenem
128	WHO AMR pipeline analysis	2021-11-01		Antibiotics	Carbapenem	cUTI	IV	Phase III	NCT03578588, CTR20190760, CTR20181302	Sichuan Pharmaceutical Holdings Group Ltd	Priority pathogens	All critical priority pathogens	Critical priority pathogens	No	No	Yes	No	Unknown	Benapenem
129	WHO AMR pipeline analysis	2021-11-01		Antibiotics	Carbapenem	cUTI	IV	Phase III	NCT03578588, CTR20190760, CTR20181302	Sichuan Pharmaceutical Holdings Group Ltd	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	Possibly	No	Yes	No	Unknown	Benapenem
130	WHO AMR pipeline analysis	2021-11-01		Antibiotics	Topoisomerase	Gram-negative and Gram-positive bacterial infections	IV	Phase I	NCT05088421	Bugworks Research	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	Yes	Inconclusive	Yes	No	Unknown	BWC0977
131	WHO AMR pipeline analysis	2021-11-01		Antibiotics	Topoisomerase	Gram-negative and Gram-positive bacterial infections	IV	Phase I	NCT05088421	Bugworks Research	Priority pathogens	Staphylococcus aureus	Other priority pathogens	Yes	Inconclusive	Yes	No	Unknown	BWC0977
132	WHO AMR pipeline analysis	2021-11-01		Antibiotics	Topoisomerase	Gram-negative and Gram-positive bacterial infections	IV	Phase I	NCT05088421	Bugworks Research	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	Possibly	Inconclusive	Yes	No	Unknown	BWC0977
133	WHO AMR pipeline analysis	2021-11-01		Antibiotics	Topoisomerase	Gram-negative and Gram-positive bacterial infections	IV	Phase I	NCT05088421	Bugworks Research	Priority pathogens	Other priority pathogens	Other priority pathogens	Yes	Inconclusive	Yes	No	Unknown	BWC0977
134	WHO AMR pipeline analysis	2021-11-01		Antibiotics	Topoisomerase	Gram-negative and Gram-positive bacterial infections	IV	Phase I	NCT05088421	Bugworks Research	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	No	Inconclusive	Yes	No	Unknown	BWC0977
135	WHO AMR pipeline analysis	2021-11-01		Antibiotics	Topoisomerase	Gram-negative and Gram-positive bacterial infections	IV	Phase I	NCT05088421	Bugworks Research	Priority pathogens	Helicobacter pylori	Other priority pathogens	No	Inconclusive	Yes	No	Unknown	BWC0977
136	WHO AMR pipeline analysis	2021-11-01		Antibiotics	Topoisomerase	Gram-negative and Gram-positive bacterial infections	IV	Phase I	NCT05088421	Bugworks Research	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	Yes	Inconclusive	Yes	No	Unknown	BWC0977
137	WHO AMR pipeline analysis	2021-11-01		Antibiotics	Topoisomerase	Gram-negative and Gram-positive bacterial infections	IV	Phase I	NCT05088421	Bugworks Research	Priority pathogens	Enterococcus faecium	Other priority pathogens	Yes	Inconclusive	Yes	No	Unknown	BWC0977
138	WHO AMR pipeline analysis	2021-11-01		Antibiotics	Topoisomerase	Gram-negative and Gram-positive bacterial infections	IV	Phase I	NCT05088421	Bugworks Research	Priority pathogens	Enterobacterales	Critical priority pathogens	Possibly	Inconclusive	Yes	No	Unknown	BWC0977
139	WHO AMR pipeline analysis	2021-11-01		Antibiotics	Topoisomerase	Gram-negative and Gram-positive bacterial infections	IV	Phase I	NCT05088421	Bugworks Research	Priority pathogens	Critical priority pathogens	Critical priority pathogens	Possibly	Inconclusive	Yes	No	Unknown	BWC0977
140	WHO AMR pipeline analysis	2021-11-01		Antibiotics	Topoisomerase	Gram-negative and Gram-positive bacterial infections	IV	Phase I	NCT05088421	Bugworks Research	Priority pathogens	Campylobacter spp.	Other priority pathogens	No	Inconclusive	Yes	No	Unknown	BWC0977
141	WHO AMR pipeline analysis	2021-11-01		Antibiotics	Topoisomerase	Gram-negative and Gram-positive bacterial infections	IV	Phase I	NCT05088421	Bugworks Research	Priority pathogens	All critical priority pathogens	Critical priority pathogens	Yes	Inconclusive	Yes	No	Unknown	BWC0977
142	WHO AMR pipeline analysis	2021-11-01		Antibiotics	Topoisomerase	Gram-negative and Gram-positive bacterial infections	IV	Phase I	NCT05088421	Bugworks Research	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	Possibly	Inconclusive	Yes	No	Unknown	BWC0977
143	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT05010577	BiomX	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
144	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT05010577	BiomX	Priority pathogens	Staphylococcus aureus	Other priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
145	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT05010577	BiomX	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	Yes	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
146	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT05010577	BiomX	Priority pathogens	Other priority pathogens	Other priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
147	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT05010577	BiomX	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
148	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT05010577	BiomX	Priority pathogens	Helicobacter pylori	Other priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
149	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT05010577	BiomX	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
150	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT05010577	BiomX	Priority pathogens	Enterococcus faecium	Other priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
151	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT05010577	BiomX	Priority pathogens	Enterobacterales	Critical priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
152	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT05010577	BiomX	Priority pathogens	Critical priority pathogens	Critical priority pathogens	Yes	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
153	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT05010577	BiomX	Priority pathogens	Campylobacter spp.	Other priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
154	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT05010577	BiomX	Priority pathogens	All critical priority pathogens	Critical priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
155	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT05010577	BiomX	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
156	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Broad spectrum anti-toxin liposomal agent and nanoparticle	S. pneumonia severe pneumonia	IV	Phase I	NCT02583373	"Eagle Pharmaceuticals
(Combioxin SA)"	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	Yes	No	Yes	No	Unknown	Miscellaneous
157	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Broad spectrum anti-toxin liposomal agent and nanoparticle	S. pneumonia severe pneumonia	IV	Phase I	NCT02583373	"Eagle Pharmaceuticals
(Combioxin SA)"	Priority pathogens	Staphylococcus aureus	Other priority pathogens	No	No	Yes	No	Unknown	Miscellaneous
158	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Broad spectrum anti-toxin liposomal agent and nanoparticle	S. pneumonia severe pneumonia	IV	Phase I	NCT02583373	"Eagle Pharmaceuticals
(Combioxin SA)"	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	No	No	Yes	No	Unknown	Miscellaneous
159	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Broad spectrum anti-toxin liposomal agent and nanoparticle	S. pneumonia severe pneumonia	IV	Phase I	NCT02583373	"Eagle Pharmaceuticals
(Combioxin SA)"	Priority pathogens	Other priority pathogens	Other priority pathogens	No	No	Yes	No	Unknown	Miscellaneous
160	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Broad spectrum anti-toxin liposomal agent and nanoparticle	S. pneumonia severe pneumonia	IV	Phase I	NCT02583373	"Eagle Pharmaceuticals
(Combioxin SA)"	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	No	No	Yes	No	Unknown	Miscellaneous
161	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Broad spectrum anti-toxin liposomal agent and nanoparticle	S. pneumonia severe pneumonia	IV	Phase I	NCT02583373	"Eagle Pharmaceuticals
(Combioxin SA)"	Priority pathogens	Helicobacter pylori	Other priority pathogens	No	No	Yes	No	Unknown	Miscellaneous
162	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Broad spectrum anti-toxin liposomal agent and nanoparticle	S. pneumonia severe pneumonia	IV	Phase I	NCT02583373	"Eagle Pharmaceuticals
(Combioxin SA)"	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	Yes	No	Yes	No	Unknown	Miscellaneous
163	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Broad spectrum anti-toxin liposomal agent and nanoparticle	S. pneumonia severe pneumonia	IV	Phase I	NCT02583373	"Eagle Pharmaceuticals
(Combioxin SA)"	Priority pathogens	Enterococcus faecium	Other priority pathogens	No	No	Yes	No	Unknown	Miscellaneous
164	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Broad spectrum anti-toxin liposomal agent and nanoparticle	S. pneumonia severe pneumonia	IV	Phase I	NCT02583373	"Eagle Pharmaceuticals
(Combioxin SA)"	Priority pathogens	Enterobacterales	Critical priority pathogens	No	No	Yes	No	Unknown	Miscellaneous
165	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Broad spectrum anti-toxin liposomal agent and nanoparticle	S. pneumonia severe pneumonia	IV	Phase I	NCT02583373	"Eagle Pharmaceuticals
(Combioxin SA)"	Priority pathogens	Critical priority pathogens	Critical priority pathogens	No	No	Yes	No	Unknown	Miscellaneous
166	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Broad spectrum anti-toxin liposomal agent and nanoparticle	S. pneumonia severe pneumonia	IV	Phase I	NCT02583373	"Eagle Pharmaceuticals
(Combioxin SA)"	Priority pathogens	Campylobacter spp.	Other priority pathogens	No	No	Yes	No	Unknown	Miscellaneous
167	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Broad spectrum anti-toxin liposomal agent and nanoparticle	S. pneumonia severe pneumonia	IV	Phase I	NCT02583373	"Eagle Pharmaceuticals
(Combioxin SA)"	Priority pathogens	All critical priority pathogens	Critical priority pathogens	No	No	Yes	No	Unknown	Miscellaneous
168	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Broad spectrum anti-toxin liposomal agent and nanoparticle	S. pneumonia severe pneumonia	IV	Phase I	NCT02583373	"Eagle Pharmaceuticals
(Combioxin SA)"	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	No	No	Yes	No	Unknown	Miscellaneous
169	WHO AMR pipeline analysis	2021-11-01	Exebacase	Non-traditional	Phage endolysin	S. aureus bacteremia	IV	Phase III	NCT04160468	Contrafect	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
170	WHO AMR pipeline analysis	2021-11-01	Exebacase	Non-traditional	Phage endolysin	S. aureus bacteremia	IV	Phase III	NCT04160468	Contrafect	Priority pathogens	Staphylococcus aureus	Other priority pathogens	Yes	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
171	WHO AMR pipeline analysis	2021-11-01	Exebacase	Non-traditional	Phage endolysin	S. aureus bacteremia	IV	Phase III	NCT04160468	Contrafect	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
172	WHO AMR pipeline analysis	2021-11-01	Exebacase	Non-traditional	Phage endolysin	S. aureus bacteremia	IV	Phase III	NCT04160468	Contrafect	Priority pathogens	Other priority pathogens	Other priority pathogens	Yes	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
173	WHO AMR pipeline analysis	2021-11-01	Exebacase	Non-traditional	Phage endolysin	S. aureus bacteremia	IV	Phase III	NCT04160468	Contrafect	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
174	WHO AMR pipeline analysis	2021-11-01	Exebacase	Non-traditional	Phage endolysin	S. aureus bacteremia	IV	Phase III	NCT04160468	Contrafect	Priority pathogens	Helicobacter pylori	Other priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
175	WHO AMR pipeline analysis	2021-11-01	Exebacase	Non-traditional	Phage endolysin	S. aureus bacteremia	IV	Phase III	NCT04160468	Contrafect	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	Yes	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
176	WHO AMR pipeline analysis	2021-11-01	Exebacase	Non-traditional	Phage endolysin	S. aureus bacteremia	IV	Phase III	NCT04160468	Contrafect	Priority pathogens	Enterococcus faecium	Other priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
177	WHO AMR pipeline analysis	2021-11-01	Exebacase	Non-traditional	Phage endolysin	S. aureus bacteremia	IV	Phase III	NCT04160468	Contrafect	Priority pathogens	Enterobacterales	Critical priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
178	WHO AMR pipeline analysis	2021-11-01	Exebacase	Non-traditional	Phage endolysin	S. aureus bacteremia	IV	Phase III	NCT04160468	Contrafect	Priority pathogens	Critical priority pathogens	Critical priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
179	WHO AMR pipeline analysis	2021-11-01	Exebacase	Non-traditional	Phage endolysin	S. aureus bacteremia	IV	Phase III	NCT04160468	Contrafect	Priority pathogens	Campylobacter spp.	Other priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
180	WHO AMR pipeline analysis	2021-11-01	Exebacase	Non-traditional	Phage endolysin	S. aureus bacteremia	IV	Phase III	NCT04160468	Contrafect	Priority pathogens	All critical priority pathogens	Critical priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
181	WHO AMR pipeline analysis	2021-11-01	Exebacase	Non-traditional	Phage endolysin	S. aureus bacteremia	IV	Phase III	NCT04160468	Contrafect	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
182	WHO AMR pipeline analysis	2021-11-01	LCB01-0371	Antibiotics	Oxazolidinone	Pulmonary tuberculosis, Gram-positive bacterial infections	Oral	Phase II	NCT02836483, NCT04550832	LegoChem Biosciences Inc., HaiHe Biopharma	Priority pathogens	Staphylococcus aureus	Other priority pathogens	Yes	No	Yes	Yes	Unknown	Delpazolid
183	WHO AMR pipeline analysis	2021-11-01	ETX2514	Antibiotics	DBO-BLI /PBP2 binder + β-lactam-BLI/PBP1,3 binder	A. baumannii HAP, VAP	IV	Phase III	NCT03445195, NCT03894046	Entasis Therapeutics Inc.	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	No	No	Yes	No	Unknown	Durlobactam + sulbactam
184	WHO AMR pipeline analysis	2021-11-01	ETX2514	Antibiotics	DBO-BLI /PBP2 binder + β-lactam-BLI/PBP1,3 binder	A. baumannii HAP, VAP	IV	Phase III	NCT03445195, NCT03894046	Entasis Therapeutics Inc.	Priority pathogens	Staphylococcus aureus	Other priority pathogens	No	No	Yes	No	Unknown	Durlobactam + sulbactam
185	WHO AMR pipeline analysis	2021-11-01	ETX2514	Antibiotics	DBO-BLI /PBP2 binder + β-lactam-BLI/PBP1,3 binder	A. baumannii HAP, VAP	IV	Phase III	NCT03445195, NCT03894046	Entasis Therapeutics Inc.	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	Possibly	No	Yes	No	Unknown	Durlobactam + sulbactam
186	WHO AMR pipeline analysis	2021-11-01	ETX2514	Antibiotics	DBO-BLI /PBP2 binder + β-lactam-BLI/PBP1,3 binder	A. baumannii HAP, VAP	IV	Phase III	NCT03445195, NCT03894046	Entasis Therapeutics Inc.	Priority pathogens	Other priority pathogens	Other priority pathogens	No	No	Yes	No	Unknown	Durlobactam + sulbactam
187	WHO AMR pipeline analysis	2021-11-01	ETX2514	Antibiotics	DBO-BLI /PBP2 binder + β-lactam-BLI/PBP1,3 binder	A. baumannii HAP, VAP	IV	Phase III	NCT03445195, NCT03894046	Entasis Therapeutics Inc.	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	No	No	Yes	No	Unknown	Durlobactam + sulbactam
188	WHO AMR pipeline analysis	2021-11-01	ETX2514	Antibiotics	DBO-BLI /PBP2 binder + β-lactam-BLI/PBP1,3 binder	A. baumannii HAP, VAP	IV	Phase III	NCT03445195, NCT03894046	Entasis Therapeutics Inc.	Priority pathogens	Helicobacter pylori	Other priority pathogens	No	No	Yes	No	Unknown	Durlobactam + sulbactam
189	WHO AMR pipeline analysis	2021-11-01	ETX2514	Antibiotics	DBO-BLI /PBP2 binder + β-lactam-BLI/PBP1,3 binder	A. baumannii HAP, VAP	IV	Phase III	NCT03445195, NCT03894046	Entasis Therapeutics Inc.	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	No	No	Yes	No	Unknown	Durlobactam + sulbactam
190	WHO AMR pipeline analysis	2021-11-01	ETX2514	Antibiotics	DBO-BLI /PBP2 binder + β-lactam-BLI/PBP1,3 binder	A. baumannii HAP, VAP	IV	Phase III	NCT03445195, NCT03894046	Entasis Therapeutics Inc.	Priority pathogens	Enterococcus faecium	Other priority pathogens	No	No	Yes	No	Unknown	Durlobactam + sulbactam
191	WHO AMR pipeline analysis	2021-11-01	ETX2514	Antibiotics	DBO-BLI /PBP2 binder + β-lactam-BLI/PBP1,3 binder	A. baumannii HAP, VAP	IV	Phase III	NCT03445195, NCT03894046	Entasis Therapeutics Inc.	Priority pathogens	Enterobacterales	Critical priority pathogens	Possibly	No	Yes	No	Unknown	Durlobactam + sulbactam
192	WHO AMR pipeline analysis	2021-11-01	ETX2514	Antibiotics	DBO-BLI /PBP2 binder + β-lactam-BLI/PBP1,3 binder	A. baumannii HAP, VAP	IV	Phase III	NCT03445195, NCT03894046	Entasis Therapeutics Inc.	Priority pathogens	Critical priority pathogens	Critical priority pathogens	Yes	No	Yes	No	Unknown	Durlobactam + sulbactam
193	WHO AMR pipeline analysis	2021-11-01	ETX2514	Antibiotics	DBO-BLI /PBP2 binder + β-lactam-BLI/PBP1,3 binder	A. baumannii HAP, VAP	IV	Phase III	NCT03445195, NCT03894046	Entasis Therapeutics Inc.	Priority pathogens	Campylobacter spp.	Other priority pathogens	No	No	Yes	No	Unknown	Durlobactam + sulbactam
194	WHO AMR pipeline analysis	2021-11-01	ETX2514	Antibiotics	DBO-BLI /PBP2 binder + β-lactam-BLI/PBP1,3 binder	A. baumannii HAP, VAP	IV	Phase III	NCT03445195, NCT03894046	Entasis Therapeutics Inc.	Priority pathogens	All critical priority pathogens	Critical priority pathogens	No	No	Yes	No	Unknown	Durlobactam + sulbactam
195	WHO AMR pipeline analysis	2021-11-01	ETX2514	Antibiotics	DBO-BLI /PBP2 binder + β-lactam-BLI/PBP1,3 binder	A. baumannii HAP, VAP	IV	Phase III	NCT03445195, NCT03894046	Entasis Therapeutics Inc.	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	Yes	No	Yes	No	Unknown	Durlobactam + sulbactam
196	WHO AMR pipeline analysis	2021-11-01	Apramycin	Antibiotics	Aminoglycoside	Bacterial infections	IV	Phase I	NCT04105205	Juvabis	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	No	No	Yes	No	Unknown	EBL-1003
197	WHO AMR pipeline analysis	2021-11-01	Apramycin	Antibiotics	Aminoglycoside	Bacterial infections	IV	Phase I	NCT04105205	Juvabis	Priority pathogens	Staphylococcus aureus	Other priority pathogens	No	No	Yes	No	Unknown	EBL-1003
198	WHO AMR pipeline analysis	2021-11-01	Apramycin	Antibiotics	Aminoglycoside	Bacterial infections	IV	Phase I	NCT04105205	Juvabis	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	Possibly	No	Yes	No	Unknown	EBL-1003
199	WHO AMR pipeline analysis	2021-11-01	Apramycin	Antibiotics	Aminoglycoside	Bacterial infections	IV	Phase I	NCT04105205	Juvabis	Priority pathogens	Other priority pathogens	Other priority pathogens	No	No	Yes	No	Unknown	EBL-1003
200	WHO AMR pipeline analysis	2021-11-01	Apramycin	Antibiotics	Aminoglycoside	Bacterial infections	IV	Phase I	NCT04105205	Juvabis	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	No	No	Yes	No	Unknown	EBL-1003
201	WHO AMR pipeline analysis	2021-11-01	Apramycin	Antibiotics	Aminoglycoside	Bacterial infections	IV	Phase I	NCT04105205	Juvabis	Priority pathogens	Helicobacter pylori	Other priority pathogens	No	No	Yes	No	Unknown	EBL-1003
202	WHO AMR pipeline analysis	2021-11-01	Apramycin	Antibiotics	Aminoglycoside	Bacterial infections	IV	Phase I	NCT04105205	Juvabis	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	No	No	Yes	No	Unknown	EBL-1003
203	WHO AMR pipeline analysis	2021-11-01	Apramycin	Antibiotics	Aminoglycoside	Bacterial infections	IV	Phase I	NCT04105205	Juvabis	Priority pathogens	Enterococcus faecium	Other priority pathogens	No	No	Yes	No	Unknown	EBL-1003
204	WHO AMR pipeline analysis	2021-11-01	Apramycin	Antibiotics	Aminoglycoside	Bacterial infections	IV	Phase I	NCT04105205	Juvabis	Priority pathogens	Enterobacterales	Critical priority pathogens	Yes	No	Yes	No	Unknown	EBL-1003
205	WHO AMR pipeline analysis	2021-11-01	Apramycin	Antibiotics	Aminoglycoside	Bacterial infections	IV	Phase I	NCT04105205	Juvabis	Priority pathogens	Critical priority pathogens	Critical priority pathogens	Yes	No	Yes	No	Unknown	EBL-1003
206	WHO AMR pipeline analysis	2021-11-01	Apramycin	Antibiotics	Aminoglycoside	Bacterial infections	IV	Phase I	NCT04105205	Juvabis	Priority pathogens	Campylobacter spp.	Other priority pathogens	No	No	Yes	No	Unknown	EBL-1003
207	WHO AMR pipeline analysis	2021-11-01	Apramycin	Antibiotics	Aminoglycoside	Bacterial infections	IV	Phase I	NCT04105205	Juvabis	Priority pathogens	All critical priority pathogens	Critical priority pathogens	No	No	Yes	No	Unknown	EBL-1003
208	WHO AMR pipeline analysis	2021-11-01	Apramycin	Antibiotics	Aminoglycoside	Bacterial infections	IV	Phase I	NCT04105205	Juvabis	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	Yes	No	Yes	No	Unknown	EBL-1003
209	WHO AMR pipeline analysis	2021-11-01	AAl101 + cefepime	Antibiotics	β-lactam BLI + cephalosporin	cUTI, AP	IV	Phase III	EudraCT 2017-004868-35, NCT03687255	Allecra therapeutics	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	Possibly	No	Yes	No	Unknown	Enmetazobactam + cefepime
210	WHO AMR pipeline analysis	2021-11-01	AAl101 + cefepime	Antibiotics	β-lactam BLI + cephalosporin	cUTI, AP	IV	Phase III	EudraCT 2017-004868-35, NCT03687255	Allecra therapeutics	Priority pathogens	Enterobacterales	Critical priority pathogens	Possibly	No	Yes	No	Unknown	Enmetazobactam + cefepime
211	WHO AMR pipeline analysis	2021-11-01	AAl101 + cefepime	Antibiotics	β-lactam BLI + cephalosporin	cUTI, AP	IV	Phase III	EudraCT 2017-004868-35, NCT03687255	Allecra therapeutics	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	Possibly	No	Yes	No	Unknown	Enmetazobactam + cefepime
212	WHO AMR pipeline analysis	2021-11-01	AAl101 + cefepime	Antibiotics	β-lactam BLI + cephalosporin	cUTI, AP	IV	Phase III	EudraCT 2017-004868-35, NCT03687255	Allecra therapeutics	Priority pathogens	Campylobacter spp.	Other priority pathogens	No	No	Yes	No	Unknown	Enmetazobactam + cefepime
213	WHO AMR pipeline analysis	2021-11-01	AAl101 + cefepime	Antibiotics	β-lactam BLI + cephalosporin	cUTI, AP	IV	Phase III	EudraCT 2017-004868-35, NCT03687255	Allecra therapeutics	Priority pathogens	Enterococcus faecium	Other priority pathogens	No	No	Yes	No	Unknown	Enmetazobactam + cefepime
214	WHO AMR pipeline analysis	2021-11-01	AAl101 + cefepime	Antibiotics	β-lactam BLI + cephalosporin	cUTI, AP	IV	Phase III	EudraCT 2017-004868-35, NCT03687255	Allecra therapeutics	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	No	No	Yes	No	Unknown	Enmetazobactam + cefepime
215	WHO AMR pipeline analysis	2021-11-01	AAl101 + cefepime	Antibiotics	β-lactam BLI + cephalosporin	cUTI, AP	IV	Phase III	EudraCT 2017-004868-35, NCT03687255	Allecra therapeutics	Priority pathogens	Helicobacter pylori	Other priority pathogens	No	No	Yes	No	Unknown	Enmetazobactam + cefepime
216	WHO AMR pipeline analysis	2021-11-01	AAl101 + cefepime	Antibiotics	β-lactam BLI + cephalosporin	cUTI, AP	IV	Phase III	EudraCT 2017-004868-35, NCT03687255	Allecra therapeutics	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	No	No	Yes	No	Unknown	Enmetazobactam + cefepime
217	WHO AMR pipeline analysis	2021-11-01	AAl101 + cefepime	Antibiotics	β-lactam BLI + cephalosporin	cUTI, AP	IV	Phase III	EudraCT 2017-004868-35, NCT03687255	Allecra therapeutics	Priority pathogens	Other priority pathogens	Other priority pathogens	No	No	Yes	No	Unknown	Enmetazobactam + cefepime
218	WHO AMR pipeline analysis	2021-11-01	AAl101 + cefepime	Antibiotics	β-lactam BLI + cephalosporin	cUTI, AP	IV	Phase III	EudraCT 2017-004868-35, NCT03687255	Allecra therapeutics	Priority pathogens	Staphylococcus aureus	Other priority pathogens	No	No	Yes	No	Unknown	Enmetazobactam + cefepime
219	WHO AMR pipeline analysis	2021-11-01	AAl101 + cefepime	Antibiotics	β-lactam BLI + cephalosporin	cUTI, AP	IV	Phase III	EudraCT 2017-004868-35, NCT03687255	Allecra therapeutics	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	No	No	Yes	No	Unknown	Enmetazobactam + cefepime
220	WHO AMR pipeline analysis	2021-11-01	AAl101 + cefepime	Antibiotics	β-lactam BLI + cephalosporin	cUTI, AP	IV	Phase III	EudraCT 2017-004868-35, NCT03687255	Allecra therapeutics	Priority pathogens	All critical priority pathogens	Critical priority pathogens	No	No	Yes	No	Unknown	Enmetazobactam + cefepime
221	WHO AMR pipeline analysis	2021-11-01	AAl101 + cefepime	Antibiotics	β-lactam BLI + cephalosporin	cUTI, AP	IV	Phase III	EudraCT 2017-004868-35, NCT03687255	Allecra therapeutics	Priority pathogens	Critical priority pathogens	Critical priority pathogens	Yes	No	Yes	No	Unknown	Enmetazobactam + cefepime
222	WHO AMR pipeline analysis	2021-11-01	–	Antibiotics	DBO-BLI/PBP2 binder + cephalosporin	Active against ESBL, OXA-48 and KPC, but not MBL-producing Enterobacterales	Oral	Phase I	NCT03491748	Entasis Therapeutics Inc.	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	No	No	Yes	No	Unknown	ETX0282 + cefpodoxime
223	WHO AMR pipeline analysis	2021-11-01	–	Antibiotics	DBO-BLI/PBP2 binder + cephalosporin	Active against ESBL, OXA-48 and KPC, but not MBL-producing Enterobacterales	Oral	Phase I	NCT03491748	Entasis Therapeutics Inc.	Priority pathogens	Staphylococcus aureus	Other priority pathogens	No	No	Yes	No	Unknown	ETX0282 + cefpodoxime
224	WHO AMR pipeline analysis	2021-11-01	–	Antibiotics	DBO-BLI/PBP2 binder + cephalosporin	Active against ESBL, OXA-48 and KPC, but not MBL-producing Enterobacterales	Oral	Phase I	NCT03491748	Entasis Therapeutics Inc.	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	Possibly	No	Yes	No	Unknown	ETX0282 + cefpodoxime
225	WHO AMR pipeline analysis	2021-11-01	–	Antibiotics	DBO-BLI/PBP2 binder + cephalosporin	Active against ESBL, OXA-48 and KPC, but not MBL-producing Enterobacterales	Oral	Phase I	NCT03491748	Entasis Therapeutics Inc.	Priority pathogens	Other priority pathogens	Other priority pathogens	No	No	Yes	No	Unknown	ETX0282 + cefpodoxime
226	WHO AMR pipeline analysis	2021-11-01	–	Antibiotics	DBO-BLI/PBP2 binder + cephalosporin	Active against ESBL, OXA-48 and KPC, but not MBL-producing Enterobacterales	Oral	Phase I	NCT03491748	Entasis Therapeutics Inc.	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	No	No	Yes	No	Unknown	ETX0282 + cefpodoxime
227	WHO AMR pipeline analysis	2021-11-01	–	Antibiotics	DBO-BLI/PBP2 binder + cephalosporin	Active against ESBL, OXA-48 and KPC, but not MBL-producing Enterobacterales	Oral	Phase I	NCT03491748	Entasis Therapeutics Inc.	Priority pathogens	Helicobacter pylori	Other priority pathogens	No	No	Yes	No	Unknown	ETX0282 + cefpodoxime
228	WHO AMR pipeline analysis	2021-11-01	–	Antibiotics	DBO-BLI/PBP2 binder + cephalosporin	Active against ESBL, OXA-48 and KPC, but not MBL-producing Enterobacterales	Oral	Phase I	NCT03491748	Entasis Therapeutics Inc.	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	No	No	Yes	No	Unknown	ETX0282 + cefpodoxime
229	WHO AMR pipeline analysis	2021-11-01	–	Antibiotics	DBO-BLI/PBP2 binder + cephalosporin	Active against ESBL, OXA-48 and KPC, but not MBL-producing Enterobacterales	Oral	Phase I	NCT03491748	Entasis Therapeutics Inc.	Priority pathogens	Enterococcus faecium	Other priority pathogens	No	No	Yes	No	Unknown	ETX0282 + cefpodoxime
230	WHO AMR pipeline analysis	2021-11-01	–	Antibiotics	DBO-BLI/PBP2 binder + cephalosporin	Active against ESBL, OXA-48 and KPC, but not MBL-producing Enterobacterales	Oral	Phase I	NCT03491748	Entasis Therapeutics Inc.	Priority pathogens	Enterobacterales	Critical priority pathogens	Yes	No	Yes	No	Unknown	ETX0282 + cefpodoxime
231	WHO AMR pipeline analysis	2021-11-01	–	Antibiotics	DBO-BLI/PBP2 binder + cephalosporin	Active against ESBL, OXA-48 and KPC, but not MBL-producing Enterobacterales	Oral	Phase I	NCT03491748	Entasis Therapeutics Inc.	Priority pathogens	Critical priority pathogens	Critical priority pathogens	Yes	No	Yes	No	Unknown	ETX0282 + cefpodoxime
232	WHO AMR pipeline analysis	2021-11-01	–	Antibiotics	DBO-BLI/PBP2 binder + cephalosporin	Active against ESBL, OXA-48 and KPC, but not MBL-producing Enterobacterales	Oral	Phase I	NCT03491748	Entasis Therapeutics Inc.	Priority pathogens	Campylobacter spp.	Other priority pathogens	No	No	Yes	No	Unknown	ETX0282 + cefpodoxime
233	WHO AMR pipeline analysis	2021-11-01	–	Antibiotics	DBO-BLI/PBP2 binder + cephalosporin	Active against ESBL, OXA-48 and KPC, but not MBL-producing Enterobacterales	Oral	Phase I	NCT03491748	Entasis Therapeutics Inc.	Priority pathogens	All critical priority pathogens	Critical priority pathogens	No	No	Yes	No	Unknown	ETX0282 + cefpodoxime
234	WHO AMR pipeline analysis	2021-11-01	–	Antibiotics	DBO-BLI/PBP2 binder + cephalosporin	Active against ESBL, OXA-48 and KPC, but not MBL-producing Enterobacterales	Oral	Phase I	NCT03491748	Entasis Therapeutics Inc.	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	Possibly	No	Yes	No	Unknown	ETX0282 + cefpodoxime
235	WHO AMR pipeline analysis	2021-11-01	Fluorothyazinone	Non-traditional	Type III secretion system inhibition + cefepime	P. aeruginosa cUTI	Oral	Phase II	NCT03638830	Gamaleya Research Institute of Epidemiology and Microbiology	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	No	No	Yes	No	Unknown	Miscellaneous
236	WHO AMR pipeline analysis	2021-11-01	Fluorothyazinone	Non-traditional	Type III secretion system inhibition + cefepime	P. aeruginosa cUTI	Oral	Phase II	NCT03638830	Gamaleya Research Institute of Epidemiology and Microbiology	Priority pathogens	Staphylococcus aureus	Other priority pathogens	No	No	Yes	No	Unknown	Miscellaneous
237	WHO AMR pipeline analysis	2021-11-01	Fluorothyazinone	Non-traditional	Type III secretion system inhibition + cefepime	P. aeruginosa cUTI	Oral	Phase II	NCT03638830	Gamaleya Research Institute of Epidemiology and Microbiology	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	Yes	No	Yes	No	Unknown	Miscellaneous
238	WHO AMR pipeline analysis	2021-11-01	Fluorothyazinone	Non-traditional	Type III secretion system inhibition + cefepime	P. aeruginosa cUTI	Oral	Phase II	NCT03638830	Gamaleya Research Institute of Epidemiology and Microbiology	Priority pathogens	Other priority pathogens	Other priority pathogens	No	No	Yes	No	Unknown	Miscellaneous
239	WHO AMR pipeline analysis	2021-11-01	Fluorothyazinone	Non-traditional	Type III secretion system inhibition + cefepime	P. aeruginosa cUTI	Oral	Phase II	NCT03638830	Gamaleya Research Institute of Epidemiology and Microbiology	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	No	No	Yes	No	Unknown	Miscellaneous
240	WHO AMR pipeline analysis	2021-11-01	Fluorothyazinone	Non-traditional	Type III secretion system inhibition + cefepime	P. aeruginosa cUTI	Oral	Phase II	NCT03638830	Gamaleya Research Institute of Epidemiology and Microbiology	Priority pathogens	Helicobacter pylori	Other priority pathogens	No	No	Yes	No	Unknown	Miscellaneous
241	WHO AMR pipeline analysis	2021-11-01	Fluorothyazinone	Non-traditional	Type III secretion system inhibition + cefepime	P. aeruginosa cUTI	Oral	Phase II	NCT03638830	Gamaleya Research Institute of Epidemiology and Microbiology	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	No	No	Yes	No	Unknown	Miscellaneous
242	WHO AMR pipeline analysis	2021-11-01	Fluorothyazinone	Non-traditional	Type III secretion system inhibition + cefepime	P. aeruginosa cUTI	Oral	Phase II	NCT03638830	Gamaleya Research Institute of Epidemiology and Microbiology	Priority pathogens	Enterococcus faecium	Other priority pathogens	No	No	Yes	No	Unknown	Miscellaneous
243	WHO AMR pipeline analysis	2021-11-01	Fluorothyazinone	Non-traditional	Type III secretion system inhibition + cefepime	P. aeruginosa cUTI	Oral	Phase II	NCT03638830	Gamaleya Research Institute of Epidemiology and Microbiology	Priority pathogens	Enterobacterales	Critical priority pathogens	No	No	Yes	No	Unknown	Miscellaneous
244	WHO AMR pipeline analysis	2021-11-01	Fluorothyazinone	Non-traditional	Type III secretion system inhibition + cefepime	P. aeruginosa cUTI	Oral	Phase II	NCT03638830	Gamaleya Research Institute of Epidemiology and Microbiology	Priority pathogens	Critical priority pathogens	Critical priority pathogens	Yes	No	Yes	No	Unknown	Miscellaneous
245	WHO AMR pipeline analysis	2021-11-01	Fluorothyazinone	Non-traditional	Type III secretion system inhibition + cefepime	P. aeruginosa cUTI	Oral	Phase II	NCT03638830	Gamaleya Research Institute of Epidemiology and Microbiology	Priority pathogens	Campylobacter spp.	Other priority pathogens	No	No	Yes	No	Unknown	Miscellaneous
246	WHO AMR pipeline analysis	2021-11-01	Fluorothyazinone	Non-traditional	Type III secretion system inhibition + cefepime	P. aeruginosa cUTI	Oral	Phase II	NCT03638830	Gamaleya Research Institute of Epidemiology and Microbiology	Priority pathogens	All critical priority pathogens	Critical priority pathogens	No	No	Yes	No	Unknown	Miscellaneous
247	WHO AMR pipeline analysis	2021-11-01	Fluorothyazinone	Non-traditional	Type III secretion system inhibition + cefepime	P. aeruginosa cUTI	Oral	Phase II	NCT03638830	Gamaleya Research Institute of Epidemiology and Microbiology	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	No	No	Yes	No	Unknown	Miscellaneous
248	WHO AMR pipeline analysis	2021-11-01	GSK2140944	Antibiotics	Topoisomerase Inhibitors (Triazaacenaphthylene)	Uncomplicated urogenital gonorrhea and uUTI	IV, Oral	Phase III	 NCT04010539, NCT04020341	GSK	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	No	Yes	Yes	No	Unknown	Gepotidacin
249	WHO AMR pipeline analysis	2021-11-01	GSK2140944	Antibiotics	Topoisomerase Inhibitors (Triazaacenaphthylene)	Uncomplicated urogenital gonorrhea and uUTI	IV, Oral	Phase III	 NCT04010539, NCT04020341	GSK	Priority pathogens	All critical priority pathogens	Critical priority pathogens	No	Yes	Yes	No	Unknown	Gepotidacin
250	WHO AMR pipeline analysis	2021-11-01	GSK2140944	Antibiotics	Topoisomerase Inhibitors (Triazaacenaphthylene)	Uncomplicated urogenital gonorrhea and uUTI	IV, Oral	Phase III	 NCT04010539, NCT04020341	GSK	Priority pathogens	Critical priority pathogens	Critical priority pathogens	No	Yes	Yes	No	Unknown	Gepotidacin
251	WHO AMR pipeline analysis	2021-11-01	GSK2140944	Antibiotics	Topoisomerase Inhibitors (Triazaacenaphthylene)	Uncomplicated urogenital gonorrhea and uUTI	IV, Oral	Phase III	 NCT04010539, NCT04020341	GSK	Priority pathogens	Enterobacterales	Critical priority pathogens	No	Yes	Yes	No	Unknown	Gepotidacin
252	WHO AMR pipeline analysis	2021-11-01	GSK2140944	Antibiotics	Topoisomerase Inhibitors (Triazaacenaphthylene)	Uncomplicated urogenital gonorrhea and uUTI	IV, Oral	Phase III	 NCT04010539, NCT04020341	GSK	Priority pathogens	Campylobacter spp.	Other priority pathogens	No	Yes	Yes	No	Unknown	Gepotidacin
253	WHO AMR pipeline analysis	2021-11-01	GSK2140944	Antibiotics	Topoisomerase Inhibitors (Triazaacenaphthylene)	Uncomplicated urogenital gonorrhea and uUTI	IV, Oral	Phase III	 NCT04010539, NCT04020341	GSK	Priority pathogens	Enterococcus faecium	Other priority pathogens	No	Yes	Yes	No	Unknown	Gepotidacin
254	WHO AMR pipeline analysis	2021-11-01	GSK2140944	Antibiotics	Topoisomerase Inhibitors (Triazaacenaphthylene)	Uncomplicated urogenital gonorrhea and uUTI	IV, Oral	Phase III	 NCT04010539, NCT04020341	GSK	Priority pathogens	Helicobacter pylori	Other priority pathogens	No	Yes	Yes	No	Unknown	Gepotidacin
255	WHO AMR pipeline analysis	2021-11-01	GSK2140944	Antibiotics	Topoisomerase Inhibitors (Triazaacenaphthylene)	Uncomplicated urogenital gonorrhea and uUTI	IV, Oral	Phase III	 NCT04010539, NCT04020341	GSK	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	No	Yes	Yes	No	Unknown	Gepotidacin
256	WHO AMR pipeline analysis	2021-11-01	GSK2140944	Antibiotics	Topoisomerase Inhibitors (Triazaacenaphthylene)	Uncomplicated urogenital gonorrhea and uUTI	IV, Oral	Phase III	 NCT04010539, NCT04020341	GSK	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	No	Yes	Yes	No	Unknown	Gepotidacin
257	WHO AMR pipeline analysis	2021-11-01	GSK2140944	Antibiotics	Topoisomerase Inhibitors (Triazaacenaphthylene)	Uncomplicated urogenital gonorrhea and uUTI	IV, Oral	Phase III	 NCT04010539, NCT04020341	GSK	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	Yes	Yes	Yes	No	Unknown	Gepotidacin
258	WHO AMR pipeline analysis	2021-11-01	GSK2140944	Antibiotics	Topoisomerase Inhibitors (Triazaacenaphthylene)	Uncomplicated urogenital gonorrhea and uUTI	IV, Oral	Phase III	 NCT04010539, NCT04020341	GSK	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	Yes	Yes	Yes	No	Unknown	Gepotidacin
259	WHO AMR pipeline analysis	2021-11-01	GSK2140944	Antibiotics	Topoisomerase Inhibitors (Triazaacenaphthylene)	Uncomplicated urogenital gonorrhea and uUTI	IV, Oral	Phase III	 NCT04010539, NCT04020341	GSK	Priority pathogens	Other priority pathogens	Other priority pathogens	Yes	Yes	Yes	No	Unknown	Gepotidacin
260	WHO AMR pipeline analysis	2021-11-01	GSK2140944	Antibiotics	Topoisomerase Inhibitors (Triazaacenaphthylene)	Uncomplicated urogenital gonorrhea and uUTI	IV, Oral	Phase III	 NCT04010539, NCT04020341	GSK	Priority pathogens	Staphylococcus aureus	Other priority pathogens	Yes	Yes	Yes	No	Unknown	Gepotidacin
261	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Undisclosed (FimH)	E.coli UTI	Oral	Phase I	NCT04488770	GSK	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	No	No	Yes	No	Unknown	Miscellaneous
262	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Undisclosed (FimH)	E.coli UTI	Oral	Phase I	NCT04488770	GSK	Priority pathogens	Staphylococcus aureus	Other priority pathogens	No	No	Yes	No	Unknown	Miscellaneous
263	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Undisclosed (FimH)	E.coli UTI	Oral	Phase I	NCT04488770	GSK	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	No	No	Yes	No	Unknown	Miscellaneous
264	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Undisclosed (FimH)	E.coli UTI	Oral	Phase I	NCT04488770	GSK	Priority pathogens	Other priority pathogens	Other priority pathogens	No	No	Yes	No	Unknown	Miscellaneous
265	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Undisclosed (FimH)	E.coli UTI	Oral	Phase I	NCT04488770	GSK	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	No	No	Yes	No	Unknown	Miscellaneous
266	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Undisclosed (FimH)	E.coli UTI	Oral	Phase I	NCT04488770	GSK	Priority pathogens	Helicobacter pylori	Other priority pathogens	No	No	Yes	No	Unknown	Miscellaneous
267	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Undisclosed (FimH)	E.coli UTI	Oral	Phase I	NCT04488770	GSK	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	No	No	Yes	No	Unknown	Miscellaneous
268	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Undisclosed (FimH)	E.coli UTI	Oral	Phase I	NCT04488770	GSK	Priority pathogens	Enterococcus faecium	Other priority pathogens	No	No	Yes	No	Unknown	Miscellaneous
269	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Undisclosed (FimH)	E.coli UTI	Oral	Phase I	NCT04488770	GSK	Priority pathogens	Enterobacterales	Critical priority pathogens	Yes	No	Yes	No	Unknown	Miscellaneous
270	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Undisclosed (FimH)	E.coli UTI	Oral	Phase I	NCT04488770	GSK	Priority pathogens	Critical priority pathogens	Critical priority pathogens	No	No	Yes	No	Unknown	Miscellaneous
271	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Undisclosed (FimH)	E.coli UTI	Oral	Phase I	NCT04488770	GSK	Priority pathogens	Campylobacter spp.	Other priority pathogens	No	No	Yes	No	Unknown	Miscellaneous
272	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Undisclosed (FimH)	E.coli UTI	Oral	Phase I	NCT04488770	GSK	Priority pathogens	All critical priority pathogens	Critical priority pathogens	No	No	Yes	No	Unknown	Miscellaneous
273	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Undisclosed (FimH)	E.coli UTI	Oral	Phase I	NCT04488770	GSK	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	No	No	Yes	No	Unknown	Miscellaneous
274	WHO AMR pipeline analysis	2021-11-01	–	Antibiotics	Tetracycline	Multi-drug resistant bacterial infections including (CABP, DFI, cUTI, cIAI)	Oral	Phase I	NCT02454361, NCT02654626, NCT04532957	KBP BioSciences Pharmaceutical Technical Co., Ltd.	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	No	No	Yes	No	Unknown	KBP-7072
275	WHO AMR pipeline analysis	2021-11-01	–	Antibiotics	Tetracycline	Multi-drug resistant bacterial infections including (CABP, DFI, cUTI, cIAI)	Oral	Phase I	NCT02454361, NCT02654626, NCT04532957	KBP BioSciences Pharmaceutical Technical Co., Ltd.	Priority pathogens	Staphylococcus aureus	Other priority pathogens	Yes	No	Yes	No	Unknown	KBP-7072
276	WHO AMR pipeline analysis	2021-11-01	–	Antibiotics	Tetracycline	Multi-drug resistant bacterial infections including (CABP, DFI, cUTI, cIAI)	Oral	Phase I	NCT02454361, NCT02654626, NCT04532957	KBP BioSciences Pharmaceutical Technical Co., Ltd.	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	Possibly	No	Yes	No	Unknown	KBP-7072
277	WHO AMR pipeline analysis	2021-11-01	–	Antibiotics	Tetracycline	Multi-drug resistant bacterial infections including (CABP, DFI, cUTI, cIAI)	Oral	Phase I	NCT02454361, NCT02654626, NCT04532957	KBP BioSciences Pharmaceutical Technical Co., Ltd.	Priority pathogens	Other priority pathogens	Other priority pathogens	Yes	No	Yes	No	Unknown	KBP-7072
278	WHO AMR pipeline analysis	2021-11-01	–	Antibiotics	Tetracycline	Multi-drug resistant bacterial infections including (CABP, DFI, cUTI, cIAI)	Oral	Phase I	NCT02454361, NCT02654626, NCT04532957	KBP BioSciences Pharmaceutical Technical Co., Ltd.	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	No	No	Yes	No	Unknown	KBP-7072
279	WHO AMR pipeline analysis	2021-11-01	–	Antibiotics	Tetracycline	Multi-drug resistant bacterial infections including (CABP, DFI, cUTI, cIAI)	Oral	Phase I	NCT02454361, NCT02654626, NCT04532957	KBP BioSciences Pharmaceutical Technical Co., Ltd.	Priority pathogens	Helicobacter pylori	Other priority pathogens	No	No	Yes	No	Unknown	KBP-7072
280	WHO AMR pipeline analysis	2021-11-01	–	Antibiotics	Tetracycline	Multi-drug resistant bacterial infections including (CABP, DFI, cUTI, cIAI)	Oral	Phase I	NCT02454361, NCT02654626, NCT04532957	KBP BioSciences Pharmaceutical Technical Co., Ltd.	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	Yes	No	Yes	No	Unknown	KBP-7072
281	WHO AMR pipeline analysis	2021-11-01	–	Antibiotics	Tetracycline	Multi-drug resistant bacterial infections including (CABP, DFI, cUTI, cIAI)	Oral	Phase I	NCT02454361, NCT02654626, NCT04532957	KBP BioSciences Pharmaceutical Technical Co., Ltd.	Priority pathogens	Enterococcus faecium	Other priority pathogens	No	No	Yes	No	Unknown	KBP-7072
282	WHO AMR pipeline analysis	2021-11-01	–	Antibiotics	Tetracycline	Multi-drug resistant bacterial infections including (CABP, DFI, cUTI, cIAI)	Oral	Phase I	NCT02454361, NCT02654626, NCT04532957	KBP BioSciences Pharmaceutical Technical Co., Ltd.	Priority pathogens	Enterobacterales	Critical priority pathogens	Possibly	No	Yes	No	Unknown	KBP-7072
283	WHO AMR pipeline analysis	2021-11-01	–	Antibiotics	Tetracycline	Multi-drug resistant bacterial infections including (CABP, DFI, cUTI, cIAI)	Oral	Phase I	NCT02454361, NCT02654626, NCT04532957	KBP BioSciences Pharmaceutical Technical Co., Ltd.	Priority pathogens	Critical priority pathogens	Critical priority pathogens	Yes	No	Yes	No	Unknown	KBP-7072
284	WHO AMR pipeline analysis	2021-11-01	–	Antibiotics	Tetracycline	Multi-drug resistant bacterial infections including (CABP, DFI, cUTI, cIAI)	Oral	Phase I	NCT02454361, NCT02654626, NCT04532957	KBP BioSciences Pharmaceutical Technical Co., Ltd.	Priority pathogens	Campylobacter spp.	Other priority pathogens	No	No	Yes	No	Unknown	KBP-7072
285	WHO AMR pipeline analysis	2021-11-01	–	Antibiotics	Tetracycline	Multi-drug resistant bacterial infections including (CABP, DFI, cUTI, cIAI)	Oral	Phase I	NCT02454361, NCT02654626, NCT04532957	KBP BioSciences Pharmaceutical Technical Co., Ltd.	Priority pathogens	All critical priority pathogens	Critical priority pathogens	No	No	Yes	No	Unknown	KBP-7072
286	WHO AMR pipeline analysis	2021-11-01	–	Antibiotics	Tetracycline	Multi-drug resistant bacterial infections including (CABP, DFI, cUTI, cIAI)	Oral	Phase I	NCT02454361, NCT02654626, NCT04532957	KBP BioSciences Pharmaceutical Technical Co., Ltd.	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	Yes	No	Yes	No	Unknown	KBP-7072
287	WHO AMR pipeline analysis	2021-11-01	–	Non-traditional	CRISPR-Cas3 enhanced phage	E. coli	IV	Phase I	NCT04191148	Locus Bioscience	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
288	WHO AMR pipeline analysis	2021-11-01	–	Non-traditional	CRISPR-Cas3 enhanced phage	E. coli	IV	Phase I	NCT04191148	Locus Bioscience	Priority pathogens	Staphylococcus aureus	Other priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
289	WHO AMR pipeline analysis	2021-11-01	–	Non-traditional	CRISPR-Cas3 enhanced phage	E. coli	IV	Phase I	NCT04191148	Locus Bioscience	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
290	WHO AMR pipeline analysis	2021-11-01	–	Non-traditional	CRISPR-Cas3 enhanced phage	E. coli	IV	Phase I	NCT04191148	Locus Bioscience	Priority pathogens	Other priority pathogens	Other priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
291	WHO AMR pipeline analysis	2021-11-01	–	Non-traditional	CRISPR-Cas3 enhanced phage	E. coli	IV	Phase I	NCT04191148	Locus Bioscience	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
292	WHO AMR pipeline analysis	2021-11-01	–	Non-traditional	CRISPR-Cas3 enhanced phage	E. coli	IV	Phase I	NCT04191148	Locus Bioscience	Priority pathogens	Helicobacter pylori	Other priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
293	WHO AMR pipeline analysis	2021-11-01	–	Non-traditional	CRISPR-Cas3 enhanced phage	E. coli	IV	Phase I	NCT04191148	Locus Bioscience	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
294	WHO AMR pipeline analysis	2021-11-01	–	Non-traditional	CRISPR-Cas3 enhanced phage	E. coli	IV	Phase I	NCT04191148	Locus Bioscience	Priority pathogens	Enterococcus faecium	Other priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
295	WHO AMR pipeline analysis	2021-11-01	–	Non-traditional	CRISPR-Cas3 enhanced phage	E. coli	IV	Phase I	NCT04191148	Locus Bioscience	Priority pathogens	Enterobacterales	Critical priority pathogens	Yes	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
296	WHO AMR pipeline analysis	2021-11-01	–	Non-traditional	CRISPR-Cas3 enhanced phage	E. coli	IV	Phase I	NCT04191148	Locus Bioscience	Priority pathogens	Critical priority pathogens	Critical priority pathogens	Yes	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
297	WHO AMR pipeline analysis	2021-11-01	–	Non-traditional	CRISPR-Cas3 enhanced phage	E. coli	IV	Phase I	NCT04191148	Locus Bioscience	Priority pathogens	Campylobacter spp.	Other priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
298	WHO AMR pipeline analysis	2021-11-01	–	Non-traditional	CRISPR-Cas3 enhanced phage	E. coli	IV	Phase I	NCT04191148	Locus Bioscience	Priority pathogens	All critical priority pathogens	Critical priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
299	WHO AMR pipeline analysis	2021-11-01	–	Non-traditional	CRISPR-Cas3 enhanced phage	E. coli	IV	Phase I	NCT04191148	Locus Bioscience	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
300	WHO AMR pipeline analysis	2021-11-01	–	Non-traditional	"Monoclonal Ab like
recombinant protein"	E. coli and  C. jejuni infections	Oral	Phase II	NCT04098263, NCT04182490	Lumen Bioscience	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	No	No	Yes	No	Unknown	Antibodies
301	WHO AMR pipeline analysis	2021-11-01	–	Non-traditional	"Monoclonal Ab like
recombinant protein"	E. coli and  C. jejuni infections	Oral	Phase II	NCT04098263, NCT04182490	Lumen Bioscience	Priority pathogens	Staphylococcus aureus	Other priority pathogens	No	No	Yes	No	Unknown	Antibodies
302	WHO AMR pipeline analysis	2021-11-01	–	Non-traditional	"Monoclonal Ab like
recombinant protein"	E. coli and  C. jejuni infections	Oral	Phase II	NCT04098263, NCT04182490	Lumen Bioscience	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	No	No	Yes	No	Unknown	Antibodies
303	WHO AMR pipeline analysis	2021-11-01	–	Non-traditional	"Monoclonal Ab like
recombinant protein"	E. coli and  C. jejuni infections	Oral	Phase II	NCT04098263, NCT04182490	Lumen Bioscience	Priority pathogens	Other priority pathogens	Other priority pathogens	Yes	No	Yes	No	Unknown	Antibodies
304	WHO AMR pipeline analysis	2021-11-01	–	Non-traditional	"Monoclonal Ab like
recombinant protein"	E. coli and  C. jejuni infections	Oral	Phase II	NCT04098263, NCT04182490	Lumen Bioscience	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	No	No	Yes	No	Unknown	Antibodies
305	WHO AMR pipeline analysis	2021-11-01	–	Non-traditional	"Monoclonal Ab like
recombinant protein"	E. coli and  C. jejuni infections	Oral	Phase II	NCT04098263, NCT04182490	Lumen Bioscience	Priority pathogens	Helicobacter pylori	Other priority pathogens	No	No	Yes	No	Unknown	Antibodies
306	WHO AMR pipeline analysis	2021-11-01	–	Non-traditional	"Monoclonal Ab like
recombinant protein"	E. coli and  C. jejuni infections	Oral	Phase II	NCT04098263, NCT04182490	Lumen Bioscience	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	No	No	Yes	No	Unknown	Antibodies
307	WHO AMR pipeline analysis	2021-11-01	–	Non-traditional	"Monoclonal Ab like
recombinant protein"	E. coli and  C. jejuni infections	Oral	Phase II	NCT04098263, NCT04182490	Lumen Bioscience	Priority pathogens	Enterococcus faecium	Other priority pathogens	No	No	Yes	No	Unknown	Antibodies
308	WHO AMR pipeline analysis	2021-11-01	–	Non-traditional	"Monoclonal Ab like
recombinant protein"	E. coli and  C. jejuni infections	Oral	Phase II	NCT04098263, NCT04182490	Lumen Bioscience	Priority pathogens	Enterobacterales	Critical priority pathogens	Yes	No	Yes	No	Unknown	Antibodies
309	WHO AMR pipeline analysis	2021-11-01	–	Non-traditional	"Monoclonal Ab like
recombinant protein"	E. coli and  C. jejuni infections	Oral	Phase II	NCT04098263, NCT04182490	Lumen Bioscience	Priority pathogens	Critical priority pathogens	Critical priority pathogens	Yes	No	Yes	No	Unknown	Antibodies
310	WHO AMR pipeline analysis	2021-11-01	–	Non-traditional	"Monoclonal Ab like
recombinant protein"	E. coli and  C. jejuni infections	Oral	Phase II	NCT04098263, NCT04182490	Lumen Bioscience	Priority pathogens	Campylobacter spp.	Other priority pathogens	Yes	No	Yes	No	Unknown	Antibodies
311	WHO AMR pipeline analysis	2021-11-01	–	Non-traditional	"Monoclonal Ab like
recombinant protein"	E. coli and  C. jejuni infections	Oral	Phase II	NCT04098263, NCT04182490	Lumen Bioscience	Priority pathogens	All critical priority pathogens	Critical priority pathogens	No	No	Yes	No	Unknown	Antibodies
312	WHO AMR pipeline analysis	2021-11-01	–	Non-traditional	"Monoclonal Ab like
recombinant protein"	E. coli and  C. jejuni infections	Oral	Phase II	NCT04098263, NCT04182490	Lumen Bioscience	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	No	No	Yes	No	Unknown	Antibodies
313	WHO AMR pipeline analysis	2021-11-01	Tonabacase, SAL200	Non-traditional	Phage endolysin	S. aureus bacteremia	IV	Phase II	NCT03089697, NCT03446053	 Roivant Sciences/iNtRON Biotechnology	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
314	WHO AMR pipeline analysis	2021-11-01	Tonabacase, SAL200	Non-traditional	Phage endolysin	S. aureus bacteremia	IV	Phase II	NCT03089697, NCT03446053	 Roivant Sciences/iNtRON Biotechnology	Priority pathogens	Staphylococcus aureus	Other priority pathogens	Yes	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
315	WHO AMR pipeline analysis	2021-11-01	Tonabacase, SAL200	Non-traditional	Phage endolysin	S. aureus bacteremia	IV	Phase II	NCT03089697, NCT03446053	 Roivant Sciences/iNtRON Biotechnology	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
316	WHO AMR pipeline analysis	2021-11-01	Tonabacase, SAL200	Non-traditional	Phage endolysin	S. aureus bacteremia	IV	Phase II	NCT03089697, NCT03446053	 Roivant Sciences/iNtRON Biotechnology	Priority pathogens	Other priority pathogens	Other priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
317	WHO AMR pipeline analysis	2021-11-01	Tonabacase, SAL200	Non-traditional	Phage endolysin	S. aureus bacteremia	IV	Phase II	NCT03089697, NCT03446053	 Roivant Sciences/iNtRON Biotechnology	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
318	WHO AMR pipeline analysis	2021-11-01	Tonabacase, SAL200	Non-traditional	Phage endolysin	S. aureus bacteremia	IV	Phase II	NCT03089697, NCT03446053	 Roivant Sciences/iNtRON Biotechnology	Priority pathogens	Helicobacter pylori	Other priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
319	WHO AMR pipeline analysis	2021-11-01	Tonabacase, SAL200	Non-traditional	Phage endolysin	S. aureus bacteremia	IV	Phase II	NCT03089697, NCT03446053	 Roivant Sciences/iNtRON Biotechnology	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	Yes	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
320	WHO AMR pipeline analysis	2021-11-01	Tonabacase, SAL200	Non-traditional	Phage endolysin	S. aureus bacteremia	IV	Phase II	NCT03089697, NCT03446053	 Roivant Sciences/iNtRON Biotechnology	Priority pathogens	Enterococcus faecium	Other priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
321	WHO AMR pipeline analysis	2021-11-01	Tonabacase, SAL200	Non-traditional	Phage endolysin	S. aureus bacteremia	IV	Phase II	NCT03089697, NCT03446053	 Roivant Sciences/iNtRON Biotechnology	Priority pathogens	Enterobacterales	Critical priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
322	WHO AMR pipeline analysis	2021-11-01	Tonabacase, SAL200	Non-traditional	Phage endolysin	S. aureus bacteremia	IV	Phase II	NCT03089697, NCT03446053	 Roivant Sciences/iNtRON Biotechnology	Priority pathogens	Critical priority pathogens	Critical priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
323	WHO AMR pipeline analysis	2021-11-01	Tonabacase, SAL200	Non-traditional	Phage endolysin	S. aureus bacteremia	IV	Phase II	NCT03089697, NCT03446053	 Roivant Sciences/iNtRON Biotechnology	Priority pathogens	Campylobacter spp.	Other priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
324	WHO AMR pipeline analysis	2021-11-01	Tonabacase, SAL200	Non-traditional	Phage endolysin	S. aureus bacteremia	IV	Phase II	NCT03089697, NCT03446053	 Roivant Sciences/iNtRON Biotechnology	Priority pathogens	All critical priority pathogens	Critical priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
325	WHO AMR pipeline analysis	2021-11-01	Tonabacase, SAL200	Non-traditional	Phage endolysin	S. aureus bacteremia	IV	Phase II	NCT03089697, NCT03446053	 Roivant Sciences/iNtRON Biotechnology	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
326	WHO AMR pipeline analysis	2021-11-01		Antibiotics	Polymyxin	 Gram-negative infections	IV	Phase I	NCT04649541	MicuRx	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	No	No	Yes	No	Unknown	MRX-8
327	WHO AMR pipeline analysis	2021-11-01		Antibiotics	Polymyxin	 Gram-negative infections	IV	Phase I	NCT04649541	MicuRx	Priority pathogens	Staphylococcus aureus	Other priority pathogens	No	No	Yes	No	Unknown	MRX-8
328	WHO AMR pipeline analysis	2021-11-01		Antibiotics	Polymyxin	 Gram-negative infections	IV	Phase I	NCT04649541	MicuRx	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	Yes	No	Yes	No	Unknown	MRX-8
329	WHO AMR pipeline analysis	2021-11-01		Antibiotics	Polymyxin	 Gram-negative infections	IV	Phase I	NCT04649541	MicuRx	Priority pathogens	Other priority pathogens	Other priority pathogens	No	No	Yes	No	Unknown	MRX-8
330	WHO AMR pipeline analysis	2021-11-01		Antibiotics	Polymyxin	 Gram-negative infections	IV	Phase I	NCT04649541	MicuRx	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	No	No	Yes	No	Unknown	MRX-8
331	WHO AMR pipeline analysis	2021-11-01		Antibiotics	Polymyxin	 Gram-negative infections	IV	Phase I	NCT04649541	MicuRx	Priority pathogens	Helicobacter pylori	Other priority pathogens	No	No	Yes	No	Unknown	MRX-8
332	WHO AMR pipeline analysis	2021-11-01		Antibiotics	Polymyxin	 Gram-negative infections	IV	Phase I	NCT04649541	MicuRx	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	No	No	Yes	No	Unknown	MRX-8
333	WHO AMR pipeline analysis	2021-11-01		Antibiotics	Polymyxin	 Gram-negative infections	IV	Phase I	NCT04649541	MicuRx	Priority pathogens	Enterococcus faecium	Other priority pathogens	No	No	Yes	No	Unknown	MRX-8
334	WHO AMR pipeline analysis	2021-11-01		Antibiotics	Polymyxin	 Gram-negative infections	IV	Phase I	NCT04649541	MicuRx	Priority pathogens	Enterobacterales	Critical priority pathogens	Yes	No	Yes	No	Unknown	MRX-8
335	WHO AMR pipeline analysis	2021-11-01		Antibiotics	Polymyxin	 Gram-negative infections	IV	Phase I	NCT04649541	MicuRx	Priority pathogens	Critical priority pathogens	Critical priority pathogens	Yes	No	Yes	No	Unknown	MRX-8
336	WHO AMR pipeline analysis	2021-11-01		Antibiotics	Polymyxin	 Gram-negative infections	IV	Phase I	NCT04649541	MicuRx	Priority pathogens	Campylobacter spp.	Other priority pathogens	No	No	Yes	No	Unknown	MRX-8
337	WHO AMR pipeline analysis	2021-11-01		Antibiotics	Polymyxin	 Gram-negative infections	IV	Phase I	NCT04649541	MicuRx	Priority pathogens	All critical priority pathogens	Critical priority pathogens	Yes	No	Yes	No	Unknown	MRX-8
338	WHO AMR pipeline analysis	2021-11-01		Antibiotics	Polymyxin	 Gram-negative infections	IV	Phase I	NCT04649541	MicuRx	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	Yes	No	Yes	No	Unknown	MRX-8
339	WHO AMR pipeline analysis	2021-11-01	OP0595	Antibiotics	DBO-BLI/PBP2 binder + cephalosporin	Bacterial infections	IV	Phase I	NCT03174795	Meiji Seika	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	No	No	Yes	No	Unknown	Nacubactam + meropenem
340	WHO AMR pipeline analysis	2021-11-01	OP0595	Antibiotics	DBO-BLI/PBP2 binder + cephalosporin	Bacterial infections	IV	Phase I	NCT03174795	Meiji Seika	Priority pathogens	Staphylococcus aureus	Other priority pathogens	No	No	Yes	No	Unknown	Nacubactam + meropenem
341	WHO AMR pipeline analysis	2021-11-01	OP0595	Antibiotics	DBO-BLI/PBP2 binder + cephalosporin	Bacterial infections	IV	Phase I	NCT03174795	Meiji Seika	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	Possibly	No	Yes	No	Unknown	Nacubactam + meropenem
342	WHO AMR pipeline analysis	2021-11-01	OP0595	Antibiotics	DBO-BLI/PBP2 binder + cephalosporin	Bacterial infections	IV	Phase I	NCT03174795	Meiji Seika	Priority pathogens	Other priority pathogens	Other priority pathogens	No	No	Yes	No	Unknown	Nacubactam + meropenem
343	WHO AMR pipeline analysis	2021-11-01	OP0595	Antibiotics	DBO-BLI/PBP2 binder + cephalosporin	Bacterial infections	IV	Phase I	NCT03174795	Meiji Seika	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	No	No	Yes	No	Unknown	Nacubactam + meropenem
344	WHO AMR pipeline analysis	2021-11-01	OP0595	Antibiotics	DBO-BLI/PBP2 binder + cephalosporin	Bacterial infections	IV	Phase I	NCT03174795	Meiji Seika	Priority pathogens	Helicobacter pylori	Other priority pathogens	No	No	Yes	No	Unknown	Nacubactam + meropenem
345	WHO AMR pipeline analysis	2021-11-01	OP0595	Antibiotics	DBO-BLI/PBP2 binder + cephalosporin	Bacterial infections	IV	Phase I	NCT03174795	Meiji Seika	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	No	No	Yes	No	Unknown	Nacubactam + meropenem
346	WHO AMR pipeline analysis	2021-11-01	OP0595	Antibiotics	DBO-BLI/PBP2 binder + cephalosporin	Bacterial infections	IV	Phase I	NCT03174795	Meiji Seika	Priority pathogens	Enterococcus faecium	Other priority pathogens	No	No	Yes	No	Unknown	Nacubactam + meropenem
347	WHO AMR pipeline analysis	2021-11-01	OP0595	Antibiotics	DBO-BLI/PBP2 binder + cephalosporin	Bacterial infections	IV	Phase I	NCT03174795	Meiji Seika	Priority pathogens	Enterobacterales	Critical priority pathogens	Yes	No	Yes	No	Unknown	Nacubactam + meropenem
348	WHO AMR pipeline analysis	2021-11-01	OP0595	Antibiotics	DBO-BLI/PBP2 binder + cephalosporin	Bacterial infections	IV	Phase I	NCT03174795	Meiji Seika	Priority pathogens	Critical priority pathogens	Critical priority pathogens	Yes	No	Yes	No	Unknown	Nacubactam + meropenem
349	WHO AMR pipeline analysis	2021-11-01	OP0595	Antibiotics	DBO-BLI/PBP2 binder + cephalosporin	Bacterial infections	IV	Phase I	NCT03174795	Meiji Seika	Priority pathogens	Campylobacter spp.	Other priority pathogens	No	No	Yes	No	Unknown	Nacubactam + meropenem
350	WHO AMR pipeline analysis	2021-11-01	OP0595	Antibiotics	DBO-BLI/PBP2 binder + cephalosporin	Bacterial infections	IV	Phase I	NCT03174795	Meiji Seika	Priority pathogens	All critical priority pathogens	Critical priority pathogens	No	No	Yes	No	Unknown	Nacubactam + meropenem
351	WHO AMR pipeline analysis	2021-11-01	OP0595	Antibiotics	DBO-BLI/PBP2 binder + cephalosporin	Bacterial infections	IV	Phase I	NCT03174795	Meiji Seika	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	Possibly	No	Yes	No	Unknown	Nacubactam + meropenem
352	WHO AMR pipeline analysis	2021-11-01	WCK 4873	Antibiotics	Macrolide	CABP (caused by S. pneumoniae and S. aureus)	Oral	Phase III	NCT02903836, CTRI/2019/11/021964	Wockhardt Ltd.	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	No	No	Yes	No	Unknown	Nafithromycin
353	WHO AMR pipeline analysis	2021-11-01	WCK 4873	Antibiotics	Macrolide	CABP (caused by S. pneumoniae and S. aureus)	Oral	Phase III	NCT02903836, CTRI/2019/11/021964	Wockhardt Ltd.	Priority pathogens	All critical priority pathogens	Critical priority pathogens	No	No	Yes	No	Unknown	Nafithromycin
354	WHO AMR pipeline analysis	2021-11-01	WCK 4873	Antibiotics	Macrolide	CABP (caused by S. pneumoniae and S. aureus)	Oral	Phase III	NCT02903836, CTRI/2019/11/021964	Wockhardt Ltd.	Priority pathogens	Critical priority pathogens	Critical priority pathogens	No	No	Yes	No	Unknown	Nafithromycin
355	WHO AMR pipeline analysis	2021-11-01	WCK 4873	Antibiotics	Macrolide	CABP (caused by S. pneumoniae and S. aureus)	Oral	Phase III	NCT02903836, CTRI/2019/11/021964	Wockhardt Ltd.	Priority pathogens	Enterobacterales	Critical priority pathogens	No	No	Yes	No	Unknown	Nafithromycin
356	WHO AMR pipeline analysis	2021-11-01	WCK 4873	Antibiotics	Macrolide	CABP (caused by S. pneumoniae and S. aureus)	Oral	Phase III	NCT02903836, CTRI/2019/11/021964	Wockhardt Ltd.	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	No	No	Yes	No	Unknown	Nafithromycin
357	WHO AMR pipeline analysis	2021-11-01	WCK 4873	Antibiotics	Macrolide	CABP (caused by S. pneumoniae and S. aureus)	Oral	Phase III	NCT02903836, CTRI/2019/11/021964	Wockhardt Ltd.	Priority pathogens	Campylobacter spp.	Other priority pathogens	No	No	Yes	No	Unknown	Nafithromycin
358	WHO AMR pipeline analysis	2021-11-01	WCK 4873	Antibiotics	Macrolide	CABP (caused by S. pneumoniae and S. aureus)	Oral	Phase III	NCT02903836, CTRI/2019/11/021964	Wockhardt Ltd.	Priority pathogens	Enterococcus faecium	Other priority pathogens	No	No	Yes	No	Unknown	Nafithromycin
359	WHO AMR pipeline analysis	2021-11-01	WCK 4873	Antibiotics	Macrolide	CABP (caused by S. pneumoniae and S. aureus)	Oral	Phase III	NCT02903836, CTRI/2019/11/021964	Wockhardt Ltd.	Priority pathogens	Helicobacter pylori	Other priority pathogens	No	No	Yes	No	Unknown	Nafithromycin
360	WHO AMR pipeline analysis	2021-11-01	WCK 4873	Antibiotics	Macrolide	CABP (caused by S. pneumoniae and S. aureus)	Oral	Phase III	NCT02903836, CTRI/2019/11/021964	Wockhardt Ltd.	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	No	No	Yes	No	Unknown	Nafithromycin
361	WHO AMR pipeline analysis	2021-11-01	WCK 4873	Antibiotics	Macrolide	CABP (caused by S. pneumoniae and S. aureus)	Oral	Phase III	NCT02903836, CTRI/2019/11/021964	Wockhardt Ltd.	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	Yes	No	Yes	No	Unknown	Nafithromycin
362	WHO AMR pipeline analysis	2021-11-01	WCK 4873	Antibiotics	Macrolide	CABP (caused by S. pneumoniae and S. aureus)	Oral	Phase III	NCT02903836, CTRI/2019/11/021964	Wockhardt Ltd.	Priority pathogens	Other priority pathogens	Other priority pathogens	Yes	No	Yes	No	Unknown	Nafithromycin
363	WHO AMR pipeline analysis	2021-11-01	WCK 4873	Antibiotics	Macrolide	CABP (caused by S. pneumoniae and S. aureus)	Oral	Phase III	NCT02903836, CTRI/2019/11/021964	Wockhardt Ltd.	Priority pathogens	Staphylococcus aureus	Other priority pathogens	Yes	No	Yes	No	Unknown	Nafithromycin
364	WHO AMR pipeline analysis	2021-11-01	WCK 4873	Antibiotics	Macrolide	CABP (caused by S. pneumoniae and S. aureus)	Oral	Phase III	NCT02903836, CTRI/2019/11/021964	Wockhardt Ltd.	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	Yes	No	Yes	No	Unknown	Nafithromycin
365	WHO AMR pipeline analysis	2021-11-01	CF-5/20	Non-traditional	Alginate oligosaccharide (G-block) fragment	Cystic fibrosis	Inhalation	Phase II	NCT03822455	AlgiPharma AS	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	No	No	Yes	No	Unknown	Miscellaneous
366	WHO AMR pipeline analysis	2021-11-01	CF-5/20	Non-traditional	Alginate oligosaccharide (G-block) fragment	Cystic fibrosis	Inhalation	Phase II	NCT03822455	AlgiPharma AS	Priority pathogens	Staphylococcus aureus	Other priority pathogens	No	No	Yes	No	Unknown	Miscellaneous
367	WHO AMR pipeline analysis	2021-11-01	CF-5/20	Non-traditional	Alginate oligosaccharide (G-block) fragment	Cystic fibrosis	Inhalation	Phase II	NCT03822455	AlgiPharma AS	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	Yes	No	Yes	No	Unknown	Miscellaneous
368	WHO AMR pipeline analysis	2021-11-01	CF-5/20	Non-traditional	Alginate oligosaccharide (G-block) fragment	Cystic fibrosis	Inhalation	Phase II	NCT03822455	AlgiPharma AS	Priority pathogens	Other priority pathogens	Other priority pathogens	No	No	Yes	No	Unknown	Miscellaneous
369	WHO AMR pipeline analysis	2021-11-01	CF-5/20	Non-traditional	Alginate oligosaccharide (G-block) fragment	Cystic fibrosis	Inhalation	Phase II	NCT03822455	AlgiPharma AS	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	No	No	Yes	No	Unknown	Miscellaneous
370	WHO AMR pipeline analysis	2021-11-01	CF-5/20	Non-traditional	Alginate oligosaccharide (G-block) fragment	Cystic fibrosis	Inhalation	Phase II	NCT03822455	AlgiPharma AS	Priority pathogens	Helicobacter pylori	Other priority pathogens	No	No	Yes	No	Unknown	Miscellaneous
371	WHO AMR pipeline analysis	2021-11-01	CF-5/20	Non-traditional	Alginate oligosaccharide (G-block) fragment	Cystic fibrosis	Inhalation	Phase II	NCT03822455	AlgiPharma AS	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	No	No	Yes	No	Unknown	Miscellaneous
372	WHO AMR pipeline analysis	2021-11-01	CF-5/20	Non-traditional	Alginate oligosaccharide (G-block) fragment	Cystic fibrosis	Inhalation	Phase II	NCT03822455	AlgiPharma AS	Priority pathogens	Enterococcus faecium	Other priority pathogens	No	No	Yes	No	Unknown	Miscellaneous
373	WHO AMR pipeline analysis	2021-11-01	CF-5/20	Non-traditional	Alginate oligosaccharide (G-block) fragment	Cystic fibrosis	Inhalation	Phase II	NCT03822455	AlgiPharma AS	Priority pathogens	Enterobacterales	Critical priority pathogens	No	No	Yes	No	Unknown	Miscellaneous
374	WHO AMR pipeline analysis	2021-11-01	CF-5/20	Non-traditional	Alginate oligosaccharide (G-block) fragment	Cystic fibrosis	Inhalation	Phase II	NCT03822455	AlgiPharma AS	Priority pathogens	Critical priority pathogens	Critical priority pathogens	Yes	No	Yes	No	Unknown	Miscellaneous
375	WHO AMR pipeline analysis	2021-11-01	CF-5/20	Non-traditional	Alginate oligosaccharide (G-block) fragment	Cystic fibrosis	Inhalation	Phase II	NCT03822455	AlgiPharma AS	Priority pathogens	Campylobacter spp.	Other priority pathogens	No	No	Yes	No	Unknown	Miscellaneous
376	WHO AMR pipeline analysis	2021-11-01	CF-5/20	Non-traditional	Alginate oligosaccharide (G-block) fragment	Cystic fibrosis	Inhalation	Phase II	NCT03822455	AlgiPharma AS	Priority pathogens	All critical priority pathogens	Critical priority pathogens	No	No	Yes	No	Unknown	Miscellaneous
377	WHO AMR pipeline analysis	2021-11-01	CF-5/20	Non-traditional	Alginate oligosaccharide (G-block) fragment	Cystic fibrosis	Inhalation	Phase II	NCT03822455	AlgiPharma AS	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	No	No	Yes	No	Unknown	Miscellaneous
378	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Bacteriophage	E. coli	IV	Phase II	NCT04287478	"Adaptive Phage
Therapeutics"	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
379	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Bacteriophage	E. coli	IV	Phase II	NCT04287478	"Adaptive Phage
Therapeutics"	Priority pathogens	Staphylococcus aureus	Other priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
380	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Bacteriophage	E. coli	IV	Phase II	NCT04287478	"Adaptive Phage
Therapeutics"	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
381	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Bacteriophage	E. coli	IV	Phase II	NCT04287478	"Adaptive Phage
Therapeutics"	Priority pathogens	Other priority pathogens	Other priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
382	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Bacteriophage	E. coli	IV	Phase II	NCT04287478	"Adaptive Phage
Therapeutics"	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
383	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Bacteriophage	E. coli	IV	Phase II	NCT04287478	"Adaptive Phage
Therapeutics"	Priority pathogens	Helicobacter pylori	Other priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
384	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Bacteriophage	E. coli	IV	Phase II	NCT04287478	"Adaptive Phage
Therapeutics"	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
385	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Bacteriophage	E. coli	IV	Phase II	NCT04287478	"Adaptive Phage
Therapeutics"	Priority pathogens	Enterococcus faecium	Other priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
386	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Bacteriophage	E. coli	IV	Phase II	NCT04287478	"Adaptive Phage
Therapeutics"	Priority pathogens	Enterobacterales	Critical priority pathogens	Yes	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
387	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Bacteriophage	E. coli	IV	Phase II	NCT04287478	"Adaptive Phage
Therapeutics"	Priority pathogens	Critical priority pathogens	Critical priority pathogens	Yes	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
388	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Bacteriophage	E. coli	IV	Phase II	NCT04287478	"Adaptive Phage
Therapeutics"	Priority pathogens	Campylobacter spp.	Other priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
389	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Bacteriophage	E. coli	IV	Phase II	NCT04287478	"Adaptive Phage
Therapeutics"	Priority pathogens	All critical priority pathogens	Critical priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
390	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Bacteriophage	E. coli	IV	Phase II	NCT04287478	"Adaptive Phage
Therapeutics"	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
391	WHO AMR pipeline analysis	2021-11-01		Antibiotics	Boronate-BLI + undisclosed	 Gram-negative infections	IV	Phase I	NCT04380207, NCT05072444	Qpex Biopharma	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	No	Inconclusive	Yes	No	Unknown	QPX7728 + QPX2014
392	WHO AMR pipeline analysis	2021-11-01		Antibiotics	Boronate-BLI + undisclosed	 Gram-negative infections	IV	Phase I	NCT04380207, NCT05072444	Qpex Biopharma	Priority pathogens	Staphylococcus aureus	Other priority pathogens	No	Inconclusive	Yes	No	Unknown	QPX7728 + QPX2014
393	WHO AMR pipeline analysis	2021-11-01		Antibiotics	Boronate-BLI + undisclosed	 Gram-negative infections	IV	Phase I	NCT04380207, NCT05072444	Qpex Biopharma	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	Yes	Inconclusive	Yes	No	Unknown	QPX7728 + QPX2014
394	WHO AMR pipeline analysis	2021-11-01		Antibiotics	Boronate-BLI + undisclosed	 Gram-negative infections	IV	Phase I	NCT04380207, NCT05072444	Qpex Biopharma	Priority pathogens	Other priority pathogens	Other priority pathogens	No	Inconclusive	Yes	No	Unknown	QPX7728 + QPX2014
395	WHO AMR pipeline analysis	2021-11-01		Antibiotics	Boronate-BLI + undisclosed	 Gram-negative infections	IV	Phase I	NCT04380207, NCT05072444	Qpex Biopharma	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	No	Inconclusive	Yes	No	Unknown	QPX7728 + QPX2014
396	WHO AMR pipeline analysis	2021-11-01		Antibiotics	Boronate-BLI + undisclosed	 Gram-negative infections	IV	Phase I	NCT04380207, NCT05072444	Qpex Biopharma	Priority pathogens	Helicobacter pylori	Other priority pathogens	No	Inconclusive	Yes	No	Unknown	QPX7728 + QPX2014
397	WHO AMR pipeline analysis	2021-11-01		Antibiotics	Boronate-BLI + undisclosed	 Gram-negative infections	IV	Phase I	NCT04380207, NCT05072444	Qpex Biopharma	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	No	Inconclusive	Yes	No	Unknown	QPX7728 + QPX2014
398	WHO AMR pipeline analysis	2021-11-01		Antibiotics	Boronate-BLI + undisclosed	 Gram-negative infections	IV	Phase I	NCT04380207, NCT05072444	Qpex Biopharma	Priority pathogens	Enterococcus faecium	Other priority pathogens	No	Inconclusive	Yes	No	Unknown	QPX7728 + QPX2014
399	WHO AMR pipeline analysis	2021-11-01		Antibiotics	Boronate-BLI + undisclosed	 Gram-negative infections	IV	Phase I	NCT04380207, NCT05072444	Qpex Biopharma	Priority pathogens	Enterobacterales	Critical priority pathogens	Yes	Inconclusive	Yes	No	Unknown	QPX7728 + QPX2014
400	WHO AMR pipeline analysis	2021-11-01		Antibiotics	Boronate-BLI + undisclosed	 Gram-negative infections	IV	Phase I	NCT04380207, NCT05072444	Qpex Biopharma	Priority pathogens	Critical priority pathogens	Critical priority pathogens	Yes	Inconclusive	Yes	No	Unknown	QPX7728 + QPX2014
401	WHO AMR pipeline analysis	2021-11-01		Antibiotics	Boronate-BLI + undisclosed	 Gram-negative infections	IV	Phase I	NCT04380207, NCT05072444	Qpex Biopharma	Priority pathogens	Campylobacter spp.	Other priority pathogens	No	Inconclusive	Yes	No	Unknown	QPX7728 + QPX2014
402	WHO AMR pipeline analysis	2021-11-01		Antibiotics	Boronate-BLI + undisclosed	 Gram-negative infections	IV	Phase I	NCT04380207, NCT05072444	Qpex Biopharma	Priority pathogens	All critical priority pathogens	Critical priority pathogens	Yes	Inconclusive	Yes	No	Unknown	QPX7728 + QPX2014
403	WHO AMR pipeline analysis	2021-11-01		Antibiotics	Boronate-BLI + undisclosed	 Gram-negative infections	IV	Phase I	NCT04380207, NCT05072444	Qpex Biopharma	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	Yes	Inconclusive	Yes	No	Unknown	QPX7728 + QPX2014
404	WHO AMR pipeline analysis	2021-11-01		Antibiotics	Boronate-BLI + undisclosed	 Gram-negative infections	Oral	Phase I	NCT03939429	Qpex Biopharma	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	No	Inconclusive	Yes	No	Unknown	QPX7728 + QPX2015
405	WHO AMR pipeline analysis	2021-11-01		Antibiotics	Boronate-BLI + undisclosed	 Gram-negative infections	Oral	Phase I	NCT03939429	Qpex Biopharma	Priority pathogens	Staphylococcus aureus	Other priority pathogens	No	Inconclusive	Yes	No	Unknown	QPX7728 + QPX2015
406	WHO AMR pipeline analysis	2021-11-01		Antibiotics	Boronate-BLI + undisclosed	 Gram-negative infections	Oral	Phase I	NCT03939429	Qpex Biopharma	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	Possibly	Inconclusive	Yes	No	Unknown	QPX7728 + QPX2015
407	WHO AMR pipeline analysis	2021-11-01		Antibiotics	Boronate-BLI + undisclosed	 Gram-negative infections	Oral	Phase I	NCT03939429	Qpex Biopharma	Priority pathogens	Other priority pathogens	Other priority pathogens	No	Inconclusive	Yes	No	Unknown	QPX7728 + QPX2015
408	WHO AMR pipeline analysis	2021-11-01		Antibiotics	Boronate-BLI + undisclosed	 Gram-negative infections	Oral	Phase I	NCT03939429	Qpex Biopharma	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	No	Inconclusive	Yes	No	Unknown	QPX7728 + QPX2015
409	WHO AMR pipeline analysis	2021-11-01		Antibiotics	Boronate-BLI + undisclosed	 Gram-negative infections	Oral	Phase I	NCT03939429	Qpex Biopharma	Priority pathogens	Helicobacter pylori	Other priority pathogens	No	Inconclusive	Yes	No	Unknown	QPX7728 + QPX2015
410	WHO AMR pipeline analysis	2021-11-01		Antibiotics	Boronate-BLI + undisclosed	 Gram-negative infections	Oral	Phase I	NCT03939429	Qpex Biopharma	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	No	Inconclusive	Yes	No	Unknown	QPX7728 + QPX2015
411	WHO AMR pipeline analysis	2021-11-01		Antibiotics	Boronate-BLI + undisclosed	 Gram-negative infections	Oral	Phase I	NCT03939429	Qpex Biopharma	Priority pathogens	Enterococcus faecium	Other priority pathogens	No	Inconclusive	Yes	No	Unknown	QPX7728 + QPX2015
412	WHO AMR pipeline analysis	2021-11-01		Antibiotics	Boronate-BLI + undisclosed	 Gram-negative infections	Oral	Phase I	NCT03939429	Qpex Biopharma	Priority pathogens	Enterobacterales	Critical priority pathogens	Yes	Inconclusive	Yes	No	Unknown	QPX7728 + QPX2015
413	WHO AMR pipeline analysis	2021-11-01		Antibiotics	Boronate-BLI + undisclosed	 Gram-negative infections	Oral	Phase I	NCT03939429	Qpex Biopharma	Priority pathogens	Critical priority pathogens	Critical priority pathogens	Yes	Inconclusive	Yes	No	Unknown	QPX7728 + QPX2015
414	WHO AMR pipeline analysis	2021-11-01		Antibiotics	Boronate-BLI + undisclosed	 Gram-negative infections	Oral	Phase I	NCT03939429	Qpex Biopharma	Priority pathogens	Campylobacter spp.	Other priority pathogens	No	Inconclusive	Yes	No	Unknown	QPX7728 + QPX2015
415	WHO AMR pipeline analysis	2021-11-01		Antibiotics	Boronate-BLI + undisclosed	 Gram-negative infections	Oral	Phase I	NCT03939429	Qpex Biopharma	Priority pathogens	All critical priority pathogens	Critical priority pathogens	Possibly	Inconclusive	Yes	No	Unknown	QPX7728 + QPX2015
416	WHO AMR pipeline analysis	2021-11-01		Antibiotics	Boronate-BLI + undisclosed	 Gram-negative infections	Oral	Phase I	NCT03939429	Qpex Biopharma	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	Possibly	Inconclusive	Yes	No	Unknown	QPX7728 + QPX2015
417	WHO AMR pipeline analysis	2021-11-01		Antibiotics	Polymyxin	 Gram-negative infections	IV	Phase I	NCT04808414	Qpex Biopharma	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	No	Inconclusive	Yes	No	Unknown	QPX9003
418	WHO AMR pipeline analysis	2021-11-01		Antibiotics	Polymyxin	 Gram-negative infections	IV	Phase I	NCT04808414	Qpex Biopharma	Priority pathogens	Staphylococcus aureus	Other priority pathogens	No	Inconclusive	Yes	No	Unknown	QPX9003
419	WHO AMR pipeline analysis	2021-11-01		Antibiotics	Polymyxin	 Gram-negative infections	IV	Phase I	NCT04808414	Qpex Biopharma	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	Possibly	Inconclusive	Yes	No	Unknown	QPX9003
420	WHO AMR pipeline analysis	2021-11-01		Antibiotics	Polymyxin	 Gram-negative infections	IV	Phase I	NCT04808414	Qpex Biopharma	Priority pathogens	Other priority pathogens	Other priority pathogens	No	Inconclusive	Yes	No	Unknown	QPX9003
421	WHO AMR pipeline analysis	2021-11-01		Antibiotics	Polymyxin	 Gram-negative infections	IV	Phase I	NCT04808414	Qpex Biopharma	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	No	Inconclusive	Yes	No	Unknown	QPX9003
422	WHO AMR pipeline analysis	2021-11-01		Antibiotics	Polymyxin	 Gram-negative infections	IV	Phase I	NCT04808414	Qpex Biopharma	Priority pathogens	Helicobacter pylori	Other priority pathogens	No	Inconclusive	Yes	No	Unknown	QPX9003
423	WHO AMR pipeline analysis	2021-11-01		Antibiotics	Polymyxin	 Gram-negative infections	IV	Phase I	NCT04808414	Qpex Biopharma	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	No	Inconclusive	Yes	No	Unknown	QPX9003
424	WHO AMR pipeline analysis	2021-11-01		Antibiotics	Polymyxin	 Gram-negative infections	IV	Phase I	NCT04808414	Qpex Biopharma	Priority pathogens	Enterococcus faecium	Other priority pathogens	No	Inconclusive	Yes	No	Unknown	QPX9003
425	WHO AMR pipeline analysis	2021-11-01		Antibiotics	Polymyxin	 Gram-negative infections	IV	Phase I	NCT04808414	Qpex Biopharma	Priority pathogens	Enterobacterales	Critical priority pathogens	Possibly	Inconclusive	Yes	No	Unknown	QPX9003
426	WHO AMR pipeline analysis	2021-11-01		Antibiotics	Polymyxin	 Gram-negative infections	IV	Phase I	NCT04808414	Qpex Biopharma	Priority pathogens	Critical priority pathogens	Critical priority pathogens	Possibly	Inconclusive	Yes	No	Unknown	QPX9003
427	WHO AMR pipeline analysis	2021-11-01		Antibiotics	Polymyxin	 Gram-negative infections	IV	Phase I	NCT04808414	Qpex Biopharma	Priority pathogens	Campylobacter spp.	Other priority pathogens	No	Inconclusive	Yes	No	Unknown	QPX9003
428	WHO AMR pipeline analysis	2021-11-01		Antibiotics	Polymyxin	 Gram-negative infections	IV	Phase I	NCT04808414	Qpex Biopharma	Priority pathogens	All critical priority pathogens	Critical priority pathogens	Possibly	Inconclusive	Yes	No	Unknown	QPX9003
429	WHO AMR pipeline analysis	2021-11-01		Antibiotics	Polymyxin	 Gram-negative infections	IV	Phase I	NCT04808414	Qpex Biopharma	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	Possibly	Inconclusive	Yes	No	Unknown	QPX9003
430	WHO AMR pipeline analysis	2021-11-01	Abx MCP	Antibiotics	Macrocyclic peptide	Acinetobacter infections	IV	Phase I	Not registered	Roche	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	No	Inconclusive	Yes	No	Unknown	RG6006
431	WHO AMR pipeline analysis	2021-11-01	Abx MCP	Antibiotics	Macrocyclic peptide	Acinetobacter infections	IV	Phase I	Not registered	Roche	Priority pathogens	Staphylococcus aureus	Other priority pathogens	No	Inconclusive	Yes	No	Unknown	RG6006
432	WHO AMR pipeline analysis	2021-11-01	Abx MCP	Antibiotics	Macrocyclic peptide	Acinetobacter infections	IV	Phase I	Not registered	Roche	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	No	Inconclusive	Yes	No	Unknown	RG6006
433	WHO AMR pipeline analysis	2021-11-01	Abx MCP	Antibiotics	Macrocyclic peptide	Acinetobacter infections	IV	Phase I	Not registered	Roche	Priority pathogens	Other priority pathogens	Other priority pathogens	No	Inconclusive	Yes	No	Unknown	RG6006
434	WHO AMR pipeline analysis	2021-11-01	Abx MCP	Antibiotics	Macrocyclic peptide	Acinetobacter infections	IV	Phase I	Not registered	Roche	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	No	Inconclusive	Yes	No	Unknown	RG6006
435	WHO AMR pipeline analysis	2021-11-01	Abx MCP	Antibiotics	Macrocyclic peptide	Acinetobacter infections	IV	Phase I	Not registered	Roche	Priority pathogens	Helicobacter pylori	Other priority pathogens	No	Inconclusive	Yes	No	Unknown	RG6006
436	WHO AMR pipeline analysis	2021-11-01	Abx MCP	Antibiotics	Macrocyclic peptide	Acinetobacter infections	IV	Phase I	Not registered	Roche	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	No	Inconclusive	Yes	No	Unknown	RG6006
437	WHO AMR pipeline analysis	2021-11-01	Abx MCP	Antibiotics	Macrocyclic peptide	Acinetobacter infections	IV	Phase I	Not registered	Roche	Priority pathogens	Enterococcus faecium	Other priority pathogens	No	Inconclusive	Yes	No	Unknown	RG6006
438	WHO AMR pipeline analysis	2021-11-01	Abx MCP	Antibiotics	Macrocyclic peptide	Acinetobacter infections	IV	Phase I	Not registered	Roche	Priority pathogens	Enterobacterales	Critical priority pathogens	No	Inconclusive	Yes	No	Unknown	RG6006
439	WHO AMR pipeline analysis	2021-11-01	Abx MCP	Antibiotics	Macrocyclic peptide	Acinetobacter infections	IV	Phase I	Not registered	Roche	Priority pathogens	Critical priority pathogens	Critical priority pathogens	Possibly	Inconclusive	Yes	No	Unknown	RG6006
440	WHO AMR pipeline analysis	2021-11-01	Abx MCP	Antibiotics	Macrocyclic peptide	Acinetobacter infections	IV	Phase I	Not registered	Roche	Priority pathogens	Campylobacter spp.	Other priority pathogens	No	Inconclusive	Yes	No	Unknown	RG6006
441	WHO AMR pipeline analysis	2021-11-01	Abx MCP	Antibiotics	Macrocyclic peptide	Acinetobacter infections	IV	Phase I	Not registered	Roche	Priority pathogens	All critical priority pathogens	Critical priority pathogens	No	Inconclusive	Yes	No	Unknown	RG6006
442	WHO AMR pipeline analysis	2021-11-01	Abx MCP	Antibiotics	Macrocyclic peptide	Acinetobacter infections	IV	Phase I	Not registered	Roche	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	Possibly	Inconclusive	Yes	No	Unknown	RG6006
443	WHO AMR pipeline analysis	2021-11-01	Rhu-plasma gelsolin	Non-traditional	Recombinant human plasma gelsolin protein	Hospitalized CAP	IV	Phase II	NCT03466073, NCT04358406	BioAegis Therapeutics	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	Yes	No	Yes	No	Unknown	Immunomodulating agents
444	WHO AMR pipeline analysis	2021-11-01	Rhu-plasma gelsolin	Non-traditional	Recombinant human plasma gelsolin protein	Hospitalized CAP	IV	Phase II	NCT03466073, NCT04358406	BioAegis Therapeutics	Priority pathogens	Staphylococcus aureus	Other priority pathogens	Yes	No	Yes	No	Unknown	Immunomodulating agents
445	WHO AMR pipeline analysis	2021-11-01	Rhu-plasma gelsolin	Non-traditional	Recombinant human plasma gelsolin protein	Hospitalized CAP	IV	Phase II	NCT03466073, NCT04358406	BioAegis Therapeutics	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	Yes	No	Yes	No	Unknown	Immunomodulating agents
446	WHO AMR pipeline analysis	2021-11-01	Rhu-plasma gelsolin	Non-traditional	Recombinant human plasma gelsolin protein	Hospitalized CAP	IV	Phase II	NCT03466073, NCT04358406	BioAegis Therapeutics	Priority pathogens	Other priority pathogens	Other priority pathogens	Yes	No	Yes	No	Unknown	Immunomodulating agents
447	WHO AMR pipeline analysis	2021-11-01	Rhu-plasma gelsolin	Non-traditional	Recombinant human plasma gelsolin protein	Hospitalized CAP	IV	Phase II	NCT03466073, NCT04358406	BioAegis Therapeutics	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	Yes	No	Yes	No	Unknown	Immunomodulating agents
448	WHO AMR pipeline analysis	2021-11-01	Rhu-plasma gelsolin	Non-traditional	Recombinant human plasma gelsolin protein	Hospitalized CAP	IV	Phase II	NCT03466073, NCT04358406	BioAegis Therapeutics	Priority pathogens	Helicobacter pylori	Other priority pathogens	Yes	No	Yes	No	Unknown	Immunomodulating agents
449	WHO AMR pipeline analysis	2021-11-01	Rhu-plasma gelsolin	Non-traditional	Recombinant human plasma gelsolin protein	Hospitalized CAP	IV	Phase II	NCT03466073, NCT04358406	BioAegis Therapeutics	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	Yes	No	Yes	No	Unknown	Immunomodulating agents
450	WHO AMR pipeline analysis	2021-11-01	Rhu-plasma gelsolin	Non-traditional	Recombinant human plasma gelsolin protein	Hospitalized CAP	IV	Phase II	NCT03466073, NCT04358406	BioAegis Therapeutics	Priority pathogens	Enterococcus faecium	Other priority pathogens	Yes	No	Yes	No	Unknown	Immunomodulating agents
451	WHO AMR pipeline analysis	2021-11-01	Rhu-plasma gelsolin	Non-traditional	Recombinant human plasma gelsolin protein	Hospitalized CAP	IV	Phase II	NCT03466073, NCT04358406	BioAegis Therapeutics	Priority pathogens	Enterobacterales	Critical priority pathogens	Yes	No	Yes	No	Unknown	Immunomodulating agents
452	WHO AMR pipeline analysis	2021-11-01	Rhu-plasma gelsolin	Non-traditional	Recombinant human plasma gelsolin protein	Hospitalized CAP	IV	Phase II	NCT03466073, NCT04358406	BioAegis Therapeutics	Priority pathogens	Critical priority pathogens	Critical priority pathogens	Yes	No	Yes	No	Unknown	Immunomodulating agents
453	WHO AMR pipeline analysis	2021-11-01	Rhu-plasma gelsolin	Non-traditional	Recombinant human plasma gelsolin protein	Hospitalized CAP	IV	Phase II	NCT03466073, NCT04358406	BioAegis Therapeutics	Priority pathogens	Campylobacter spp.	Other priority pathogens	Yes	No	Yes	No	Unknown	Immunomodulating agents
454	WHO AMR pipeline analysis	2021-11-01	Rhu-plasma gelsolin	Non-traditional	Recombinant human plasma gelsolin protein	Hospitalized CAP	IV	Phase II	NCT03466073, NCT04358406	BioAegis Therapeutics	Priority pathogens	All critical priority pathogens	Critical priority pathogens	Yes	No	Yes	No	Unknown	Immunomodulating agents
455	WHO AMR pipeline analysis	2021-11-01	Rhu-plasma gelsolin	Non-traditional	Recombinant human plasma gelsolin protein	Hospitalized CAP	IV	Phase II	NCT03466073, NCT04358406	BioAegis Therapeutics	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	Yes	No	Yes	No	Unknown	Immunomodulating agents
456	WHO AMR pipeline analysis	2021-11-01	T-4288	Antibiotics	Macrolide	S. pneumoniae	IV & oral	Preregistration	JapicCTI163439	"Fujfilm Toyama
Chemical"	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	Yes	No	Yes	No	Unknown	Solithromycin
457	WHO AMR pipeline analysis	2021-11-01	T-4288	Antibiotics	Macrolide	S. pneumoniae	IV & oral	Preregistration	JapicCTI163439	"Fujfilm Toyama
Chemical"	Priority pathogens	Staphylococcus aureus	Other priority pathogens	No	No	Yes	No	Unknown	Solithromycin
458	WHO AMR pipeline analysis	2021-11-01	T-4288	Antibiotics	Macrolide	S. pneumoniae	IV & oral	Preregistration	JapicCTI163439	"Fujfilm Toyama
Chemical"	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	No	No	Yes	No	Unknown	Solithromycin
459	WHO AMR pipeline analysis	2021-11-01	T-4288	Antibiotics	Macrolide	S. pneumoniae	IV & oral	Preregistration	JapicCTI163439	"Fujfilm Toyama
Chemical"	Priority pathogens	Other priority pathogens	Other priority pathogens	Yes	No	Yes	No	Unknown	Solithromycin
460	WHO AMR pipeline analysis	2021-11-01	T-4288	Antibiotics	Macrolide	S. pneumoniae	IV & oral	Preregistration	JapicCTI163439	"Fujfilm Toyama
Chemical"	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	No	No	Yes	No	Unknown	Solithromycin
461	WHO AMR pipeline analysis	2021-11-01	T-4288	Antibiotics	Macrolide	S. pneumoniae	IV & oral	Preregistration	JapicCTI163439	"Fujfilm Toyama
Chemical"	Priority pathogens	Helicobacter pylori	Other priority pathogens	No	No	Yes	No	Unknown	Solithromycin
462	WHO AMR pipeline analysis	2021-11-01	T-4288	Antibiotics	Macrolide	S. pneumoniae	IV & oral	Preregistration	JapicCTI163439	"Fujfilm Toyama
Chemical"	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	Yes	No	Yes	No	Unknown	Solithromycin
463	WHO AMR pipeline analysis	2021-11-01	T-4288	Antibiotics	Macrolide	S. pneumoniae	IV & oral	Preregistration	JapicCTI163439	"Fujfilm Toyama
Chemical"	Priority pathogens	Enterococcus faecium	Other priority pathogens	No	No	Yes	No	Unknown	Solithromycin
464	WHO AMR pipeline analysis	2021-11-01	T-4288	Antibiotics	Macrolide	S. pneumoniae	IV & oral	Preregistration	JapicCTI163439	"Fujfilm Toyama
Chemical"	Priority pathogens	Enterobacterales	Critical priority pathogens	No	No	Yes	No	Unknown	Solithromycin
465	WHO AMR pipeline analysis	2021-11-01	T-4288	Antibiotics	Macrolide	S. pneumoniae	IV & oral	Preregistration	JapicCTI163439	"Fujfilm Toyama
Chemical"	Priority pathogens	Critical priority pathogens	Critical priority pathogens	No	No	Yes	No	Unknown	Solithromycin
466	WHO AMR pipeline analysis	2021-11-01	T-4288	Antibiotics	Macrolide	S. pneumoniae	IV & oral	Preregistration	JapicCTI163439	"Fujfilm Toyama
Chemical"	Priority pathogens	Campylobacter spp.	Other priority pathogens	No	No	Yes	No	Unknown	Solithromycin
467	WHO AMR pipeline analysis	2021-11-01	T-4288	Antibiotics	Macrolide	S. pneumoniae	IV & oral	Preregistration	JapicCTI163439	"Fujfilm Toyama
Chemical"	Priority pathogens	All critical priority pathogens	Critical priority pathogens	No	No	Yes	No	Unknown	Solithromycin
468	WHO AMR pipeline analysis	2021-11-01	T-4288	Antibiotics	Macrolide	S. pneumoniae	IV & oral	Preregistration	JapicCTI163439	"Fujfilm Toyama
Chemical"	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	No	No	Yes	No	Unknown	Solithromycin
469	WHO AMR pipeline analysis	2021-11-01		Antibiotics	Polymyxin	Acinetobacter infections	IV	Phase I	NCT04865393	Spero Therapeutics	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	No	No	Yes	No	Unknown	SPR-206
470	WHO AMR pipeline analysis	2021-11-01		Antibiotics	Polymyxin	Acinetobacter infections	IV	Phase I	NCT04865393	Spero Therapeutics	Priority pathogens	Staphylococcus aureus	Other priority pathogens	No	No	Yes	No	Unknown	SPR-206
471	WHO AMR pipeline analysis	2021-11-01		Antibiotics	Polymyxin	Acinetobacter infections	IV	Phase I	NCT04865393	Spero Therapeutics	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	Yes	No	Yes	No	Unknown	SPR-206
472	WHO AMR pipeline analysis	2021-11-01		Antibiotics	Polymyxin	Acinetobacter infections	IV	Phase I	NCT04865393	Spero Therapeutics	Priority pathogens	Other priority pathogens	Other priority pathogens	No	No	Yes	No	Unknown	SPR-206
473	WHO AMR pipeline analysis	2021-11-01		Antibiotics	Polymyxin	Acinetobacter infections	IV	Phase I	NCT04865393	Spero Therapeutics	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	No	No	Yes	No	Unknown	SPR-206
474	WHO AMR pipeline analysis	2021-11-01		Antibiotics	Polymyxin	Acinetobacter infections	IV	Phase I	NCT04865393	Spero Therapeutics	Priority pathogens	Helicobacter pylori	Other priority pathogens	No	No	Yes	No	Unknown	SPR-206
475	WHO AMR pipeline analysis	2021-11-01		Antibiotics	Polymyxin	Acinetobacter infections	IV	Phase I	NCT04865393	Spero Therapeutics	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	No	No	Yes	No	Unknown	SPR-206
476	WHO AMR pipeline analysis	2021-11-01		Antibiotics	Polymyxin	Acinetobacter infections	IV	Phase I	NCT04865393	Spero Therapeutics	Priority pathogens	Enterococcus faecium	Other priority pathogens	No	No	Yes	No	Unknown	SPR-206
477	WHO AMR pipeline analysis	2021-11-01		Antibiotics	Polymyxin	Acinetobacter infections	IV	Phase I	NCT04865393	Spero Therapeutics	Priority pathogens	Enterobacterales	Critical priority pathogens	Yes	No	Yes	No	Unknown	SPR-206
478	WHO AMR pipeline analysis	2021-11-01		Antibiotics	Polymyxin	Acinetobacter infections	IV	Phase I	NCT04865393	Spero Therapeutics	Priority pathogens	Critical priority pathogens	Critical priority pathogens	Yes	No	Yes	No	Unknown	SPR-206
479	WHO AMR pipeline analysis	2021-11-01		Antibiotics	Polymyxin	Acinetobacter infections	IV	Phase I	NCT04865393	Spero Therapeutics	Priority pathogens	Campylobacter spp.	Other priority pathogens	No	No	Yes	No	Unknown	SPR-206
480	WHO AMR pipeline analysis	2021-11-01		Antibiotics	Polymyxin	Acinetobacter infections	IV	Phase I	NCT04865393	Spero Therapeutics	Priority pathogens	All critical priority pathogens	Critical priority pathogens	No	No	Yes	No	Unknown	SPR-206
481	WHO AMR pipeline analysis	2021-11-01		Antibiotics	Polymyxin	Acinetobacter infections	IV	Phase I	NCT04865393	Spero Therapeutics	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	Yes	No	Yes	No	Unknown	SPR-206
482	WHO AMR pipeline analysis	2021-11-01	PF-03709270	Antibiotics	β-Lactam (penem)	uUTI, cUTI, IAI	IV, Oral	Phase III	NCT03354598, NCT03357614, NCT03358576	Iterum Therapeutics	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	No	No	Yes	No	Unknown	Sulopenem, sulopenem etzadroxil/probenecid
483	WHO AMR pipeline analysis	2021-11-01	PF-03709270	Antibiotics	β-Lactam (penem)	uUTI, cUTI, IAI	IV, Oral	Phase III	NCT03354598, NCT03357614, NCT03358576	Iterum Therapeutics	Priority pathogens	Staphylococcus aureus	Other priority pathogens	No	No	Yes	No	Unknown	Sulopenem, sulopenem etzadroxil/probenecid
484	WHO AMR pipeline analysis	2021-11-01	PF-03709270	Antibiotics	β-Lactam (penem)	uUTI, cUTI, IAI	IV, Oral	Phase III	NCT03354598, NCT03357614, NCT03358576	Iterum Therapeutics	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	Possibly	No	Yes	No	Unknown	Sulopenem, sulopenem etzadroxil/probenecid
485	WHO AMR pipeline analysis	2021-11-01	PF-03709270	Antibiotics	β-Lactam (penem)	uUTI, cUTI, IAI	IV, Oral	Phase III	NCT03354598, NCT03357614, NCT03358576	Iterum Therapeutics	Priority pathogens	Other priority pathogens	Other priority pathogens	No	No	Yes	No	Unknown	Sulopenem, sulopenem etzadroxil/probenecid
486	WHO AMR pipeline analysis	2021-11-01	PF-03709270	Antibiotics	β-Lactam (penem)	uUTI, cUTI, IAI	IV, Oral	Phase III	NCT03354598, NCT03357614, NCT03358576	Iterum Therapeutics	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	No	No	Yes	No	Unknown	Sulopenem, sulopenem etzadroxil/probenecid
487	WHO AMR pipeline analysis	2021-11-01	PF-03709270	Antibiotics	β-Lactam (penem)	uUTI, cUTI, IAI	IV, Oral	Phase III	NCT03354598, NCT03357614, NCT03358576	Iterum Therapeutics	Priority pathogens	Helicobacter pylori	Other priority pathogens	No	No	Yes	No	Unknown	Sulopenem, sulopenem etzadroxil/probenecid
488	WHO AMR pipeline analysis	2021-11-01	PF-03709270	Antibiotics	β-Lactam (penem)	uUTI, cUTI, IAI	IV, Oral	Phase III	NCT03354598, NCT03357614, NCT03358576	Iterum Therapeutics	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	No	No	Yes	No	Unknown	Sulopenem, sulopenem etzadroxil/probenecid
489	WHO AMR pipeline analysis	2021-11-01	PF-03709270	Antibiotics	β-Lactam (penem)	uUTI, cUTI, IAI	IV, Oral	Phase III	NCT03354598, NCT03357614, NCT03358576	Iterum Therapeutics	Priority pathogens	Enterococcus faecium	Other priority pathogens	No	No	Yes	No	Unknown	Sulopenem, sulopenem etzadroxil/probenecid
490	WHO AMR pipeline analysis	2021-11-01	PF-03709270	Antibiotics	β-Lactam (penem)	uUTI, cUTI, IAI	IV, Oral	Phase III	NCT03354598, NCT03357614, NCT03358576	Iterum Therapeutics	Priority pathogens	Enterobacterales	Critical priority pathogens	Possibly	No	Yes	No	Unknown	Sulopenem, sulopenem etzadroxil/probenecid
491	WHO AMR pipeline analysis	2021-11-01	PF-03709270	Antibiotics	β-Lactam (penem)	uUTI, cUTI, IAI	IV, Oral	Phase III	NCT03354598, NCT03357614, NCT03358576	Iterum Therapeutics	Priority pathogens	Critical priority pathogens	Critical priority pathogens	Yes	No	Yes	No	Unknown	Sulopenem, sulopenem etzadroxil/probenecid
492	WHO AMR pipeline analysis	2021-11-01	PF-03709270	Antibiotics	β-Lactam (penem)	uUTI, cUTI, IAI	IV, Oral	Phase III	NCT03354598, NCT03357614, NCT03358576	Iterum Therapeutics	Priority pathogens	Campylobacter spp.	Other priority pathogens	No	No	Yes	No	Unknown	Sulopenem, sulopenem etzadroxil/probenecid
493	WHO AMR pipeline analysis	2021-11-01	PF-03709270	Antibiotics	β-Lactam (penem)	uUTI, cUTI, IAI	IV, Oral	Phase III	NCT03354598, NCT03357614, NCT03358576	Iterum Therapeutics	Priority pathogens	All critical priority pathogens	Critical priority pathogens	No	No	Yes	No	Unknown	Sulopenem, sulopenem etzadroxil/probenecid
494	WHO AMR pipeline analysis	2021-11-01	PF-03709270	Antibiotics	β-Lactam (penem)	uUTI, cUTI, IAI	IV, Oral	Phase III	NCT03354598, NCT03357614, NCT03358576	Iterum Therapeutics	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	Possibly	No	Yes	No	Unknown	Sulopenem, sulopenem etzadroxil/probenecid
495	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Live biotherapeutic product	H. pylori	Oral	Phase I	ACTRN12620000923965	Servatus	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	No	No	Yes	No	Unknown	Microbiome-modulating agents
496	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Live biotherapeutic product	H. pylori	Oral	Phase I	ACTRN12620000923965	Servatus	Priority pathogens	Staphylococcus aureus	Other priority pathogens	No	No	Yes	No	Unknown	Microbiome-modulating agents
497	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Live biotherapeutic product	H. pylori	Oral	Phase I	ACTRN12620000923965	Servatus	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	No	No	Yes	No	Unknown	Microbiome-modulating agents
498	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Live biotherapeutic product	H. pylori	Oral	Phase I	ACTRN12620000923965	Servatus	Priority pathogens	Other priority pathogens	Other priority pathogens	No	No	Yes	No	Unknown	Microbiome-modulating agents
499	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Live biotherapeutic product	H. pylori	Oral	Phase I	ACTRN12620000923965	Servatus	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	No	No	Yes	No	Unknown	Microbiome-modulating agents
500	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Live biotherapeutic product	H. pylori	Oral	Phase I	ACTRN12620000923965	Servatus	Priority pathogens	Helicobacter pylori	Other priority pathogens	Yes	No	Yes	No	Unknown	Microbiome-modulating agents
501	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Live biotherapeutic product	H. pylori	Oral	Phase I	ACTRN12620000923965	Servatus	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	No	No	Yes	No	Unknown	Microbiome-modulating agents
502	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Live biotherapeutic product	H. pylori	Oral	Phase I	ACTRN12620000923965	Servatus	Priority pathogens	Enterococcus faecium	Other priority pathogens	No	No	Yes	No	Unknown	Microbiome-modulating agents
503	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Live biotherapeutic product	H. pylori	Oral	Phase I	ACTRN12620000923965	Servatus	Priority pathogens	Enterobacterales	Critical priority pathogens	No	No	Yes	No	Unknown	Microbiome-modulating agents
504	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Live biotherapeutic product	H. pylori	Oral	Phase I	ACTRN12620000923965	Servatus	Priority pathogens	Critical priority pathogens	Critical priority pathogens	No	No	Yes	No	Unknown	Microbiome-modulating agents
505	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Live biotherapeutic product	H. pylori	Oral	Phase I	ACTRN12620000923965	Servatus	Priority pathogens	Campylobacter spp.	Other priority pathogens	No	No	Yes	No	Unknown	Microbiome-modulating agents
506	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Live biotherapeutic product	H. pylori	Oral	Phase I	ACTRN12620000923965	Servatus	Priority pathogens	All critical priority pathogens	Critical priority pathogens	No	No	Yes	No	Unknown	Microbiome-modulating agents
507	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Live biotherapeutic product	H. pylori	Oral	Phase I	ACTRN12620000923965	Servatus	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	No	No	Yes	No	Unknown	Microbiome-modulating agents
508	WHO AMR pipeline analysis	2021-11-01	VNRX-5133 + cefepime	Antibiotics	Boronate BLI + β-lactam (cephalosporin)	cUTI and AP	IV	Phase III	NCT03840148	VenatoRx Pharmaceuticals, Inc/ GARDP	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	No	Yes	Yes	No	Unknown	Taniborbactam + cefepime
509	WHO AMR pipeline analysis	2021-11-01	VNRX-5133 + cefepime	Antibiotics	Boronate BLI + β-lactam (cephalosporin)	cUTI and AP	IV	Phase III	NCT03840148	VenatoRx Pharmaceuticals, Inc/ GARDP	Priority pathogens	Staphylococcus aureus	Other priority pathogens	No	Yes	Yes	No	Unknown	Taniborbactam + cefepime
510	WHO AMR pipeline analysis	2021-11-01	VNRX-5133 + cefepime	Antibiotics	Boronate BLI + β-lactam (cephalosporin)	cUTI and AP	IV	Phase III	NCT03840148	VenatoRx Pharmaceuticals, Inc/ GARDP	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	Yes	Yes	Yes	No	Unknown	Taniborbactam + cefepime
511	WHO AMR pipeline analysis	2021-11-01	VNRX-5133 + cefepime	Antibiotics	Boronate BLI + β-lactam (cephalosporin)	cUTI and AP	IV	Phase III	NCT03840148	VenatoRx Pharmaceuticals, Inc/ GARDP	Priority pathogens	Other priority pathogens	Other priority pathogens	No	Yes	Yes	No	Unknown	Taniborbactam + cefepime
512	WHO AMR pipeline analysis	2021-11-01	VNRX-5133 + cefepime	Antibiotics	Boronate BLI + β-lactam (cephalosporin)	cUTI and AP	IV	Phase III	NCT03840148	VenatoRx Pharmaceuticals, Inc/ GARDP	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	No	Yes	Yes	No	Unknown	Taniborbactam + cefepime
513	WHO AMR pipeline analysis	2021-11-01	VNRX-5133 + cefepime	Antibiotics	Boronate BLI + β-lactam (cephalosporin)	cUTI and AP	IV	Phase III	NCT03840148	VenatoRx Pharmaceuticals, Inc/ GARDP	Priority pathogens	Helicobacter pylori	Other priority pathogens	No	Yes	Yes	No	Unknown	Taniborbactam + cefepime
514	WHO AMR pipeline analysis	2021-11-01	VNRX-5133 + cefepime	Antibiotics	Boronate BLI + β-lactam (cephalosporin)	cUTI and AP	IV	Phase III	NCT03840148	VenatoRx Pharmaceuticals, Inc/ GARDP	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	No	Yes	Yes	No	Unknown	Taniborbactam + cefepime
515	WHO AMR pipeline analysis	2021-11-01	VNRX-5133 + cefepime	Antibiotics	Boronate BLI + β-lactam (cephalosporin)	cUTI and AP	IV	Phase III	NCT03840148	VenatoRx Pharmaceuticals, Inc/ GARDP	Priority pathogens	Enterococcus faecium	Other priority pathogens	No	Yes	Yes	No	Unknown	Taniborbactam + cefepime
516	WHO AMR pipeline analysis	2021-11-01	VNRX-5133 + cefepime	Antibiotics	Boronate BLI + β-lactam (cephalosporin)	cUTI and AP	IV	Phase III	NCT03840148	VenatoRx Pharmaceuticals, Inc/ GARDP	Priority pathogens	Enterobacterales	Critical priority pathogens	Yes	Yes	Yes	No	Unknown	Taniborbactam + cefepime
517	WHO AMR pipeline analysis	2021-11-01	VNRX-5133 + cefepime	Antibiotics	Boronate BLI + β-lactam (cephalosporin)	cUTI and AP	IV	Phase III	NCT03840148	VenatoRx Pharmaceuticals, Inc/ GARDP	Priority pathogens	Critical priority pathogens	Critical priority pathogens	Yes	Yes	Yes	No	Unknown	Taniborbactam + cefepime
518	WHO AMR pipeline analysis	2021-11-01	VNRX-5133 + cefepime	Antibiotics	Boronate BLI + β-lactam (cephalosporin)	cUTI and AP	IV	Phase III	NCT03840148	VenatoRx Pharmaceuticals, Inc/ GARDP	Priority pathogens	Campylobacter spp.	Other priority pathogens	No	Yes	Yes	No	Unknown	Taniborbactam + cefepime
519	WHO AMR pipeline analysis	2021-11-01	VNRX-5133 + cefepime	Antibiotics	Boronate BLI + β-lactam (cephalosporin)	cUTI and AP	IV	Phase III	NCT03840148	VenatoRx Pharmaceuticals, Inc/ GARDP	Priority pathogens	All critical priority pathogens	Critical priority pathogens	No	Yes	Yes	No	Unknown	Taniborbactam + cefepime
520	WHO AMR pipeline analysis	2021-11-01	VNRX-5133 + cefepime	Antibiotics	Boronate BLI + β-lactam (cephalosporin)	cUTI and AP	IV	Phase III	NCT03840148	VenatoRx Pharmaceuticals, Inc/ GARDP	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	Possibly	Yes	Yes	No	Unknown	Taniborbactam + cefepime
521	WHO AMR pipeline analysis	2021-11-01	–	Antibiotics	Rifamycin-quinolizinone hybrid	Gastrointestinal infections (caused by S. aureus and H. pylori)	IV, Oral	Phase II	NCT03964493	Tennor Therapeutics	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	No	No	Yes	No	Unknown	TNP-2092
522	WHO AMR pipeline analysis	2021-11-01	–	Antibiotics	Rifamycin-quinolizinone hybrid	Gastrointestinal infections (caused by S. aureus and H. pylori)	IV, Oral	Phase II	NCT03964493	Tennor Therapeutics	Priority pathogens	Staphylococcus aureus	Other priority pathogens	Possibly	No	Yes	No	Unknown	TNP-2092
523	WHO AMR pipeline analysis	2021-11-01	–	Antibiotics	Rifamycin-quinolizinone hybrid	Gastrointestinal infections (caused by S. aureus and H. pylori)	IV, Oral	Phase II	NCT03964493	Tennor Therapeutics	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	No	No	Yes	No	Unknown	TNP-2092
524	WHO AMR pipeline analysis	2021-11-01	–	Antibiotics	Rifamycin-quinolizinone hybrid	Gastrointestinal infections (caused by S. aureus and H. pylori)	IV, Oral	Phase II	NCT03964493	Tennor Therapeutics	Priority pathogens	Other priority pathogens	Other priority pathogens	Possibly	No	Yes	No	Unknown	TNP-2092
525	WHO AMR pipeline analysis	2021-11-01	–	Antibiotics	Rifamycin-quinolizinone hybrid	Gastrointestinal infections (caused by S. aureus and H. pylori)	IV, Oral	Phase II	NCT03964493	Tennor Therapeutics	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	No	No	Yes	No	Unknown	TNP-2092
526	WHO AMR pipeline analysis	2021-11-01	–	Antibiotics	Rifamycin-quinolizinone hybrid	Gastrointestinal infections (caused by S. aureus and H. pylori)	IV, Oral	Phase II	NCT03964493	Tennor Therapeutics	Priority pathogens	Helicobacter pylori	Other priority pathogens	Possibly	No	Yes	No	Unknown	TNP-2092
527	WHO AMR pipeline analysis	2021-11-01	–	Antibiotics	Rifamycin-quinolizinone hybrid	Gastrointestinal infections (caused by S. aureus and H. pylori)	IV, Oral	Phase II	NCT03964493	Tennor Therapeutics	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	Possibly	No	Yes	No	Unknown	TNP-2092
528	WHO AMR pipeline analysis	2021-11-01	–	Antibiotics	Rifamycin-quinolizinone hybrid	Gastrointestinal infections (caused by S. aureus and H. pylori)	IV, Oral	Phase II	NCT03964493	Tennor Therapeutics	Priority pathogens	Enterococcus faecium	Other priority pathogens	Possibly	No	Yes	No	Unknown	TNP-2092
529	WHO AMR pipeline analysis	2021-11-01	–	Antibiotics	Rifamycin-quinolizinone hybrid	Gastrointestinal infections (caused by S. aureus and H. pylori)	IV, Oral	Phase II	NCT03964493	Tennor Therapeutics	Priority pathogens	Enterobacterales	Critical priority pathogens	No	No	Yes	No	Unknown	TNP-2092
530	WHO AMR pipeline analysis	2021-11-01	–	Antibiotics	Rifamycin-quinolizinone hybrid	Gastrointestinal infections (caused by S. aureus and H. pylori)	IV, Oral	Phase II	NCT03964493	Tennor Therapeutics	Priority pathogens	Critical priority pathogens	Critical priority pathogens	No	No	Yes	No	Unknown	TNP-2092
531	WHO AMR pipeline analysis	2021-11-01	–	Antibiotics	Rifamycin-quinolizinone hybrid	Gastrointestinal infections (caused by S. aureus and H. pylori)	IV, Oral	Phase II	NCT03964493	Tennor Therapeutics	Priority pathogens	Campylobacter spp.	Other priority pathogens	No	No	Yes	No	Unknown	TNP-2092
532	WHO AMR pipeline analysis	2021-11-01	–	Antibiotics	Rifamycin-quinolizinone hybrid	Gastrointestinal infections (caused by S. aureus and H. pylori)	IV, Oral	Phase II	NCT03964493	Tennor Therapeutics	Priority pathogens	All critical priority pathogens	Critical priority pathogens	No	No	Yes	No	Unknown	TNP-2092
533	WHO AMR pipeline analysis	2021-11-01	–	Antibiotics	Rifamycin-quinolizinone hybrid	Gastrointestinal infections (caused by S. aureus and H. pylori)	IV, Oral	Phase II	NCT03964493	Tennor Therapeutics	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	No	No	Yes	No	Unknown	TNP-2092
534	WHO AMR pipeline analysis	2021-11-01		Antibiotics	rifamycin-nitroimidazole conjugate	Helicobacter pylori infection, Clostridioides difficile infection, and bacterial vaginosis	Oral	Phase II	CTR20190734	TenNor Therapeutics	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	No	No	Yes	No	Unknown	TNP-2198
535	WHO AMR pipeline analysis	2021-11-01		Antibiotics	rifamycin-nitroimidazole conjugate	Helicobacter pylori infection, Clostridioides difficile infection, and bacterial vaginosis	Oral	Phase II	CTR20190734	TenNor Therapeutics	Priority pathogens	Staphylococcus aureus	Other priority pathogens	No	No	Yes	No	Unknown	TNP-2198
536	WHO AMR pipeline analysis	2021-11-01		Antibiotics	rifamycin-nitroimidazole conjugate	Helicobacter pylori infection, Clostridioides difficile infection, and bacterial vaginosis	Oral	Phase II	CTR20190734	TenNor Therapeutics	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	No	No	Yes	No	Unknown	TNP-2198
537	WHO AMR pipeline analysis	2021-11-01		Antibiotics	rifamycin-nitroimidazole conjugate	Helicobacter pylori infection, Clostridioides difficile infection, and bacterial vaginosis	Oral	Phase II	CTR20190734	TenNor Therapeutics	Priority pathogens	Other priority pathogens	Other priority pathogens	Yes	No	Yes	No	Unknown	TNP-2198
538	WHO AMR pipeline analysis	2021-11-01		Antibiotics	rifamycin-nitroimidazole conjugate	Helicobacter pylori infection, Clostridioides difficile infection, and bacterial vaginosis	Oral	Phase II	CTR20190734	TenNor Therapeutics	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	Possibly	No	Yes	No	Unknown	TNP-2198
539	WHO AMR pipeline analysis	2021-11-01		Antibiotics	rifamycin-nitroimidazole conjugate	Helicobacter pylori infection, Clostridioides difficile infection, and bacterial vaginosis	Oral	Phase II	CTR20190734	TenNor Therapeutics	Priority pathogens	Helicobacter pylori	Other priority pathogens	Yes	No	Yes	No	Unknown	TNP-2198
540	WHO AMR pipeline analysis	2021-11-01		Antibiotics	rifamycin-nitroimidazole conjugate	Helicobacter pylori infection, Clostridioides difficile infection, and bacterial vaginosis	Oral	Phase II	CTR20190734	TenNor Therapeutics	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	No	No	Yes	No	Unknown	TNP-2198
541	WHO AMR pipeline analysis	2021-11-01		Antibiotics	rifamycin-nitroimidazole conjugate	Helicobacter pylori infection, Clostridioides difficile infection, and bacterial vaginosis	Oral	Phase II	CTR20190734	TenNor Therapeutics	Priority pathogens	Enterococcus faecium	Other priority pathogens	No	No	Yes	No	Unknown	TNP-2198
542	WHO AMR pipeline analysis	2021-11-01		Antibiotics	rifamycin-nitroimidazole conjugate	Helicobacter pylori infection, Clostridioides difficile infection, and bacterial vaginosis	Oral	Phase II	CTR20190734	TenNor Therapeutics	Priority pathogens	Enterobacterales	Critical priority pathogens	No	No	Yes	No	Unknown	TNP-2198
543	WHO AMR pipeline analysis	2021-11-01		Antibiotics	rifamycin-nitroimidazole conjugate	Helicobacter pylori infection, Clostridioides difficile infection, and bacterial vaginosis	Oral	Phase II	CTR20190734	TenNor Therapeutics	Priority pathogens	Critical priority pathogens	Critical priority pathogens	No	No	Yes	No	Unknown	TNP-2198
544	WHO AMR pipeline analysis	2021-11-01		Antibiotics	rifamycin-nitroimidazole conjugate	Helicobacter pylori infection, Clostridioides difficile infection, and bacterial vaginosis	Oral	Phase II	CTR20190734	TenNor Therapeutics	Priority pathogens	Campylobacter spp.	Other priority pathogens	No	No	Yes	No	Unknown	TNP-2198
545	WHO AMR pipeline analysis	2021-11-01		Antibiotics	rifamycin-nitroimidazole conjugate	Helicobacter pylori infection, Clostridioides difficile infection, and bacterial vaginosis	Oral	Phase II	CTR20190734	TenNor Therapeutics	Priority pathogens	All critical priority pathogens	Critical priority pathogens	No	No	Yes	No	Unknown	TNP-2198
546	WHO AMR pipeline analysis	2021-11-01		Antibiotics	rifamycin-nitroimidazole conjugate	Helicobacter pylori infection, Clostridioides difficile infection, and bacterial vaginosis	Oral	Phase II	CTR20190734	TenNor Therapeutics	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	No	No	Yes	No	Unknown	TNP-2198
547	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Antibody	Gram-negative and Gram-positive bacterial infections	IV	Phase I	NCT04763759	Trellis Bioscience	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	Yes	No	Yes	No	Unknown	Antibodies
548	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Antibody	Gram-negative and Gram-positive bacterial infections	IV	Phase I	NCT04763759	Trellis Bioscience	Priority pathogens	Staphylococcus aureus	Other priority pathogens	Yes	No	Yes	No	Unknown	Antibodies
549	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Antibody	Gram-negative and Gram-positive bacterial infections	IV	Phase I	NCT04763759	Trellis Bioscience	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	Yes	No	Yes	No	Unknown	Antibodies
550	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Antibody	Gram-negative and Gram-positive bacterial infections	IV	Phase I	NCT04763759	Trellis Bioscience	Priority pathogens	Other priority pathogens	Other priority pathogens	Yes	No	Yes	No	Unknown	Antibodies
551	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Antibody	Gram-negative and Gram-positive bacterial infections	IV	Phase I	NCT04763759	Trellis Bioscience	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	Yes	No	Yes	No	Unknown	Antibodies
552	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Antibody	Gram-negative and Gram-positive bacterial infections	IV	Phase I	NCT04763759	Trellis Bioscience	Priority pathogens	Helicobacter pylori	Other priority pathogens	Possibly	No	Yes	No	Unknown	Antibodies
553	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Antibody	Gram-negative and Gram-positive bacterial infections	IV	Phase I	NCT04763759	Trellis Bioscience	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	Yes	No	Yes	No	Unknown	Antibodies
554	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Antibody	Gram-negative and Gram-positive bacterial infections	IV	Phase I	NCT04763759	Trellis Bioscience	Priority pathogens	Enterococcus faecium	Other priority pathogens	Yes	No	Yes	No	Unknown	Antibodies
555	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Antibody	Gram-negative and Gram-positive bacterial infections	IV	Phase I	NCT04763759	Trellis Bioscience	Priority pathogens	Enterobacterales	Critical priority pathogens	Yes	No	Yes	No	Unknown	Antibodies
556	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Antibody	Gram-negative and Gram-positive bacterial infections	IV	Phase I	NCT04763759	Trellis Bioscience	Priority pathogens	Critical priority pathogens	Critical priority pathogens	Yes	No	Yes	No	Unknown	Antibodies
557	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Antibody	Gram-negative and Gram-positive bacterial infections	IV	Phase I	NCT04763759	Trellis Bioscience	Priority pathogens	Campylobacter spp.	Other priority pathogens	Possibly	No	Yes	No	Unknown	Antibodies
558	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Antibody	Gram-negative and Gram-positive bacterial infections	IV	Phase I	NCT04763759	Trellis Bioscience	Priority pathogens	All critical priority pathogens	Critical priority pathogens	Yes	No	Yes	No	Unknown	Antibodies
559	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Antibody	Gram-negative and Gram-positive bacterial infections	IV	Phase I	NCT04763759	Trellis Bioscience	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	Yes	No	Yes	No	Unknown	Antibodies
560	WHO AMR pipeline analysis	2021-11-01		Antibiotics	Diflurobenzamide (FtsZ inhibitor)	MRSA	IV, Oral	Phase I	Not registered	TAXIS Pharmaceuticals	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	No	Yes	Yes	No	Unknown	TXA709
561	WHO AMR pipeline analysis	2021-11-01		Antibiotics	Diflurobenzamide (FtsZ inhibitor)	MRSA	IV, Oral	Phase I	Not registered	TAXIS Pharmaceuticals	Priority pathogens	Staphylococcus aureus	Other priority pathogens	Yes	Yes	Yes	No	Unknown	TXA709
562	WHO AMR pipeline analysis	2021-11-01		Antibiotics	Diflurobenzamide (FtsZ inhibitor)	MRSA	IV, Oral	Phase I	Not registered	TAXIS Pharmaceuticals	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	No	Yes	Yes	No	Unknown	TXA709
563	WHO AMR pipeline analysis	2021-11-01		Antibiotics	Diflurobenzamide (FtsZ inhibitor)	MRSA	IV, Oral	Phase I	Not registered	TAXIS Pharmaceuticals	Priority pathogens	Other priority pathogens	Other priority pathogens	Yes	Yes	Yes	No	Unknown	TXA709
564	WHO AMR pipeline analysis	2021-11-01		Antibiotics	Diflurobenzamide (FtsZ inhibitor)	MRSA	IV, Oral	Phase I	Not registered	TAXIS Pharmaceuticals	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	No	Yes	Yes	No	Unknown	TXA709
565	WHO AMR pipeline analysis	2021-11-01		Antibiotics	Diflurobenzamide (FtsZ inhibitor)	MRSA	IV, Oral	Phase I	Not registered	TAXIS Pharmaceuticals	Priority pathogens	Helicobacter pylori	Other priority pathogens	No	Yes	Yes	No	Unknown	TXA709
566	WHO AMR pipeline analysis	2021-11-01		Antibiotics	Diflurobenzamide (FtsZ inhibitor)	MRSA	IV, Oral	Phase I	Not registered	TAXIS Pharmaceuticals	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	Yes	Yes	Yes	No	Unknown	TXA709
567	WHO AMR pipeline analysis	2021-11-01		Antibiotics	Diflurobenzamide (FtsZ inhibitor)	MRSA	IV, Oral	Phase I	Not registered	TAXIS Pharmaceuticals	Priority pathogens	Enterococcus faecium	Other priority pathogens	No	Yes	Yes	No	Unknown	TXA709
568	WHO AMR pipeline analysis	2021-11-01		Antibiotics	Diflurobenzamide (FtsZ inhibitor)	MRSA	IV, Oral	Phase I	Not registered	TAXIS Pharmaceuticals	Priority pathogens	Enterobacterales	Critical priority pathogens	Possibly	Yes	Yes	No	Unknown	TXA709
569	WHO AMR pipeline analysis	2021-11-01		Antibiotics	Diflurobenzamide (FtsZ inhibitor)	MRSA	IV, Oral	Phase I	Not registered	TAXIS Pharmaceuticals	Priority pathogens	Critical priority pathogens	Critical priority pathogens	Yes	Yes	Yes	No	Unknown	TXA709
570	WHO AMR pipeline analysis	2021-11-01		Antibiotics	Diflurobenzamide (FtsZ inhibitor)	MRSA	IV, Oral	Phase I	Not registered	TAXIS Pharmaceuticals	Priority pathogens	Campylobacter spp.	Other priority pathogens	No	Yes	Yes	No	Unknown	TXA709
571	WHO AMR pipeline analysis	2021-11-01		Antibiotics	Diflurobenzamide (FtsZ inhibitor)	MRSA	IV, Oral	Phase I	Not registered	TAXIS Pharmaceuticals	Priority pathogens	All critical priority pathogens	Critical priority pathogens	No	Yes	Yes	No	Unknown	TXA709
572	WHO AMR pipeline analysis	2021-11-01		Antibiotics	Diflurobenzamide (FtsZ inhibitor)	MRSA	IV, Oral	Phase I	Not registered	TAXIS Pharmaceuticals	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	Possibly	Yes	Yes	No	Unknown	TXA709
573	WHO AMR pipeline analysis	2021-11-01	–	Antibiotics	Boronate-BLI + cephalosporin	Gram-negative infections	Oral	Phase I	NCT04243863	Venatorx	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	No	Yes	Yes	No	Unknown	VNRX-7145 + ceftibuten
574	WHO AMR pipeline analysis	2021-11-01	–	Antibiotics	Boronate-BLI + cephalosporin	Gram-negative infections	Oral	Phase I	NCT04243863	Venatorx	Priority pathogens	Staphylococcus aureus	Other priority pathogens	No	Yes	Yes	No	Unknown	VNRX-7145 + ceftibuten
575	WHO AMR pipeline analysis	2021-11-01	–	Antibiotics	Boronate-BLI + cephalosporin	Gram-negative infections	Oral	Phase I	NCT04243863	Venatorx	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	Possibly	Yes	Yes	No	Unknown	VNRX-7145 + ceftibuten
576	WHO AMR pipeline analysis	2021-11-01	–	Antibiotics	Boronate-BLI + cephalosporin	Gram-negative infections	Oral	Phase I	NCT04243863	Venatorx	Priority pathogens	Other priority pathogens	Other priority pathogens	No	Yes	Yes	No	Unknown	VNRX-7145 + ceftibuten
577	WHO AMR pipeline analysis	2021-11-01	–	Antibiotics	Boronate-BLI + cephalosporin	Gram-negative infections	Oral	Phase I	NCT04243863	Venatorx	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	No	Yes	Yes	No	Unknown	VNRX-7145 + ceftibuten
578	WHO AMR pipeline analysis	2021-11-01	–	Antibiotics	Boronate-BLI + cephalosporin	Gram-negative infections	Oral	Phase I	NCT04243863	Venatorx	Priority pathogens	Helicobacter pylori	Other priority pathogens	No	Yes	Yes	No	Unknown	VNRX-7145 + ceftibuten
579	WHO AMR pipeline analysis	2021-11-01	–	Antibiotics	Boronate-BLI + cephalosporin	Gram-negative infections	Oral	Phase I	NCT04243863	Venatorx	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	No	Yes	Yes	No	Unknown	VNRX-7145 + ceftibuten
580	WHO AMR pipeline analysis	2021-11-01	–	Antibiotics	Boronate-BLI + cephalosporin	Gram-negative infections	Oral	Phase I	NCT04243863	Venatorx	Priority pathogens	Enterococcus faecium	Other priority pathogens	No	Yes	Yes	No	Unknown	VNRX-7145 + ceftibuten
581	WHO AMR pipeline analysis	2021-11-01	–	Antibiotics	Boronate-BLI + cephalosporin	Gram-negative infections	Oral	Phase I	NCT04243863	Venatorx	Priority pathogens	Enterobacterales	Critical priority pathogens	Yes	Yes	Yes	No	Unknown	VNRX-7145 + ceftibuten
582	WHO AMR pipeline analysis	2021-11-01	–	Antibiotics	Boronate-BLI + cephalosporin	Gram-negative infections	Oral	Phase I	NCT04243863	Venatorx	Priority pathogens	Critical priority pathogens	Critical priority pathogens	Yes	Yes	Yes	No	Unknown	VNRX-7145 + ceftibuten
583	WHO AMR pipeline analysis	2021-11-01	–	Antibiotics	Boronate-BLI + cephalosporin	Gram-negative infections	Oral	Phase I	NCT04243863	Venatorx	Priority pathogens	Campylobacter spp.	Other priority pathogens	No	Yes	Yes	No	Unknown	VNRX-7145 + ceftibuten
584	WHO AMR pipeline analysis	2021-11-01	–	Antibiotics	Boronate-BLI + cephalosporin	Gram-negative infections	Oral	Phase I	NCT04243863	Venatorx	Priority pathogens	All critical priority pathogens	Critical priority pathogens	No	Yes	Yes	No	Unknown	VNRX-7145 + ceftibuten
585	WHO AMR pipeline analysis	2021-11-01	–	Antibiotics	Boronate-BLI + cephalosporin	Gram-negative infections	Oral	Phase I	NCT04243863	Venatorx	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	Possibly	Yes	Yes	No	Unknown	VNRX-7145 + ceftibuten
586	WHO AMR pipeline analysis	2021-11-01		Antibiotics	"BLI + carbapenem + 
degradation inhibitor"	HABP/VABP	IV	Phase I	NCT04802863, NCT04482569	Sinovent	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	No	No	Yes	No	Unknown	"XNW4107 +imipenem 
+ cilastin"
587	WHO AMR pipeline analysis	2021-11-01		Antibiotics	"BLI + carbapenem + 
degradation inhibitor"	HABP/VABP	IV	Phase I	NCT04802863, NCT04482569	Sinovent	Priority pathogens	Staphylococcus aureus	Other priority pathogens	No	No	Yes	No	Unknown	"XNW4107 +imipenem 
+ cilastin"
588	WHO AMR pipeline analysis	2021-11-01		Antibiotics	"BLI + carbapenem + 
degradation inhibitor"	HABP/VABP	IV	Phase I	NCT04802863, NCT04482569	Sinovent	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	Possibly	No	Yes	No	Unknown	"XNW4107 +imipenem 
+ cilastin"
589	WHO AMR pipeline analysis	2021-11-01		Antibiotics	"BLI + carbapenem + 
degradation inhibitor"	HABP/VABP	IV	Phase I	NCT04802863, NCT04482569	Sinovent	Priority pathogens	Other priority pathogens	Other priority pathogens	No	No	Yes	No	Unknown	"XNW4107 +imipenem 
+ cilastin"
590	WHO AMR pipeline analysis	2021-11-01		Antibiotics	"BLI + carbapenem + 
degradation inhibitor"	HABP/VABP	IV	Phase I	NCT04802863, NCT04482569	Sinovent	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	No	No	Yes	No	Unknown	"XNW4107 +imipenem 
+ cilastin"
591	WHO AMR pipeline analysis	2021-11-01		Antibiotics	"BLI + carbapenem + 
degradation inhibitor"	HABP/VABP	IV	Phase I	NCT04802863, NCT04482569	Sinovent	Priority pathogens	Helicobacter pylori	Other priority pathogens	No	No	Yes	No	Unknown	"XNW4107 +imipenem 
+ cilastin"
592	WHO AMR pipeline analysis	2021-11-01		Antibiotics	"BLI + carbapenem + 
degradation inhibitor"	HABP/VABP	IV	Phase I	NCT04802863, NCT04482569	Sinovent	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	No	No	Yes	No	Unknown	"XNW4107 +imipenem 
+ cilastin"
593	WHO AMR pipeline analysis	2021-11-01		Antibiotics	"BLI + carbapenem + 
degradation inhibitor"	HABP/VABP	IV	Phase I	NCT04802863, NCT04482569	Sinovent	Priority pathogens	Enterococcus faecium	Other priority pathogens	No	No	Yes	No	Unknown	"XNW4107 +imipenem 
+ cilastin"
594	WHO AMR pipeline analysis	2021-11-01		Antibiotics	"BLI + carbapenem + 
degradation inhibitor"	HABP/VABP	IV	Phase I	NCT04802863, NCT04482569	Sinovent	Priority pathogens	Enterobacterales	Critical priority pathogens	Possibly	No	Yes	No	Unknown	"XNW4107 +imipenem 
+ cilastin"
595	WHO AMR pipeline analysis	2021-11-01		Antibiotics	"BLI + carbapenem + 
degradation inhibitor"	HABP/VABP	IV	Phase I	NCT04802863, NCT04482569	Sinovent	Priority pathogens	Critical priority pathogens	Critical priority pathogens	Possibly	No	Yes	No	Unknown	"XNW4107 +imipenem 
+ cilastin"
596	WHO AMR pipeline analysis	2021-11-01		Antibiotics	"BLI + carbapenem + 
degradation inhibitor"	HABP/VABP	IV	Phase I	NCT04802863, NCT04482569	Sinovent	Priority pathogens	Campylobacter spp.	Other priority pathogens	No	No	Yes	No	Unknown	"XNW4107 +imipenem 
+ cilastin"
597	WHO AMR pipeline analysis	2021-11-01		Antibiotics	"BLI + carbapenem + 
degradation inhibitor"	HABP/VABP	IV	Phase I	NCT04802863, NCT04482569	Sinovent	Priority pathogens	All critical priority pathogens	Critical priority pathogens	Possibly	No	Yes	No	Unknown	"XNW4107 +imipenem 
+ cilastin"
598	WHO AMR pipeline analysis	2021-11-01		Antibiotics	"BLI + carbapenem + 
degradation inhibitor"	HABP/VABP	IV	Phase I	NCT04802863, NCT04482569	Sinovent	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	Possibly	No	Yes	No	Unknown	"XNW4107 +imipenem 
+ cilastin"
599	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT04684641	Felix Biotechnology/ Yale University	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
600	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT04684641	Felix Biotechnology/ Yale University	Priority pathogens	Staphylococcus aureus	Other priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
601	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT04684641	Felix Biotechnology/ Yale University	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	Yes	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
602	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT04684641	Felix Biotechnology/ Yale University	Priority pathogens	Other priority pathogens	Other priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
603	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT04684641	Felix Biotechnology/ Yale University	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
604	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT04684641	Felix Biotechnology/ Yale University	Priority pathogens	Helicobacter pylori	Other priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
605	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT04684641	Felix Biotechnology/ Yale University	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
606	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT04684641	Felix Biotechnology/ Yale University	Priority pathogens	Enterococcus faecium	Other priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
607	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT04684641	Felix Biotechnology/ Yale University	Priority pathogens	Enterobacterales	Critical priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
608	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT04684641	Felix Biotechnology/ Yale University	Priority pathogens	Critical priority pathogens	Critical priority pathogens	Yes	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
609	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT04684641	Felix Biotechnology/ Yale University	Priority pathogens	Campylobacter spp.	Other priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
610	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT04684641	Felix Biotechnology/ Yale University	Priority pathogens	All critical priority pathogens	Critical priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
611	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Bacteriophage	CF subjects with P. aeruginosa infections	Inhalation	Phase II	NCT04684641	Felix Biotechnology/ Yale University	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	No	No	Yes	No	Unknown	Bacteriophages and phage-derived enzymes
612	WHO AMR pipeline analysis	2021-11-01	–	Antibiotics	DBO-BLI/ PBP2 binder + cephalosporin	Gram-negative bacterial infections	IV	Phase I	NCT02532140, NCT02942810, NCT02707107	Wockhardt Ltd.	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	No	No	Yes	No	Unknown	Zidebactam + cefepime
613	WHO AMR pipeline analysis	2021-11-01	–	Antibiotics	DBO-BLI/ PBP2 binder + cephalosporin	Gram-negative bacterial infections	IV	Phase I	NCT02532140, NCT02942810, NCT02707107	Wockhardt Ltd.	Priority pathogens	Staphylococcus aureus	Other priority pathogens	No	No	Yes	No	Unknown	Zidebactam + cefepime
614	WHO AMR pipeline analysis	2021-11-01	–	Antibiotics	DBO-BLI/ PBP2 binder + cephalosporin	Gram-negative bacterial infections	IV	Phase I	NCT02532140, NCT02942810, NCT02707107	Wockhardt Ltd.	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	Yes	No	Yes	No	Unknown	Zidebactam + cefepime
615	WHO AMR pipeline analysis	2021-11-01	–	Antibiotics	DBO-BLI/ PBP2 binder + cephalosporin	Gram-negative bacterial infections	IV	Phase I	NCT02532140, NCT02942810, NCT02707107	Wockhardt Ltd.	Priority pathogens	Other priority pathogens	Other priority pathogens	No	No	Yes	No	Unknown	Zidebactam + cefepime
616	WHO AMR pipeline analysis	2021-11-01	–	Antibiotics	DBO-BLI/ PBP2 binder + cephalosporin	Gram-negative bacterial infections	IV	Phase I	NCT02532140, NCT02942810, NCT02707107	Wockhardt Ltd.	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	No	No	Yes	No	Unknown	Zidebactam + cefepime
617	WHO AMR pipeline analysis	2021-11-01	–	Antibiotics	DBO-BLI/ PBP2 binder + cephalosporin	Gram-negative bacterial infections	IV	Phase I	NCT02532140, NCT02942810, NCT02707107	Wockhardt Ltd.	Priority pathogens	Helicobacter pylori	Other priority pathogens	No	No	Yes	No	Unknown	Zidebactam + cefepime
618	WHO AMR pipeline analysis	2021-11-01	–	Antibiotics	DBO-BLI/ PBP2 binder + cephalosporin	Gram-negative bacterial infections	IV	Phase I	NCT02532140, NCT02942810, NCT02707107	Wockhardt Ltd.	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	No	No	Yes	No	Unknown	Zidebactam + cefepime
619	WHO AMR pipeline analysis	2021-11-01	–	Antibiotics	DBO-BLI/ PBP2 binder + cephalosporin	Gram-negative bacterial infections	IV	Phase I	NCT02532140, NCT02942810, NCT02707107	Wockhardt Ltd.	Priority pathogens	Enterococcus faecium	Other priority pathogens	No	No	Yes	No	Unknown	Zidebactam + cefepime
620	WHO AMR pipeline analysis	2021-11-01	–	Antibiotics	DBO-BLI/ PBP2 binder + cephalosporin	Gram-negative bacterial infections	IV	Phase I	NCT02532140, NCT02942810, NCT02707107	Wockhardt Ltd.	Priority pathogens	Enterobacterales	Critical priority pathogens	Yes	No	Yes	No	Unknown	Zidebactam + cefepime
621	WHO AMR pipeline analysis	2021-11-01	–	Antibiotics	DBO-BLI/ PBP2 binder + cephalosporin	Gram-negative bacterial infections	IV	Phase I	NCT02532140, NCT02942810, NCT02707107	Wockhardt Ltd.	Priority pathogens	Critical priority pathogens	Critical priority pathogens	Yes	No	Yes	No	Unknown	Zidebactam + cefepime
622	WHO AMR pipeline analysis	2021-11-01	–	Antibiotics	DBO-BLI/ PBP2 binder + cephalosporin	Gram-negative bacterial infections	IV	Phase I	NCT02532140, NCT02942810, NCT02707107	Wockhardt Ltd.	Priority pathogens	Campylobacter spp.	Other priority pathogens	No	No	Yes	No	Unknown	Zidebactam + cefepime
623	WHO AMR pipeline analysis	2021-11-01	–	Antibiotics	DBO-BLI/ PBP2 binder + cephalosporin	Gram-negative bacterial infections	IV	Phase I	NCT02532140, NCT02942810, NCT02707107	Wockhardt Ltd.	Priority pathogens	All critical priority pathogens	Critical priority pathogens	Yes	No	Yes	No	Unknown	Zidebactam + cefepime
624	WHO AMR pipeline analysis	2021-11-01	–	Antibiotics	DBO-BLI/ PBP2 binder + cephalosporin	Gram-negative bacterial infections	IV	Phase I	NCT02532140, NCT02942810, NCT02707107	Wockhardt Ltd.	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	Yes	No	Yes	No	Unknown	Zidebactam + cefepime
625	WHO AMR pipeline analysis	2021-11-01	–	Antibiotics	Topoisomerase Inhibitors (Spiropyrimidenetrione)	Uncomplicated N. gonorrhoeae	Oral	Phase III	NCT03959527	Entasis Therapeutics Inc./ GARDP	Priority pathogens	Streptococcus pneumoniae	Other priority pathogens	No	Yes	Yes	No	Unknown	Zoliflodacin
626	WHO AMR pipeline analysis	2021-11-01	–	Antibiotics	Topoisomerase Inhibitors (Spiropyrimidenetrione)	Uncomplicated N. gonorrhoeae	Oral	Phase III	NCT03959527	Entasis Therapeutics Inc./ GARDP	Priority pathogens	Staphylococcus aureus	Other priority pathogens	No	Yes	Yes	No	Unknown	Zoliflodacin
627	WHO AMR pipeline analysis	2021-11-01	–	Antibiotics	Topoisomerase Inhibitors (Spiropyrimidenetrione)	Uncomplicated N. gonorrhoeae	Oral	Phase III	NCT03959527	Entasis Therapeutics Inc./ GARDP	Priority pathogens	Pseudomonas aeruginosa	Critical priority pathogens	No	Yes	Yes	No	Unknown	Zoliflodacin
628	WHO AMR pipeline analysis	2021-11-01	–	Antibiotics	Topoisomerase Inhibitors (Spiropyrimidenetrione)	Uncomplicated N. gonorrhoeae	Oral	Phase III	NCT03959527	Entasis Therapeutics Inc./ GARDP	Priority pathogens	Other priority pathogens	Other priority pathogens	Yes	Yes	Yes	No	Unknown	Zoliflodacin
629	WHO AMR pipeline analysis	2021-11-01	–	Antibiotics	Topoisomerase Inhibitors (Spiropyrimidenetrione)	Uncomplicated N. gonorrhoeae	Oral	Phase III	NCT03959527	Entasis Therapeutics Inc./ GARDP	Priority pathogens	Neisseria gonnorhoeae	Other priority pathogens	Yes	Yes	Yes	No	Unknown	Zoliflodacin
630	WHO AMR pipeline analysis	2021-11-01	–	Antibiotics	Topoisomerase Inhibitors (Spiropyrimidenetrione)	Uncomplicated N. gonorrhoeae	Oral	Phase III	NCT03959527	Entasis Therapeutics Inc./ GARDP	Priority pathogens	Helicobacter pylori	Other priority pathogens	No	Yes	Yes	No	Unknown	Zoliflodacin
631	WHO AMR pipeline analysis	2021-11-01	–	Antibiotics	Topoisomerase Inhibitors (Spiropyrimidenetrione)	Uncomplicated N. gonorrhoeae	Oral	Phase III	NCT03959527	Entasis Therapeutics Inc./ GARDP	Priority pathogens	Gram-positive priority pathogens	Other priority pathogens	No	Yes	Yes	No	Unknown	Zoliflodacin
632	WHO AMR pipeline analysis	2021-11-01	–	Antibiotics	Topoisomerase Inhibitors (Spiropyrimidenetrione)	Uncomplicated N. gonorrhoeae	Oral	Phase III	NCT03959527	Entasis Therapeutics Inc./ GARDP	Priority pathogens	Enterococcus faecium	Other priority pathogens	No	Yes	Yes	No	Unknown	Zoliflodacin
633	WHO AMR pipeline analysis	2021-11-01	–	Antibiotics	Topoisomerase Inhibitors (Spiropyrimidenetrione)	Uncomplicated N. gonorrhoeae	Oral	Phase III	NCT03959527	Entasis Therapeutics Inc./ GARDP	Priority pathogens	Enterobacterales	Critical priority pathogens	No	Yes	Yes	No	Unknown	Zoliflodacin
634	WHO AMR pipeline analysis	2021-11-01	–	Antibiotics	Topoisomerase Inhibitors (Spiropyrimidenetrione)	Uncomplicated N. gonorrhoeae	Oral	Phase III	NCT03959527	Entasis Therapeutics Inc./ GARDP	Priority pathogens	Critical priority pathogens	Critical priority pathogens	No	Yes	Yes	No	Unknown	Zoliflodacin
635	WHO AMR pipeline analysis	2021-11-01	–	Antibiotics	Topoisomerase Inhibitors (Spiropyrimidenetrione)	Uncomplicated N. gonorrhoeae	Oral	Phase III	NCT03959527	Entasis Therapeutics Inc./ GARDP	Priority pathogens	Campylobacter spp.	Other priority pathogens	No	Yes	Yes	No	Unknown	Zoliflodacin
636	WHO AMR pipeline analysis	2021-11-01	–	Antibiotics	Topoisomerase Inhibitors (Spiropyrimidenetrione)	Uncomplicated N. gonorrhoeae	Oral	Phase III	NCT03959527	Entasis Therapeutics Inc./ GARDP	Priority pathogens	All critical priority pathogens	Critical priority pathogens	No	Yes	Yes	No	Unknown	Zoliflodacin
637	WHO AMR pipeline analysis	2021-11-01	–	Antibiotics	Topoisomerase Inhibitors (Spiropyrimidenetrione)	Uncomplicated N. gonorrhoeae	Oral	Phase III	NCT03959527	Entasis Therapeutics Inc./ GARDP	Priority pathogens	Acinetobacter baumannii	Critical priority pathogens	No	Yes	Yes	No	Unknown	Zoliflodacin
638	WHO AMR pipeline analysis	2021-11-01	GSK070	Antibiotics	Leu RS inhibitor (oxaborole)	Pulmonary tuberculosis	Oral	Phase II	NCT03557281	GlaxoSmithKline PLC	Mycobacterium tuberculosis	Mycobacterium tuberculosis	Other priority pathogens	No	Yes	Yes	Yes	Unknown	 GSK3036656
639	WHO AMR pipeline analysis	2021-11-01		Antibiotics	DprE1 inhibitor (benzothiazinone)	Tuberculosis	Oral	Phase II	NCT03590600, NCT04044001	University of Munich; Hans Knöll Institute, Jena; German Center for Infection Research	Mycobacterium tuberculosis	Mycobacterium tuberculosis	Other priority pathogens	No	Yes	Yes	Yes	Unknown	BTZ-043
640	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Amido piperidine (inactivation of TetR-like repressor, EthR2)	Tuberculosis	Oral	Phase I	NCT04654143	Bioversys/ GSK	Mycobacterium tuberculosis	Mycobacterium tuberculosis	Other priority pathogens	No	No	Yes	Yes	Unknown	Miscellaneous
641	WHO AMR pipeline analysis	2021-11-01	LCB01-0371	Antibiotics	Oxazolidinone	Pulmonary tuberculosis, Gram-positive bacterial infections	Oral	Phase II	NCT02836483, NCT04550832	LegoChem Biosciences Inc., HaiHe Biopharma	Mycobacterium tuberculosis	Mycobacterium tuberculosis	Other priority pathogens	No	No	Yes	Yes	Unknown	Delpazolid
642	WHO AMR pipeline analysis	2021-11-01	GSK286	Antibiotics	Undisclosed	Tuberculosis	Oral	Phase I	NCT04472897	GSK. TB Drug Accelarator/ Bill & Melinda Gates Foundation	Mycobacterium tuberculosis	Mycobacterium tuberculosis	Other priority pathogens	No	Yes	Yes	Yes	Unknown	GSK2556286
643	WHO AMR pipeline analysis	2021-11-01	PBTZ-169	Antibiotics	DprE1 inhibitor (Benzothiazinone)	Pulmonary tuberculosis	Oral	Phase I	NCT03036163, NCT03776500, NCT03334734	Innovative Medicines for Tuberculosis Foundation and Nearmedic Plus	Mycobacterium tuberculosis	Mycobacterium tuberculosis	Other priority pathogens	No	Yes	Yes	Yes	Unknown	Macozinone
644	WHO AMR pipeline analysis	2021-11-01	–	Antibiotics	DprE1 inhibitor (3,4-dihydrocarbostyril)	Pulmonary tuberculosis	Oral	Phase II	NCT03678688	Otsuka Pharmaceutical Co., Ltd.	Mycobacterium tuberculosis	Mycobacterium tuberculosis	Other priority pathogens	No	Yes	Yes	Yes	Unknown	OPC-167832
645	WHO AMR pipeline analysis	2021-11-01	PNU-100480	Antibiotics	Oxazolidinone	Pulmonary tuberculosis, Gram-positive bacterial infections	Oral	Phase II	NCT03959566	TB Alliance/ Sequella	Mycobacterium tuberculosis	Mycobacterium tuberculosis	Other priority pathogens	No	No	Yes	Yes	Unknown	Sutezolid
646	WHO AMR pipeline analysis	2021-11-01	–	Antibiotics	DprE1 inhibitor (azaindole)	Tuberculosis	Oral	Phase II	NCT04176250, NCT03199339	TB Alliance/ Bill & Melinda Gates Medical Research Institute/ Foundation for Neglected Disease Research	Mycobacterium tuberculosis	Mycobacterium tuberculosis	Other priority pathogens	No	Yes	Yes	Yes	Unknown	TBA-7371
647	WHO AMR pipeline analysis	2021-11-01		Antibiotics	Diarylquinoline	Tuberculosis	Oral	Phase I	NCT04890535	TB Alliance	Mycobacterium tuberculosis	Mycobacterium tuberculosis	Other priority pathogens	No	No	Yes	Yes	Unknown	TBAJ-587
648	WHO AMR pipeline analysis	2021-11-01		Antibiotics	Diarylquinoline	Tuberculosis	Oral	Phase I	NCT04493671	TB Alliance	Mycobacterium tuberculosis	Mycobacterium tuberculosis	Other priority pathogens	No	No	Yes	Yes	Unknown	TBAJ-876
649	WHO AMR pipeline analysis	2021-11-01	pyrifazimine	Antibiotics	Riminophenazine (clofazimine-analogue)	Tuberculosis	Oral	Phase I	NCT04670120	Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College	Mycobacterium tuberculosis	Mycobacterium tuberculosis	Other priority pathogens	No	No	Yes	Yes	Unknown	TBI-166
650	WHO AMR pipeline analysis	2021-11-01		Antibiotics	Oxazolidinone	Tuberculosis	Oral	Phase I	NCT03758612, NCT04865536	Institute of Materia Medica/ TB Alliance	Mycobacterium tuberculosis	Mycobacterium tuberculosis	Other priority pathogens	No	No	Yes	Yes	Unknown	TBI-223
651	WHO AMR pipeline analysis	2021-11-01	Q203	Antibiotics	Imidazopyridine amide	Pulmonary tuberculosis	Oral	Phase II	NCT03563599, NCT04847583	Qurient Co	Mycobacterium tuberculosis	Mycobacterium tuberculosis	Other priority pathogens	No	Yes	Yes	Yes	Unknown	Telacebec
652	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Live biotherapeutic product	C. difficile infections	Oral	Phase I	NCT04891965	Artugen Therapeutics	Clostridioides difficile	Clostridioides difficile	Other priority pathogens	No	No	Yes	No	Yes	Microbiome-modulating agents
653	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Live biotherapeutic product	Recurring C. difficile infections	Colonoscopy	Preregistration		BiomeBank	Clostridioides difficile	Clostridioides difficile	Other priority pathogens	No	No	Yes	No	Yes	Microbiome-modulating agents
654	WHO AMR pipeline analysis	2021-11-01	–	Non-traditional	Live biotherapeutic product	Recurring C. difficile infections	Oral	Phase II	NCT03110133, NCT03497806	Finch Theraputics	Clostridioides difficile	Clostridioides difficile	Other priority pathogens	No	No	Yes	No	Yes	Microbiome-modulating agents
655	WHO AMR pipeline analysis	2021-11-01	REP 3123	Antibiotics	 Diaryldiamine (Methionyl-tRNA synthetase inhibitor)	C. difficile infections	Oral	Phase II	NCT04781387	Crestone/ National Institute of Allergy and Infectious Diseases	Clostridioides difficile	Clostridioides difficile	Other priority pathogens	No	Yes	Yes	No	Yes	CRS3123
656	WHO AMR pipeline analysis	2021-11-01	–	Non-traditional	Antibiotic inactivator and protective colon-targeted adsorbent	C. difficile infections	Oral	Phase II	NCT03710694	Da Volterra	Clostridioides difficile	Clostridioides difficile	Other priority pathogens	No	No	Yes	No	Yes	Microbiome-modulating agents
657	WHO AMR pipeline analysis	2021-11-01	MCB-3837	Antibiotics	Oxazolidinone-quinolone hybrid	C. difficile infections	IV	Phase II	NCT03988855	Deinove	Clostridioides difficile	Clostridioides difficile	Other priority pathogens	No	Inconclusive	Yes	No	Yes	DNV3837
658	WHO AMR pipeline analysis	2021-11-01	ACX-362E	Antibiotics	Substituted guanine (DNA polymerae IIIIC inhibitor))	C. difficile infections	Oral, Not absorbed	Phase II	NCT04247542	Acurx Pharmaceuticals	Clostridioides difficile	Clostridioides difficile	Other priority pathogens	No	Yes	Yes	No	Yes	Ibezapolstat
659	WHO AMR pipeline analysis	2021-11-01	–	Non-traditional	anti-C. difficile polcyclonal Ab	C. difficile infections	Oral	Phase II	NCT04121169	ImmuniMed	Clostridioides difficile	Clostridioides difficile	Other priority pathogens	No	No	Yes	No	Yes	Antibodies
660	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Phage endolysin and three toxin-binding proteins (5D, E3, and 7F)s	C. difficile infections	Oral	Phase I	NCT04893239	Lumen Bioscience	Clostridioides difficile	Clostridioides difficile	Other priority pathogens	No	No	Yes	No	Yes	Bacteriophages and phage-derived enzymes
661	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Live biotherapeutic product	Recurring C. difficile infections	Oral	Phase I	NCT02865616, NCT04602715	NuBiyota/ Takeda	Clostridioides difficile	Clostridioides difficile	Other priority pathogens	No	No	Yes	No	Yes	Microbiome-modulating agents
662	WHO AMR pipeline analysis	2021-11-01	–	Antibiotics	DNA minor groove binder (distamycin)	C. difficile-associated diarrhea	Oral, Not absorbed	Phase II	NCT03824795	MGB Biopharma Ltd.	Clostridioides difficile	Clostridioides difficile	Other priority pathogens	No	Yes	Yes	No	Yes	MGB-BP-3
663	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Live biotherapeutic product	C. difficile	Enema	Phase III	NCT03931941	Ferring Pharmaceuticals	Clostridioides difficile	Clostridioides difficile	Other priority pathogens	No	No	Yes	No	Yes	Microbiome-modulating agents
664	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Live biotherapeutic product	Recurring C. difficile infections	Oral	Phase I	NCT02981316	Ferring (Rebiotix)	Clostridioides difficile	Clostridioides difficile	Other priority pathogens	No	No	Yes	No	Yes	Microbiome-modulating agents
665	WHO AMR pipeline analysis	2021-11-01	SMT19969	Antibiotics	Bis-benzimidazole	C. difficile infections	Oral, Not absorbed	Phase III	NCT02784002, NCT02092935, NCT03595553, NCT03595566, NCT04802837	Summit Therapeutics Inc.	Clostridioides difficile	Clostridioides difficile	Other priority pathogens	No	Yes	Yes	No	Yes	Ridinilazole
666	WHO AMR pipeline analysis	2021-11-01		Non-traditional	Live biotherapeutic product	C. difficile infections	Oral	Phase III	NCT03183128, NCT03183141	Seres Theraputics	Clostridioides difficile	Clostridioides difficile	Other priority pathogens	No	No	Yes	No	Yes	Microbiome-modulating agents
667	WHO AMR pipeline analysis	2021-11-01	Ribaxamase	Non-traditional	Antibiotic inactivator	C. difficile infections	Oral	Phase II	NCT02563106, NCT04692181	Synthetic Biologics	Clostridioides difficile	Clostridioides difficile	Other priority pathogens	No	No	Yes	No	Yes	Microbiome-modulating agents
668	WHO AMR pipeline analysis	2021-11-01	–	Non-traditional	Live biotherapeutic product	Recurring C. difficile infections	Oral	Phase II	NCT03788434	Vedanta Biosciences	Clostridioides difficile	Clostridioides difficile	Other priority pathogens	No	No	Yes	No	Yes	Microbiome-modulating agents
